1
Status: Approved ,  Date: 28 August 2019Janssen Research & Development *
Clinical Protocol
A Phase 2a Randomized, Double -blind, Placebo- Controlled, Parallel -Group, Multi -center 
Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of JNJ -
67953964 in Subjects with Major Depressive Disorder.
Short Title :
A study to explore the efficacy JNJ-67953964
in the treatment of depression.
Protocol 67953964MDD2001, Amendment INT -3; Phase 2a
JNJ-67953964
*Janssen Research & Development is a global organization that operates through different legal entities in
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen
Biologics, BV; Janssen -Cilag International NV; Janssen Pharmaceutica NV; Janssen, Inc; Janssen
Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is u sed throughout
the protocol to represent these various legal entities; the sponsor is identified on the Contact Information
page that accompanies the protocol.
This study  will be conducted under US Food & Drug Administration IND regulations (21 CFR 
Part 312)
EudraCT NUMBER : 2019 -000695 -41.
Status: Approved
Date: 28 August 2019
Prepared by: Janssen Research & Development, a division of Janssen Pharmaceutica NV   
EDMS number: EDMS- ERI-158697750, 6.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidenti al and 
may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed
by them. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as 
privileged or confidential.
[STUDY_ID_REMOVED]
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
2
Approved , Date: 28 August 2019TABLE OF CONTENTS
TABLE OF CONTENTS ............................................................................................................................... 2
LIST OF IN -TEXT FIGURES ........................................................................................................................ 4
PROTOCOL A MENDMENT S UMM ARY OF CHA NGES T ABLE ............................................................... 5
1. PROTOCOL SUMMA RY................................................................................................................... 14
1.1. Synopsis ......................................................................................................................................... 14
1.2. Time and Events Schedule (TES) .................................................................................................. 25
2. INTRODUCTION ................................................................................................................................ 27
2.1. Study Rationale .............................................................................................................................. 27
2.2. Background .................................................................................................................................... 28
2.2.1. Nonclinical Studies ..................................................................................................................... 28
2.2.2. Clinical Studies ........................................................................................................................... 29
2.3. Benefit/Risk Assessment ............................................................................................................... 32
3. OBJECTIVES .................................................................................................................................... 33
4. STUDY DESIGN ................................................................................................................................ 34
4.1. Overall Design ................................................................................................................................ 34
4.2. Scientific Rationale for Study Design ............................................................................................. 36
4.2.1. Study-Specific Ethical Design Considerations ........................................................................... 41
4.3. Justification for Dose ...................................................................................................................... 42
4.4. End of Study Definition ................................................................................................................... 42
5. STUDY POPUL ATION...................................................................................................................... 43
5.1. General Considerations ................................................................................................................. 43
5.2. Inclusion Criteria ............................................................................................................................ 43
5.3. Exclusion Criteria ........................................................................................................................... 46
5.4. Lifestyle Considerations ................................................................................................................. 50
5.5. Screen Failures .............................................................................................................................. 51
6. STUDY TREA TMENTS ..................................................................................................................... 51
6.1. Study Treatments Administered ..................................................................................................... 51
6.2. Preparation, Handling, and Storage ............................................................................................... 52
6.3. Measures to Minimize Bias: Randomization and Blinding ............................................................. 53
6.4. Study Medication Compliance ....................................................................................................... 54
6.5. Concomitant Therapy ..................................................................................................................... 54
6.6. Intervention After the End of the Study .......................................................................................... 56
7. DISCONTINUATION OF STUDY TREA TMENT A ND PA RTICIPA NT 
DISCON TINUA TION/WITHDRA WAL............................................................................................... 56
7.1. Unblinded Data Review .................................................................................................................. 56
7.2. Completion ..................................................................................................................................... 56
7.3. Participant Discontinuation/W ithdrawal from the Study ................................................................ .57
7.4. Protocol Stopping Criteria .............................................................................................................. 58
7.5. Withdrawal from the Use of Research Samples ............................................................................ 58
7.6. Lost to Follow -up............................................................................................................................ 58
8. STUDY A SSESSMENTS AN D PROCEDURES ............................................................................... 58
8.1. Overview ........................................................................................................................................ 58
8.2. Study procedures ........................................................................................................................... 60
8.2.1. Screening .................................................................................................................................... 60
8.2.2. Baseline Visit (Visit 2) ................................................................................................................. 61
8.2.3. Double -blind Treatment Period ................................................................................................... 61
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
3
Approved , Date: 28 August 20198.2.4. Early W ithdrawal Visit ................................................................................................................. 62
8.3. Efficacy  Assessments .................................................................................................................... 62
8.3.1. Rater Qualification ...................................................................................................................... 62
8.3.2. Primary........................................................................................................................................ 62
8.3.3. Secondary ................................................................................................................................... 63
8.3.4. Explorator y.................................................................................................................................. 65
8.4. Safety Assessments ....................................................................................................................... 65
8.4.1. Physical and Neurological Examination ..................................................................................... 65
8.4.2. Vital Signs ................................................................................................................................... 65
8.4.3. Electrocardiogram (ECG) ........................................................................................................... 66
8.4.4. Clinical Safety Laborator y Assessments .................................................................................... 66
8.4.5. Suicidal Risk Monitoring ............................................................................................................. 66
8.4.6. Other Safety Evaluations ............................................................................................................ 66
8.5. Adverse Events and Serious Adverse Events ............................................................................... 67
8.5.1. Time Period and Frequency for Collecting Adverse Event and Serious Adverse Event 
Information .................................................................................................................................. 68
8.5.2. Follow -up of Adverse Events and Serious Adverse Events ....................................................... 68
8.5.3. Regulatory Reporting Requirements for Serious Adverse Events ............................................. 68
8.5.4. Pregnancy ................................................................................................................................... 68
8.6. Treatment of Overdose .................................................................................................................. 69
8.7. Pharmacokinetics ........................................................................................................................... 69
8.8. Genetics ......................................................................................................................................... 70
8.9. Biom arkers ..................................................................................................................................... 70
9. STATISTICA L CONSIDER ATIONS .................................................................................................. 71
9.1. Sample Size Determination ........................................................................................................... 71
9.2. Efficacy  Analyses ........................................................................................................................... 71
9.2.1. Primary........................................................................................................................................ 71
9.2.2. Secondary ................................................................................................................................... 72
9.2.3. Explorator y.................................................................................................................................. 73
9.3. Biom arker Analyses ....................................................................................................................... 73
9.4. PK analy sis.................................................................................................................................... 73
9.5. Safety Analyses ............................................................................................................................. 74
9.6. Interim Analysis .............................................................................................................................. 75
10. SUPPORTING DOCUMENT ATION A ND OPERA TIONA LCONSIDERA TIONS ............................ 76
10.1. Appendix 1: Abbreviations ............................................................................................................. 76
10.2. Appendix 2: Clinical Laboratory Tests ........................................................................................... 80
10.3. Appendix 3: Regulatory, Ethical, and Study Overs ight Considerations ......................................... 82
10.4. Appendix 4: Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting ............................................................................................................... 93
10.5. Appendix 5: Drugs to be avoided ................................................................................................... 98
10.6. Appendix 6: Contraceptive Guidance and Collection of Pregnanc y Information ........................... 99
10.7. Appendix 7: Liver Safety: Suggested Actions and Follow -up Assessments ................................ 100
10.8. Appendix 8: The SHAPS .............................................................................................................. 103
10.9. Appendix 9: Self -Assessment of Treatment Experience ............................................................. 106
10.10. Appendix 10: Cognitive and Physical Functioning Questionnaire (CPFQ) .................................. 107
10.11. Appendix 11: Columbia Suicide Severity Rating Scale. .............................................................. 108
10.12. Appendix 12: Arizona sexual experiences scale (ASEX)© .......................................................... 112
10.13. Appendix 13: The Karolinska S leepiness Scale. ......................................................................... 114
10.14. Appendix 14: Protocol Amendment History ................................................................................. 115
11. REFERENCES ................................................................................................................................ .116
INVESTIGA TOR A GREEME NT............................................................................................................... 118
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
4
Approved , Date: 28 August 2019LIST OF IN -TEXT FIGURE S
Figure 1: Flow diagram of the study ......................................................................................................... 16
Figure 2: Flow d iagram of the study ......................................................................................................... 35
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
5
Approved , Date: 28 August 2019PROTOCOL A MENDMENT S UMMA RY OF CHA NGES TA BLE
DOCUMENT HISTORY
Document Date
Amendment INT -3 28August 2019
Amendment INT2, GER -1 04 July 2019
Amendment INT2, GBR -1 21 May 2019
Amendment INT -2 26February 2019
Amendment INT -1 18-June-2018
Original Protocol 14-March -2018
Amendment INT -3 (2 8-August -2019)
Overall Rationale for the Amendment: To harmonize aspects of local amendment s(GBR -1 and 
GER -1) into one common protocol; to include corrections already documented in note -to-files and to 
include some administrative corrections.
Section number
and Nam eDescription of Change Brief Rationale
Section 4.4, End of Study 
DefinitionFollowing text was added:
End of Study Definition
The end of study is considered as the last 
visit for the last participant in the study .
A header Study Completion Def inition was addedBased on Amendment 
GER -1: An end of study 
definition was missing in 
the protocol
Section 5.2, Inclusion 
Criteria, Inclusion 
criterion 5.Original text:
Men who are sexually active with a woman 
of childbearing potential and have not had a 
vasectomy must agree to use a barrier 
method of birth control e.g., either condom 
or partner with occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal 
foam/gel/film/cream/suppository for the 
duration of the study plus 3 months after 
receiving the last dose of study drug, and all 
men must not donate sperm during the study 
and for 3 months after receiving the last dose 
of study drug. In addition, their female 
partners should also use an additional 
method of birth control (which may include 
a horm onal method, an intrauterine device 
[IUD] or an intrauterine system [IUS]) for at 
least the same duration.
Changed into:
Men who are sexually active with a woman 
of childbearing potential and have not had a 
vasectomy must agree to use a barrier 
method of birth control i.e., a condom with 
spermicidal foam/gel/film/cream/suppository 
for the duration of the study plus 3 months 
after receiving the last dose of study drug, 
and all men must not donate sperm during 
the study and for 3months after receiving Based on Amendment 
GER -1: Men with WOCBP 
partners should u se a 
barrier method of birth 
control (condom) in every 
case.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
6
Approved , Date: 28 August 2019Section number
and Nam eDescription of Change Brief Rationale
the last dose of study drug. In addition, their 
fema le partners should also use an additional 
method of birth control (which may include 
a horm onal method, an intrauterine device 
[IUD] or an intrauterine system [IUS]) for at 
least the same duration.
Section 5.2, Inclusion 
Criteria, inclusion criterion 
6.1.Original text:
Not of childbearing potential: postmenopausal (>45 
years of age with amenorrhea for at least 12 months, 
or any age with amenorrhea for at least 6 months and 
a serum follicle stimulating horm one (FSH) level at 
screening >40 IU/L  without horm onal replacement 
therapy); perm anently sterilized (e.g., tubal occlusion 
[tubal cauterization and other comparable methods], 
hysterectom y, bilateral salpingectomy); or otherw ise 
be incapable of pregnancy .
Changed into:
Not of childbearing potential defined as: 
Postmenopausal (amenorrhea for at least 12months 
without an alternative medical cause. A serum 
follicle stimulating horm one (FSH) level at 
screening >40IU/L  in women notusing horm onal 
contraception or hormonal replacement therapy may 
be used for confirmation ,however in the absence of 
12months of amenorrhea, a single FSH 
measurement is insufficient ) or 
Perm anently sterilized (including hysterectomy , 
bilateral salpingectomy and bilateral oophorectomy) 
or
Otherwise be incapable of pregnancy .Based on Amendment 
GBR -1.
Section 5.3, Exclusion 
Criteria, Exclusion criterion 
13.Original text:
Subject has a history of hepatitis B surface antigen 
(HBsAg) or hepatitis C antibody (anti -HCV) positive, 
or other clinically active liver disease, or tests positive 
for HBsAg or anti -HCV at Screening. If su bjects have 
been successfully treated for HCV and are RNA  
negative, they will be allow ed in the study .
Changed into:
Subject has a history of hepatitis B surface antigen 
(HBsAg) or hepatitis C antibody (anti -HCV) positive, 
or other clinically active liver disease, or tests positive 
for HBsAg or anti -HCV at Screening. If subjects have 
been successfully treated for or have been 
spontaneously recovered from HCV and are RNA  
negative, they will be allow ed in the study .Some subjects recover 
spontaneously from HC V 
without any treatment. 
These subjects have a 
positive antibody test but a 
negative RNA -test.
Section 5.3, Exclusion 
Criteria, Exclusion 
criterion 16.Original text:
Subject has positive test result(s) for alcohol or drugs 
of abuse (including barbiturates, methadone, opiates, 
cocaine, cannabinoids, As benzodiazepines may 
be allow ed under certain 
conditions, a positive urine 
drug screen on 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
7
Approved , Date: 28 August 2019Section number
and Nam eDescription of Change Brief Rationale
amphetamine/methamphetamine, benzodiazepines 
and ecstasy) at Screening or at baseline (V isit 2).
Subjects with a pos itive alcohol or drug screen may 
have the test repeated once, based on the 
investigator's discretion. This determination, and the 
reason for permitting a repeat test, must be recorded 
in the subject's source documents and initialed by the 
investigator . A positive, repeat alcohol or drug screen 
is exclusionary .
Changed into:
Subject has positive test result(s) for alcohol or drugs 
of abuse (including barbiturates, methadone, opiates, 
cocaine, cannabinoids, 
amphetamine/methamphetamine, and ecstasy) at 
Screeni ng or at baseline (V isit 2).
A positive test result for benzodiazepines is not 
exclusionary if the subject is taking such drugs per 
protocol.
Subjects with a positive alcohol or drug screen may 
have the test repeated once, based on the 
investigator's discr etion. This determination, and the 
reason for permitting a repeat test, must be recorded 
in the subject's source documents and initialed by the 
investigator . A positive, repeat alcohol or drug screen 
is exclusionary .benzodiazepines is not 
always exclusionary. 
Section 5.3, Exclusion 
Criteria, Exclusion 
criterion 25.Original text:
Has known allergies, hypersensitivity , or 
intolerance or any contraindication to 
JNJ-67953964 (refer to IB for JNJ-
67953964 ).
Changed into:
Has known allergies, hypersensitivity , or 
intolerance or any contraindication to any of 
the excipients of JNJ-67953964 or placebo 
(refer to IB for JNJ-67953964 ).Based on Amendment 
GER -1: To exclude 
subjects with an allergy, 
hypersensitivit y, 
intolerance or any 
contraindication to the use 
of placebo
Section 7.3, Participant 
Discontinuation/W ithdraw al 
from the StudyOriginal text:
Subjects who drop out will be replaced if the 
number of subjects completing the study will 
be below  96. Replacement subjects will 
receive a new subject ID -number and will be 
assigned to a new randomization code in the 
IWRS .
Changed into:
Subjects who drop out, other than for safety 
reasons related to the study drug or study 
procedures, will be replaced if th e number of 
subjects completing the study will be below 
96. A maximum of 32 subjects (1/3 of 
targeted subjects) will be allow ed to be Based on Amendment 
GER -1: To define a 
maximum number of 
replacement subjects. In 
addition, only those 
subjects will be replaced 
which have not withdrawn 
due to adverse drug 
reactions or adverse events 
based on study procedures.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
8
Approved , Date: 28 August 2019Section number
and Nam eDescription of Change Brief Rationale
replaced. Replacement subjects will receive 
a new subject ID-number and will be 
assigned to a new randomization code in the 
IWRS .
Section 7.3, Partic ipant 
Discontinuation/W ithdraw al 
from the StudyThe text in section 7.3 will be changed from:
A subject will be discontinued from the study if the 
QTcF interval is higher than 500 msec or is prolonged 
>60 msec from the baseline value. Similarly , subjects 
presenting with a first-degree bundle branch block 
(BBB; PR > 200 msec) will be discontinued. QTc 
interval prolongation and BBB should be confirmed 
by collecting 2 additional ECGs as soon as possible 
after the initial ECG. The average value of the QTcF 
interval of the three ECG’ s will be used to determine 
whether a subject should be discontinued. If the QT cF 
is not readily available, the QTcB may be used 
instead. The subject will continue to be monitored 
(maximum 12 hours) by repeated 12 lead ECGs (at 
least every 60 minutes) until the ECG normalizes.
To
A subject will be discontinued from the study if the 
QTcF interval is higher than 500 msec or is prolonged 
>60 msec from the baseline value. QTc interval 
prolongation should be confirmed by collecting 
2additional ECGs as soon as possible after the initial 
ECG. The average value of the QTcF interval of the 
three ECG’ s will be used to determine whether a 
subject should be discontinued. If the QTcF is not 
readily available, the QTcB may be used instead. The 
subject will continue to be monitored (maximum 12 
hours) by repeated 12 lead ECGs (at least every 60 
minutes) until the ECG normalizes.A withdrawal criterion for 
the PR-interval (> 200 
msec) has been included 
which is conflicting with 
inclusion criterion 3 
(subject w ith PR -interval 
>220 are excluded). 
This w ithdrawal criterion 
on the PR -interval will be 
removed from Section 7.3. 
The rationale for this 
removal is
•Subjects with a PR -
interval ≥220 msec are 
already excluded from the 
study per inclusion 
criterion 3.
•The PR -interval does 
not increase under the 
influence of any medicinal 
product.
Section 8.5.1 , Time Period 
and Frequency for 
Collecting Adverse Event 
and Serious Adverse Event 
InformationOriginal T ext:
All SAEs occurring during the study must be 
reported to the appropriate sponsor contact 
person by study -site within 24 hours after 
their knowledge of the event.
Changed into:
All SAEs occurring during the study must be 
reported to the appropriate sponsor contact 
person by study -site personnel immediately , 
without undue delay , under no circumstances 
later than 24 hours after their knowledge of 
the event.Based on Amendment 
GER -1: To adjust the 
wording of the timeframe 
for reporting SAEs in line 
with the German law 
(Section 12 para 4 GCP 
ordinance) and European 
rules (2011/C 172/01/EC, 
„CT-3", 4.3.1, 29.).
Section 10.1 1, Appendix 1 1Added: Past x years = Past 1 yearCorrection of omission
Protocol amendments Correct date of Amendment INT-2 to 26 February 
2019This date was not 
consistent in Amendment 
INT-2.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
9
Approved , Date: 28 August 2019Amendment INT -2 (2 6-February-2019)
Overall Rationale for the Amendment: Administrative change to add the EudraCT number because of 
addit ional trial execution in the EU, changes of inclusion criterion on female sterilization, exclusion
criteria on concomitant medication due to reconsideration of current clinical practices and some changes 
on request of clinical sites.
Section number
and Nam eDescription of Change Brief Rationale
Section 5.3, 
Exclusion Criteria, 
exclusion criterion
5.Has failed (no more than 25% response on ATRQ) 
three or more antidepressant treatments incl uding 
the current SSRI/SNRI and including the current 
and all previous depressive episodes despite an 
adequate dose (per ATRQ) and duration (at least 6 
weeks).
Changes into: 
Has failed (no more than 25% response on ATRQ) 
three or more antidepressant treatments including 
the current SSRI/SNRI during the current
depressive episode despite an adequate dose (per 
ATRQ) and duration (at least 6 w eeks).To align better to the current clinical 
practice. Obtaining data from 
previous episodes is complex in 
clinical practice.
Section 5.3, 
Exclusion Criteria, 
exclusion 
criterion 17.Original text:
Antipsychotic drugs (D2-antagonists) 
within 2 weeks before screening.
Changed into:
Antipsychotic drugs (D2-antagonists) 
within 2 weeks before screening. 
How ever, Seroquel (quetiapine) in a dose 
≤100 mg is allowed when used in a stable 
dose for at least 8 weeks prior to 
screening. Quetiapine treatment should be 
continued unchanged during the study .Low dose quetiapine and trazodone 
are used a sedative drug during 
treatment of depression. The effect on 
depression itself when used in a 
stable low  dose is limited
Section 5.3, 
exclusion criterion 
18.Original text:
benzodiazepines .
Changed into:
Benzodiazepines when used only as needed
(PRN) is not allow ed. A subject may continue 
to take a benzodiazepine treatment only if:
• The subject has been taking a stable daily 
dose for at least 6 w eeks prior to screening
•The dose does not exceed an equivalent of 
2mg of lorazepam per day .
•Allowed benzodiazepines are lorazepam 
(≤2mg/day), clonazepam (≤0.5 mg/day) and 
alprazolam (≤1 mg/day)being taken daily . 
Other benzodiazepines should be discussed 
before subject enrollment with the study 
responsible physician.
•Treatment will be continued unchanged 
during the study .Benzodiazepines in stable use have 
limited effects o n current depression 
and anxiety severity levels.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
10
Approved , Date: 28 August 2019Section number
and Nam eDescription of Change Brief Rationale
Section 6.5
Concomitant 
medicationOriginal text:
benzodiazepines .
Changed into:
Benzodiazepines when used only as needed
(PRN) is not allow ed. A subject may continue 
to take a benzodiazepine treatment only if:
• The subject has been taking a stable daily 
dose for at least 6 w eeks prior to screening
•The dose does not exceed an equivalent of 
2mg of lorazepam per day .
•Allowed benzodiazepines are lorazepam 
(≤2mg/day), clonazepam (≤0.5 mg/day) and 
alprazolam (≤1 mg/day). Other 
benzodiazepines should be discussed before 
subject enrollment with the study responsible 
physician.
•Treatment will be continued unchanged 
during the study .Benzodiazepines in stable use have 
limited effects on current depression 
and anxiety severity levels.
Section 6.5
Concomitant 
medicationOriginal text:
Antipsychotic drug (D2-antagonists), lithium 
and other mood stabilizers from 2 weeks before 
screening. 
Changed into:
Antipsychotic drugs (D2-antagonists) within 2 
weeks before screening. How ever, Seroquel 
(quetiapine) in a dose ≤100 mg is allowed when 
used in a stable dose for at least 8 weeks prior 
to screening. Quetiapine treatment should be 
conti nued unchanged during the study .
Trazodone for treatment ofinsomnia in a dose 
≤100 mg when used for at least 8 weeks at a 
stable dose w ill be allowed.Low dose quetiapine and trazodone 
are used a sedative drug during 
treatment of depression. The effect on 
depression itself when used in a 
stable low  dose is limited
Section 2.3and 
references.Update: Investigator brochure is now edition 3, 
January 2019
Section 4.1Overall 
designAdded “audio” to recording specification
Section 5.2
Inclusion criteria, 
inclusion criterion 6 
first bullet pointAdded: tubal cauterization and other surgical 
interruption of the fallopian tubes as an allowed
means for female sterilization.Update on current medical practice.
Section 5.4
Lifestyle 
considerations. 
No 3.Added units of alcohol (UK standards) On request of UK -based sites
Section 8.2.3
Double -blind 
treatment periodAdded: At their last study visit, each study 
participant will be invited to complete an IEC/IRB 
approved Experience Survey , to share to his/her 
experience as a volunteer in this study . The 
responses will be collected by an external party  and 
anonymously provided to the sponsor .Was missing in previous version.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
11
Approved , Date: 28 August 2019Section number
and Nam eDescription of Change Brief Rationale
Section 8.3.1 , Rater 
QualificationThis section about the rater qualification and 
training process has been added.Policy to optimize rater training.
Section 10.2 Follicle stimulating hormone (FSH)
Changed into
For postmenopausal women only: Follicle 
stimulating hormone (FSH)To limit unnecessary testing
Section 1.2Time 
and Events 
scheduleAdded: meals during study visits.
Download and install Q.16 app
Change dinto
Download and install app(s) at screening and
baseline .Missing elements in previous version 
of protocol.
Amendment INT -1(18-June -2018 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union .
Overall Rationale for the Amendment :To harmonize with procedures of some vendors, to update dosing 
instructions and to correct some typo’s.
Section number
and Nam eDescription of Change Brief Rationale
Section 5.3, 
Exclusion Criteria, 
exclusion 
criterion 5.Original text:
5.Has failed (no more than 20% response) three or more 
antidepressant treatments with a different 
pharmacological mode of action including the current 
SSRI/SNRI despite an adequate dose (per ATRQ) and 
duration (at least 6 weeks) during a previous or the 
current depressive episode.
Changed into:
1.Has failed (no more than 25% response on ATRQ) three 
or more antidepressant treatments including the current 
SSRI/SNRI and including the current and all previous 
depressive episodes despite an adequate dose (per 
ATRQ) and duration (at least 6 w eeks) .The A TRQ form uses ≤25% 
as the lowest response 
criterion . The exclusion 
criterion is now harmonized 
with the ATRQ.
To harmonize the study 
procedures w ith those of the 
independent reviewers and to 
prevent that too m any 
‘unrecognized therapy 
resistant subjects’ will be 
randomized in the study, the 
wording “with a different 
pharmacological mode of 
action” has been removed.
Section 5.3, 
exclusion criterion 
17.Original text:
Proton pump inhibitors within 2 weeks before 
screening.
Changed into:
Proton pump inhibitors within 4weeks before 
screening.Typo, w as inconsistent with 
exclusion criterion 3.
Time and Events 
Schedule (TES); 
PROTOCOL 
SUMMARY , 
Sections 4.1,6.1Remove “ morning” from several sections.
Time and Events schedule , footno te “d” : 
Original text: At home: In the morning in fasting condition.
At clinic visit days: In fasting condition after completion of Study med ication should be 
taken after 4 -hours fasting. 
This is preferably done in the 
morning. However, 
medication may also be 
taken before lunch and 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
12
Approved , Date: 28 August 2019Section number
and Nam eDescription of Change Brief Rationale
and 8.2.2 . predose assessments.
Changed into: At home: In fasting condition . At clinic visit 
days: Use blisters dispensed at the previous visit. In fasting 
condition after completion of predose assessments.
Section 4.1andsummary:
Original text: 
The first dose w ill be taken at home next morning on Day 2.
Changed into: 
The first dose w ill be taken at home on Day 2.
Section 6.1and summary:
Original text:
All subjects will take 2 capsules QD. The capsules will be 
taken daily from Day 2 to Day 78 every morning (at home 
and when being in the clinic) in fasting condition with some 
water (fasting for at least 4 hours before dosing; water 
intake is permitted during that period).
The subjects will take the study medication with them at 
each study visit and will take study medication at the site in 
fasting condition after completion of predose study 
assessments and blood co llections. Dosing will be witnessed 
by the study staff.
Changed into:
All subjects will take 2 capsules QD. The capsules will be 
taken daily from Day 2 to Day 78 (at home and when being 
in the clinic) in fasting condition with some water (fasting 
for at least 4 hours before dosing; water intake is perm itted 
during that period Study medication will be taken before 
breakfast. If the subject has forgotten to take the study 
medication before breakfast, this should be done before the 
next following meal, at the latest at dinner of the same day. 
If the subject remembers later than dinner , the dose of that 
day should be omitted, and the subject should take his dose 
before breakfast on the next day .
The subjects will take the study medication with them at 
each study visit and will take study medication -from the 
blisters dispensed at the previous study visit - at the site in 
fasting condition after completion of predose study 
assessments and blood collections. Dosing will be witnessed 
by the study staff.before dinner. Because of the 
long t ½of the study drug, 
drug intake may be up to 12 
hours after the planned 
dosin g time.
Additionally, during a study 
visit, study drug f rom the 
blisters dispensed at the 
previous visit should be 
dosed.
Section 6.4 Original text: 
Dosing will be documented by an app using the subjects’  
smartphone.To add specif ic information 
about the AiC ure-app to 
record compliance of drug 
intake.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
13
Approved , Date: 28 August 2019Section number
and Nam eDescription of Change Brief Rationale
Changed into:
Dosing will be documented by app’s using the subjects’  
smartphone, or on a smartphone provided to the subject if 
they are unable to use their own. The Q1.6 -app will present 
an electronic diary asking subjects to confirm dosing of 
study medication. When available, also a medication 
adherence monitoring platform (AiCure® -app) will be used. 
The Platform uses artificial intelligence on smartphones to 
visually confirm  proper medication administration and 
ingestion of the study drug in real time without human 
intervention.  Video recordings of the drug intake are also 
recorded and stored to AiCure’ s secure server for further 
analysis to reconfirm proper medication administration, to 
identify any usability issues or intentional non-adherence, 
and to check for dupli cate enrollment. In addition, built-in 
reminders and a communication system allow  real-time 
intervention by study personnel in case of improper drug 
administration or interruptions by the subject.
Section 8.1 Added:
•Manuals for investigator and subject for the AiCure -app to 
assess treatment compliance by video recording the drug 
intake. The AiCure -app w ill be downloaded on the subjects’  
own smartphone, or a smartphone with the app included w ill 
be provided to the subject.To inform about addit ional 
materials supplied for 
AiCure-app
Section 8.2.1 Original text:
As duplicate enrollment and protocol violations are risk 
factors for poor quality data and safety concerns, each 
subject in this study must have their current study status 
checked by a clinical trials verification system. This is a 
mandatory process.
Changed into:
As duplicate enrollment and protocol violations are risk 
factors for poor quality data and safety conce rns, each 
subject in this study will have their current study status 
checked by a  c linical trials verification system when 
available .The verification system may 
not be available for this 
study due to new privacy 
regulations in the EU. As a 
global compan y, Janssen has 
determined that the 
requirements of the EU 
privacy regulations will be 
followed for all studies even 
in cases where no study sites 
are located in the EU.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
14
Approved , Date: 28 August 20191. PROTOCOL SUMMARY
1.1. Synopsisa
A Phase 2a Randomized, Double -blind, Placebo- Controlled, Parallel -Group, Multi -center 
Study Investigating the Efficacy, Safety, Tolerability and Pharmacokinetics of 
JNJ-67953964 in Subjects with Major Depressive Disorder.
JNJ-67953964, previously known as Cerecor (CERC )-501 and LY2456302, is a small molecule, 
high-affinity , selective kappa opioid receptor (KOR) antagonist. JNJ-67953964 is orally 
bioavailable and suitable for once -daily(QD) administration. 
KORs and their native ligand dynorphin are localized in areas of the brain that effect reward and 
stress and may play  a key role in mood, stress, and addictive disorders. Chronic stress, substance 
abuse, and acute withdrawal lead to increased dynorphin expression, activating KORs and 
subsequent downstr eam signaling pathway s to inhibit mesolimbic dopamine surge, contributing 
to negative affective states. The behavioral pharmacology  of KOR antagonism has been tested in 
animal models of anhedonia, depression, and anxiety  and found to have meaningful effect s that 
may translate to therapeutic benefit in humans. KOR antagonists may be effective for the 
treatment of patients with mood disorders, perhaps by modulating the negative affective state 
associated with stress response.
Only  about 50% of patients with major depressive disorder (MDD) show a meaningful response 
(>50% improvement to a first line antidepressant treatment ), leaving many  patients with 
substantial persistent impairment . Therapeutic strategies such as switching antidepressants and 
using adjuvant drug treatments can improve response, however almost 40% of patients remain 
symptomatic and fail to achieve full remission. Recently , Alkermes ( ALKS ) 5461 , a combination 
of buprenorphine, which is a partial -opioid receptor agonist and KOR antagonist , and 
samidorphan, a potent -opioid receptor antagonist , has been tested in Phase 2 trials in subjects 
with MDD who have had only  a partial response to treatment with a selective serotonin reuptake 
inhibitor (SSRI) or aserotonin -norepinephrine reuptake inhibitor (SNRI) . Adjunctive treatment 
with ALKS 5461 was associated with greater symptom reduction compared to placebo, 
suggesting that a KOR antagonist could provide a meaningful clinical benefit for patients being 
treated for MDD . 
OBJECTIVES AND HYPOTH ESIS
Primary Objective
The primary  objective of this study  is to evaluate the efficacy  of JNJ-67953964 compared to 
placebo when administered as adjunctive treatment in subjects with MDD partiall y responsive to 
SSRI /SNRI treatment in terms of reduction of symptoms of depression, as assessed by the 
change from baseline on the Montgomery  Asberg Depression Rating Scale (MADRS) in non-
responders during the placebo lead -in period.
                                                
aThis section has been amended by amendment INT -1
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
15
Approved , Date: 28 August 2019Secondary Objectives
The secondary  objectives of this study  are:
To evaluate the efficacy  of JNJ-67953964 compared to placebo when administered as 
adjunctive treatment in subjects with MDD partially  responsive to SSRI /SNRI  treatment in 
terms of reduction of symptoms of depression, as assessed by the change from baseline on 
the Montgomery Asberg Depression Rating Scale (MADRS) in both responders and non-
responders during the placebo lead -in period .
To investigate the overall safety  and tolerability  of treatment with adjunctive JNJ-67953964
in subjects with MDD when used in combination with a SSRI  or SNRI .
To investigate the effect of JNJ-67953964 versus placebo on depression related anhedonia 
as assessed b y the Snaith -Hamilton Pleasure Scale (SHAPS).
To investigate the effect of JNJ-67953964 on symptoms of depression using the Clinical 
Global Impression- Severity  (CGI-S), the patient reported Symptoms of Major Depressive 
Disorder Scale (SMDDS) and the self -assessment of treatment experience (SATE). 
To investigate the effect of JNJ-67953964 on symptoms of anxiety  using the Hamilton 
Anxiety  Scale ( HAM -A) and on core s ymptoms of anxiety using the HAM -A6subscale .
To assess the plasma pharmacokinetics (PK) of JNJ-67953964 in subjects with MDD and 
explore its relationship with efficacy  and safet y parameters.
Exploratory objectives:
To explore theeffect of JNJ-67953964 on aspects of cognitive and executive function using 
the Cognitive and Ph ysical Functioning Questionnaire (CPFQ).
To explore mood -related biomarkers (including but not limited to growth factors, 
hypothalamic –pituitary –adrenal [HPA] axis markers, immune system activation, metabolic 
markers) and genetic/epigenetic variation that may be related to clinical response, 
nonresponse, or safety and tolerability parameters of JNJ -67953964.
Hypothesis
The primary  hypothesis is that 6 -weeks of adjunctive treatment with JNJ -67953964 is superior to 
placebo in improving symptoms of depression, as measured by the change from baseline in the 
MADRS , in subjects with MDD who are partiall y responsive to SSRI /SNRI treatment .
OVERVIEW OF STUDY DESIGN
This will be a multi -center, placebo -controlled, randomized, double -blind study  in subjects with 
MDD who have had inadequate response to SSRI/SNRI treatment . Approximately  142subjects 
will be included in the study .
For each subject, the study  will consist of twophase s: a screening phase of up to 5weeks and a 
double -blind treatment phase lasting 11 weeks.
Subjects with MDD who have had treatment initiated with an SSRI /SNRI  allowed by the 
protocol and have had an inadequate or only  partial response to this treatment will be screened at 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
16
Approved , Date: 28 August 2019the investigation alsite. Assessments by qualified site personnel including the MINI, 
Antidepressant Treatment History  Questionnaire (ATRQ , Chandler 2010 ), and MADRS will be 
audio recorded at screening for review of eligibil ity of the subject for enrollment into the study  
by an independent central reviewer contracted by the sponsor. The following key inclusion 
criteria/assessments will be reviewed by a central independent reviewer: the clinical history  of 
MDD, SSRI /SNRI treat ment of adequate dose and duration for the current episode of depression, 
and current symptom severity  on the MADRS. In case of discrepancy  of central reviewer and 
local rater, the central reviewer will discuss the discrepancy  with the local rater. If the 
discrepancy  persists, the local rater will overrule central review.
If 2 weeks or more elapse between the MADRS rating at screening and Visit 2, the local rater 
will complete the MADRS again by a telephone interview up to 4 days before Visit 2 to 
determine whether the subject still meets the thresholds for inclusion. 
Subjects who meet the inclusion and exclusion criteria and are enrolled will be maintained on the 
SSRI /SNRI without change throughout the study  to determine whether adjunctive treatment with 
JNJ-67953964 can reduce symptoms of MDD.
The treatment phase of the trial will consist of 3 periods. Aplacebo lead-in period of concealed 
duration , after which subjects will enter thedouble -blind treatment period when they will be 
randomly  assigned to 10 mg JNJ-67953964 or continue placebo for 6weeks. Subjects who 
complete the treatment period, will then enter the withdrawal period and be treated with placebo 
for the remaining time of the treatment phase of the study . The total study  duration for each 
subject will be approximately  16 w eeks. There will be 11 scheduled visits to the clinical research 
center including screening during the study . An overall flow diagram of the study  is shown in 
Figure 1.
Figure 1: Flow diagram  of the study 

JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
17
Approved , Date: 28 August 2019Eligibility  Screening Examination
After giving written informed consent, subjects will be screened within 35to 2days prior to 
Day 1 to ascertain their eligibility  for the study  per the inclusion and exclusion criteria. Upon 
completion of allinformed consent form (ICF)procedures, recording of adverse events (AEs) 
andconcomitant medication will start. Each subject in this study  must have their current study 
participation status checked by a clinical trials verification system when such a system is 
available for this study .
The symptoms of depression will be assessed using the (structured interview guide for the) 
MADRS .
Double- blind Treatment Phase
The duration of the double -blind treatment phase will be 11weeks divided into 3 periods.
Subjects will visit the study  center for baseline visits on Day 1.The subject will receive study 
medication after completion of the visit on Day  1. The first dose will be taken at home on Day  2.
Medication will be dispensed at each study  visit during this double -blind period. All study  
medication will be taken in fasting condition. 
During the double -blind study  phase, the subjects will visit the study  center for out-patient visits 
every  1 to 2 weeks as indicated in the Time and Events Schedule (TES).
Lead -in period
Subjects who successfully  compl ete the baseline examination visit at the clinical site/unit, will be 
treated with placebo for the entire duration of the lead-in period . Investigators and subjects will 
be blinded to the exact duration of lead -in period for each subject in the study .
Treatment period
At the end of the lead-in period both placebo lead-in responders and placebo lead-in 
non-responders will be randomized to receive either placebo or 10 mg JNJ-67953964 in a 1:1 
ratio for 6 week s.Investigators and subjects will remain blinded to exact timing of the 
randomization, response criterion and stud y drug treatment assignment for each subject.
Withdrawal period
Subjects who complete the double -blind treatment period prior to the end of Week 11will enter 
the withdrawal period where they will be treated with placebo for the remaining time of the 
treatment phase of the study . Investigators and subjects will be blinded to the exact duration of 
withdrawal period for each subject in the study .
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
18
Approved , Date: 28 August 2019Early withdrawal vis it
Subject who prematurely withdraw from the study  are encouraged to complete Visit 11. The 
procedures to be completed during thisvisit are listed in the TES.
SUBJECT POPULATION
Approximately  142subjects with MDD who have inadequately  responded to a SSRI /SNRI will 
be enrolled in this study .
Subjects will be enrolled after reading the subject information sheet and signing the ICF 
indicating that they understand the purpose ofand procedures required for the study  and are 
willing to participate in the study  and comply  with the study  procedures.
DOSAGE AND ADMINISTRATION
JNJ-67953964 will be supplied for this study  as 5-mg capsules. Placebo will be supplied as 
matching capsules.
All subjects will take 2 capsules QD. The capsules will be taken daily  from Day 2 to Day 78 (at 
home and when being in the clinic) in fasting condition with some water (fasting for at least 
4hours before dosing; water intake is permitted during that period). Study  medication will be 
taken before breakfast. If the subject has forgotten to take the study  medication before breakfast, 
this should be done before the next following meal, at the latest at dinner of the same day. If the 
subject remembers later than dinner, the dose of that day should be omitted, and the subject 
should take his dose before breakfast on the next day .
The capsules must be swallowed whole and not chewed, divided, dissolved or crushed. After 
having taken the study  medication, subjects should try not to eat or drink for at least 30 minutes. 
This period should be controlled when the subject is in the clinic. When outside the clinic, 
violation of this effort (including drug intake in fasting condition) will not be considered a 
protocol vi olation.
The first dose will be taken in fasting condition on Day 2of the double -blind phase when the 
subject is at home. 
The subjects will take the study  medication with them at each study  visit and will take study  
medication -from the blisters dispens ed at the previous study  visit -at the site in fasting 
condition after completion of predose study  assessments and blood collections. Dosing will be 
witnessed by  the study  staff .
The dose of the stud y medication is:
10 mg JNJ -67953964: 2 capsules of 5 mg JNJ -67953964 
Placebo: 2 placebo capsules.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
19
Approved , Date: 28 August 2019Study  medication dose may be adjusted to 5 mg QDbased on the results of a blinded review of 
the safet y data by the study  responsible physician (SRP) or by an unblinded review by the Data 
Review Committee (DRC ) or a physician who is not a member of the study  team (See 
Section 7.1). When a dose reduction has been decided on, this will only apply to new subjects in 
study  and the dose of study  medication will be:
5 mg JNJ -67953964: 1 capsule of 5 mg JNJ -67953964 
Placebo: 1 placebo capsule.
EVALUATIONS OF EFFICACY
Clinician rate dmeasures for d epression
Montgomery –Åsberg Depression Rating Scale (MADRS )
Clinical Global Impression scale -Severity of Illness (CGI-S)
Patient rated measures for d epression
Symptoms of Major Depressive Disorder Scale (SMDDS )
The Self -Assessment of Treatment Experience (SATE) 
Patient rated measure for a nhedonia
Snaith–Hamilton Pleasure Scale (SHAPS )
Clinician rated measures for anxiety
Structured Interview Guide for the Hamilton Anxiety scale (SIGH -A)
HAM -A6. The HAM -A6 is a 6 -item subscale derived from the original HAM -A.
Patient rated measure for c ognition
Cognitive and Physical F unctioning Questionnaire (CPFQ).
PHARMACOKINETIC EVALUATIONS
Venous blood samples of 6mL will be collected for determination of JNJ-67953964 plasma 
concentrations and metabolites when required specified in the TES. In addition, some samples 
may be used to measure plasma concentrations of the SSRI /SNRI used by  the subject.
A PK blood sample will be collected at the same time as the blood samples for biomarkers when 
indicated in the TES. 
BIOMARKER EVALUATIONS 
During the study , blood and saliva will be collected for the assessment of biomarkers at the time 
points indicated in the TES.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
20
Approved , Date: 28 August 2019In blood and/or saliva , biomarkers related to the HPA axis activation including but not limited to
adrenocorticotropic hormone (ACTH) and cortisol, neurotropic factors, inflammation and 
metabolic factors may be investigated.
Biomarker essay s may be added or deleted based on scientific information or technical 
innovations under the condition that the total volume of blood collected will not be increased. 
The biomarker evaluations will include blood collection for genetic /pharmacogenomic and 
epigenetic testing to characterize gene expression in relation MDD symptoms and biomarker 
results. Participation in the genetic/pharmacogenomic part of this study  is mandatory .
SAFETY EVALUATIONS
The collection of AEs and concomitant medications will start after the ICFhas been signed and 
will continue until the final visit. AEs of special interest include pruritus and gastrointestinal (GI)
complaints such as dy spepsia, abdominal pain, constipation, or diarrhea . Ifthese are of moderate 
or severe intensity  (sufficient discomfort to cause interference with normal activity  and/or 
warrant treatment), investigators should provide a narrative to describe th e event. At a minimum, 
a description of the event (including any known precipitating circumstances), the time relative to 
dose administration, the duration, concomitant treatment, and outcome of the event will be 
reported. 
Apart from this,the following safety assessments will be done: physical examination, 
neurological examination, body  weight, vital signs (including temperature), 12-lead 
electrocardiogram (ECG ), urine drug testing, pregnancy  testing (female subjects only), clinical 
labs (hematology , chem istry panel, gastric mucosa integrit ypanel ) andurinaly sis. At screening 
only:serology , thyroid function , and HbA1c (diabetic subjects only ).
Additional blood and urine samples may be taken or vital signs and ECGs recorded at the 
discretion of the investigators.   
Additionally , emergence of suicidal ideation will be assessed using the Colombia suicide 
severit y rating scale (C-SSRS )atscreening, and during each study visit. Arizona Sexual 
Experiences (ASEX) will be used to document sexual dy sfunction and the Karolinska Sleepiness 
Scale (KSS) will be used to document sleepiness/sedation.
STATISTICAL METHODS
Sample size determination
The sample size for the study is determined based on the ass umption of a treatment effect size of 
0.45in the mean change from baseline (Visit 2) in MADRS total score between JNJ-67953964
treatment group and placebo. The assumed effect size is based on review of the literature looking 
at the adjunctive treatment with ALKS 5461 , a combination of buprenorphine (partial -opioid 
receptor agonist and KOR antagonist) and samidorphan (a potent -opioid receptor antagonist )
inMDD patients with an inadequate response to one or two courses of an antidepressant (Fava 
2016 and Enrich 2015).
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
21
Approved , Date: 28 August 2019Using the data from the same studies, an estimate of 11for standard deviation in the change in 
MADRS total score from baseline was made. Detection of 0.45 effect size with a power of 90% 
at an overall 1-sided significance level of 0.20, requires 45 subje cts in each treatment group 
(90subjects i n total).
When adjusted for a drop-out rate of approximately  5% of subjects during the treatment period, 
the required number of subjects to be randomized is 96. To achieve this, the estimated number of 
subjects to enter the lead inperiod is 142, after adjusting for an estimated placebo response rate 
of 25% and drop -out rate of 10% during the lead -in period. 
A blinded sample size re -estimation is anticipated with 180 as the maximal number of subj ects to 
be enrolled in the trial.
Efficacy analysis
Primary
Primary  efficacy  analyses will be based on the intention -to-treat analysis set from enriched
population (eITT) which consists of randomized lead-in placebo non -responders receiving at
least one dose of study medication and having at least one post-treatment baseline efficacy  
measurement.
The JNJ-67953964 treatment group will be compared with placebo using the primary  efficacy
endpoint: change from treatment baseline in MADRS score during the treatment period. The 
comparison will be performed by means of a mixed- effects model forrepeated measures 
(MMRM), with time, treatment (placebo, JNJ-67953964 ) and time-by-treatment interaction as 
factors andbaseline total MADRS score as a continuou s covariate. Other covariates of interest 
may be included in the MMRM model. The treatment -placebo differences will be obtained using 
the appropriate contrast in the MMRM models at the 6 -week endpoint.
Descriptive statistics for actual values and changes f rom baseline for MADRS Score at each time 
point of the double -blind treatment phase will beprovided by treatment group using both: eITT 
and fITT analysis sets. Mean differences between the treatments with corresponding confidence 
intervals (CIs) will be r eported.
Frequency  tables for response and remission of depressive symptoms (derived from the 
MADRS ) will be provided by treatment group at each time point of the double -blind treatment 
phase using both: eITT and fITT analysis sets. Chi square test to testthe overall differences 
between the treatment groups will be performed .
Secondary
Evaluation of Anhedonia
Change from treatment baseline in SHAPS score during the treatment period will be analyzed 
with the same MMRM model as primary  efficacy  variable (MADRS) using both: eITT and fITT 
analysis sets. The JNJ-67953964 treatment group will be compared with placebo using the 
appropriate cont rast in the MMRM model at the 6-week endpoint.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
22
Approved , Date: 28 August 2019The effect of JNJ-67953964 on depression symptoms across different baseline levels of 
anhedonia will be explored. Descriptive statistics for actual values and changes from baseline in 
MADRS Score within different anhedonia levels (no anhedonia, low level of anhedonia and high 
level of anhedonia; cutoff values will be provided in Statistical Analy sis Plan) will be presented 
by treatment group using both: eI TT and fITT analy sis set.
Evaluation of Depression
Descriptive statistics for actual values and chan ges from baseline for CGI-S and SMDDS (total) 
scores at each time point of the double -blind treatment phase will be provided by treatment 
group using both: eITT and fITT analysis sets. In addition, for CGI, frequency  tables will be 
provided b y treatment an d time -point.
Evaluation of Anxiety
Descriptive statistics for actual values and changes from baseline for SIGH-A total score as well 
as HAM -A6score at each time point of the double -blind treatment phase will be provided by 
treatment group using both: eITT and fITT analy sis sets. Mean differences between the 
treatments with corresponding confidence intervals (CI s) will be reported.
Exploratory
Cognitive Functioning Analysis
The actual values of CPFQ and changes from baseline will be summarized at each scheduled 
time p oint by  treatment. These analy ses will be performed on bo th: eITT and fITT analy sis sets .
Biomarker Analyses
Biomarker levels will be tabulated for each time point and summary  statistics will be calculated. 
Posttreatment changes in biomarker levels will be assessed by treatment group. Anal ysis of 
variance (ANOVA) and t-test will be used to assess differences across groups and time points. 
Correlations between biomarker levels and clinical endpoints will be evaluated.
All biomarker data obtained from this study  may also be included in an ongoing cross- study 
analysis to investigate the relationship between depression severit y, phenotypes, and biomarkers.
Pharmacokinetic Analyses
Plasma concentrations for JNJ-67953964 will be analyzed. Based on the individual plasma 
concentration -time data from all subjects, exposure parameters of JNJ-67953964 will be derived 
using population PK (popPK) modeling. Potential baseline covariates (eg, demographics such as 
age, sex and race, body  weight, laboratory  variables such as creatinine clearance, etc.) may be 
included in the models, if relevant. The following exposure parameters will be derived using 
Bayesian feedback analysis: AUC 24hand C0h.Results will be tabulated and summary  statistics 
will be generated. Individual plasma concentrations per study  visit will be listed. 
Pharmacokinetic and pharmacod ynamic relationship will be explored, if feasible. Details of 
population PK analy sis and PK/PD analy sis will be given in ananalysis plan and the results will 
be pr esented in a separate report.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
23
Approved , Date: 28 August 2019Safety analyses
Statistical analy sis of the safet y data will be done by the sponsor or under the authorit y of the 
sponsor. Specific details will be provided in the Statistical Analy sis Plan.
All subjects receiving at least one dose of study  drug will be included in the safet y analysis. 
AEs will be coded using the current version of Medical Dictionary  for Regulatory  Activities 
(MedDRA ). All reported AEs with onset during the double-blind treatment phase (i.e., treatment-
emergen t adverse events [TEAEs] , and AEs that have worsened since baseline) will be included 
in the anal ysis. Serious adverse events (SAEs) will be summarized separately .
Laboratory  data will be summarized by type of laboratory  testand treatment . Descriptive 
statistics will be calculated for each laboratory  analyte at baseline and at each scheduled time 
point, and for changes from baseline. The percentage of subjects with values out of normal
limits will be summarized. Data listings of subjects with at least oneabnormal value will be 
provided.
Descriptive statistics of pulse, supine blood pressure (systolic and diastolic), temperature and 
body  weight values and changes from baseline will be summarized at each scheduled time point 
by treatment. The percentage of subjects with values beyond clinically  important limits will be 
summarized. Data listings of subjects with at least one abnormal value will be provided.
Heart rate and ECG intervals (RR, PR, QRS and QT), corrected QT intervals according to 
Bazett’s formula (QTcB) and Fridericia’s formula (QTcF) and changes from baseline will be 
summarized at each scheduled time point using descriptive statistics. The number and percentage 
of subjects with at least one occurrence of a treatment -emergent potentially  clinicall y important 
QTc measurement (QTc value >450, >480, or >500 msec ) or with a change from baseline in 
QTc>30 msec or 60 msec, will be summarized by  treatment group. Data listings of subjects with 
any potentiall y clinically  important values or with a change from baseline in QTc will be 
provided.
Subjects with abnormal physical and neurological examination findings will be presented in a 
data listing .
The suicidal ideation and behavior data collected from the C-SSRS will be summarized 
descriptivel y at each scheduled timepoint by treatment group. Data from the subjects with 
suicidal ideation and behavior will be presented in data listing. ASEX and KSS data collected 
will be summarized descriptively  at each scheduled timepoint by treatment group. All the data 
will be listed.
Interim Analysis 
An interim analy sis may be executed. The procedures for the interim analy sis will be described 
in a separate charter.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
24
Approved , Date: 28 August 2019A blinded data review for purpose of sample size re-estimation may be performed during the 
study after minimally  50% of the subjects are randomized and have completed Week 6 of the 
double -blind treatment period. Sample size may be re-adjusted if the observed SD substantiall y
deviates from the hypothesized SDor if the lead-in response and dropout rate substantially 
deviate from the assumed values. The maximal number of subjects to be enrolled in the trial will 
not surpass 180.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
25
Approved , Date: 28 August 20191.2. Time and Events Schedule (TES)a
                                                
aThis section has been amended by amendment INT -1and INT -2Phase Scr een ing
Visit num ber 1 2 3 4 5 6 7 8 9 1011 or EWb
Week  (end of) -5 to 0 0 1 2 3 4 6 7 8 9 11
Study Day -35 to -2 1 8 15 22 29 43 50 57 64 78
Screen ing
Informed consent X
Medical History and study participation status X
Demographic inform ation X
Prestudy therapy by ATRQ X
Serology, thyroid function, HbA1c (only in 
diabeti c subjects)X
MINI 7.0 in terview X
Down load and install app(s) at screening and 
baselinemX X
Inclusion/exclusion criteria X X
Safety assessments
Physical and neur ologi cal examination X X X X
Height X
Weight X X X
Urine drug and alcohol  breath  test X X
Pregnancy testcX X X X
12-Lead ECG X X X X X X X
Vital signs (supine BP, p ulse) X X X X X X X X X X X
Tympanic or oral temperature X X X X X X X
ASEX X X X X X X
KSS X X X X X X
Suicidality by C-SSRS X X X X X X X X X X X
Dosing
Random ization X X X X
Supply new study medication X X X X X X X X X
Oral dose study medicationd
Meal after dosing Xl
Xl
Xl
Xl
Xl
Xl
Xl
Xl
Xl
Xl
Blood and urine collect ion
Clinical laboratory Tests: hematology,  serum 
chem istry, and ur inalysisXf
Xf
Xg
Xg
Xg
Gastric mucosa panel Xf
Xg
Xg
Supply subject with tubes for saliva collection X X X
Saliva collection for cortisol Xh
Xh
Xh
Blood sample for p harmacokinetics X Xi
Xi
Xi
Xi
Blood sample for b iomarkers and (epi)genetics Xf
Xg
Xg
Clinical Assessments
Structured Interview Guide MAD RS XjX X X X X X X X X X
Structured Interview Guide SIGH-A X X X X X X X X X X
CGI-S X X X X X X X X X X
SMDDS X X X X X
CPFQ X X X X X
SHA PS X X X X X X X X X X X
SATEk
Ong oing subject review
Asse ssment of subject study engagementk
X
Adver se events
Concom itant medicationDouble-blind tr eatment phas ea
Day 2 until and including Day 78e
once weekly while at home
up to 3 occas ion when at home
conti nuous
conti nuous
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
26
Approved , Date: 28 August 2019EW= early withdrawal
(a) Visits should be conducted ± 3days of the scheduled day (based on Visit 2, not based on previous visit).
(b) If a subject discontinues treatment before the end of the double- blind treatment phase, early withdraw al (EW) 
visit should be completed. 
(c) WOCBP only, serum pregnancy test at screening; urine pregnancy test at the other visits.  
(d) At home: In f asting condition. At clinic visit days: Use blisters dispensed at the previous visit. In fasting 
condition after completion of predose assessments.
(e) When Visit 11 is planned up to 3 days later, continue medication until study visit. 
(f) Collected in fasted condition when possible.
(g) In fasted condition, before dosing in the clinic.
(h) At home: Between 7:00 and 10:00 pm in the evening before the study visit and immediately after aw akening on 
the day of the study visit. 
(i) Before and 2 hours after dosing in the clinic.
(j) During the first screening visit and by telephone up to 4 days before Visit 2, if 2 w eeks or more elapse betw een 
the MADRS rating at screening and Visit 2. 
(k) Using Q1.6 -app on subjects' smartphone. 
(l) Breakfast, lunch or dinner after drug intake at site.
(m) Download and install Q.16 app and Aicure at screening. At screening check for Aicure if the phone is 
compatible. If the subject has an older phone, reinstall on provided phone at Visit 2.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
27
Approved , Date: 28 August 20192. INTRODUCTION
JNJ-67953964, previously known as Cerecor (CERC )-501 and LY2456302, is a small molecule, 
high-affinity , selective kappa opioid receptor (KOR) antagonist. JN J-67953964 is orally  bioavailable 
and suitable for once -daily (QD) administration. 
KORs and their native ligand dynorphin are localized in areas of the brain that effect reward and 
stress and may play a key role in mood, stress, and addictive disorders. Chronic stress, substance 
abuse, and acute withdrawal lead to increased dynorphin expression, activating KORs and 
subsequent downstream signaling pathway s to inhibit mesolimbic dopamine surge, contributing to 
negative affective states. The behavioral phar macology of KOR antagonism has been tested in animal 
models of anhedonia, depression, and anxiety and found to have meaningful effects that may 
translate to therapeutic benefit in humans. KOR antagonists may be effective for the treatment of 
patients with mood disorders, perhaps by modulating the negative affective state associated with 
stress response.
Only  about 50% of patients with major depressive disorder (MDD) show a meaningful response 
(>50% improvement to a first line antidepressant treatment ), leaving many  patients with 
substantial persistent impairment . Therapeutic strategies such as switching antidepressants and 
using adjuvant drug treatments can improve response, however almost 40% of patients remain 
symptomatic and fail to achieve full remission . Recently , Alkermes ( ALKS ) 5461 , a combination 
of buprenorphine, which is a partial -opioid receptor agonist and KOR antagonist , and 
samidorphan, a potent -opioid receptor antagonist , has been tested in Phase 2 trials in subjects 
with MDD who have had o nly a partial response to treatment with a selective serotonin reuptake 
inhibitor (SSRI) or aserotonin -norepinephrine reuptake inhibitor (SNRI) . Adjunctive treatment 
with ALKS 5461 was associated with greater symptom reduction compared to placebo, 
suggest ing that a KOR antagonist could provide a meaningful clinical benefit for patients being 
treated for MDD. 
For the most comprehensive nonclinical and clinical information regarding JNJ-67953964 , refer 
to the latest version of the Investigator's Brochure (IB) for JNJ-67953964 (Janssen R&D 2018 ).
The term "sponsor" used throughout this document refers to the entities listed in the Contact 
Information page(s), which will be provided as a separate document.
2.1. Study Rationale
Based on non clinical data, the compound is expected to show stress -reduction activit y and 
reduction in anhedonia and,therefore ,may also be expected to be potentially  effective in the 
treatment of MDD. The current study  will be conducted to assess the efficacy , safet y, 
tolerability , pha rmacokinetics (PK) , and pharmacod ynamics (PD) of treatment with 
JNJ-67953964 adjunctive treatment in subjects with MDD who have an inadequate response to 
an SSRI  or SNRI .
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
28
Approved , Date: 28 August 20192.2. Background
2.2.1. Nonclinical Studies
In nonclinical safet y pharmacology  studies with JNJ-67953964 , there were no effects on the 
central or peripheral nervous sy stems or respiratory  functio n in rats given doses up to 800 mg/kg.
In dog, cardiovascular safety  study of single doses up to 1,000 mg/kg, there were no statistically 
significant changes in blood pressure, heart rate, or QT and corrected QT (QTc) by Fridericia’s
method (QTcF) intervals. However, there was an apparent trend for increased QT and QTc 
intervals following 1,000 mg/kg compared to vehicle, which was not statistically  significant .
Toxicology
The toxicity  profile of JNJ-67953964 has been characterized in rat, mouse, dog, rabbit, and 
monkey  through a package of in vitro, safety  pharmacology , repeat -dose toxicity  (up to 2 weeks 
in mice, 6 months in rats and dogs, and 1 week in monkey s), reproductive toxicity , genotoxicity , 
and other toxicity  studies. No adverse effects were observed in dogs at a high dose of 
2,000mg/kg/day .
In the 6-month repeated dose toxicity  study in rats, doses were given at 30, 150 and 500 mg/kg. 
Gastric lesions (non-inflammatory  gastropath y that is mainly  characterized by apoptosis of the 
parietal cells [acid producing cells])were mainly  present from 150 mg/kg onwards. Since 1 male 
in the low dose also showed gastric lesions, a NOAEL dose could not be established in this 
6-month repeated dose study . These lesions are regarded as compound related and were also 
present in mice. The effects are reversible. Mechanistic studies are initiated to find the 
mechanism behind these lesions and to look for the relevan ce to men. In addition, a GLP 
3-month repeated dose toxicity  study in rats is planned with lower doses in order to set a 
NOAEL.
Dose levels of 2,000 mg/kg /day in mice, ≥800 mg/kg/day  in rats, or ≥200 mg/kg/day  in rabbits 
exceeded the maximum tolerated dose (MTD) resulting in adverse clinical signs, decreased food 
consumption and body  weight, and mortalit y/euthanasia. Convulsions were also noted after 1 or 
2doses of JNJ-67953964 at 2,000 mg/kg (mice), 1,500 mg/kg (rats), or 1,000 mg/kg (rabbits). 
JNJ-67953964 was not genotoxic in a standard battery  of genotoxicity  tests.
In the 6-month studies, the dose level of 30mg/kg/day  in rats and 2,000 mg/kg/day  in dogs, 
corresponded to animal -to-human exposure multiples (AUC24h basis) of 4-fold and 10-fold in 
male and female rats, respectivel y, and >800 -fold in dogs, based on a 10- mg clinical dose.
These nonclinical toxicology  results demonstrate an acceptable safet y profile for the proposed 
clinical study  of JNJ -67953964.
Pharmacokinetics and Metabolism in Anima ls
Single -dose PK of JNJ-67953964 was determined in rats and dogs. Intravenous clearance and 
oral bioavailability  were 89.3 mL /min/kg and 25%, respectivel y, in rats, and 20.3 mL /min/kg and 
88%, respectively , in dogs.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
29
Approved , Date: 28 August 2019Rats were given daily  oral doses of 30, 150, or 500 mg/kg of JNJ -67953964 for 6 months. In rats, 
AUC 0-24hrincreased with dose and trended higher (up to approximately  3-fold at 30 and 
150mg/kg) in females than in males. Exposure (AUC from 0 to time t [AUC 0-t]) in rabbits was 
greater than propo rtional to dose and increased approximately  2-fold at the mid-and high-dose 
levels following multiple dosing compared with a single dose. In dogs, AUC 0-24hrwas less than 
proportional to dose and increased approximately 3-fold after multiple dosing for 3 months (no 
further increase was noted from 3 to 6 months of dosing). In monkey s, the mean AUC 0-24hr
increased with dose from 100 to 600 mg/kg following a single dose and 300to 1,000 mg/kg 
following 5 doses.
Metabolites were characterized in rat, guinea pig, dog, and monkey  hepatocy tes in addition to 
human. The major metabolites of JNJ-67953964 in hepatocy tes were carboxamide hydroly sis, 
sequential N-deamina tion and oxidation to LSN2559342, and sequential oxidations of the 
parent. These major metabolites were also observed as circulating metabolites in rat and dog 
from toxicokinetic studies and in monkey  from high dose exposure studies.
2.2.2. Clinical Studies
Thre e phase -1 clinical pharmacology  studies, I2Z-MC-LAFA (referred as “LAFA ”), I2Z-MC-
LAFB(referred as “ LAFB ”), and I2Z-MC- LAFC (referred as “ LAFC ”), have been completed. 
Four studies to investigate the efficacy  of JNJ -67953964 have been executed or are in progress:
In arecent completed clinical study (Referred as Study  D), 70 subjects (40 healthy 
volunteers, 23 subjects diagnosed with cocaine dependence in early abstinence and 7 drug-
free former cocaine -dependent subjects) have been dosed for 4 days with 10 mg 
JNJ-67953964 (Reed 2018 ).  
Astudy  in subjects who were cigarette smokers not seeking treatment for tobacco use 
disorder (study  C501 -201, referred as Study  E)in 71subjects has been completed . Subjects 
received 15 mg JNJ -67953964 and placebo over 7 days each in a cross -over design. 
A study on Smoking Cessation (C501 -202,referred as Study  F) has been stopped for 
business reasons. This is a double -blind, placebo -controlled, two-period, crossover design 
study  examining 10 mg/day JNJ -67953964 compared to placebo in subjects who are cigarette 
smokers currentl y not seeking tre atment for tobacco use disorder and who currentl y smoke at 
least 10 cigarettes per day. Subjects received 10 mg JNJ 67953964 and placebo over 7 days 
each in a cross -over design. 13 subjects completed the study . Data are pending.
A phase 2a study  in 88 subjects with mood and anxiety  disorders and anhedonia who are 
treated with 10 mg JNJ-67953964 or placebo over 8 weeks has been recentl y completed
(Referred as Study  G).Data analysis is in progress . However , safet y listings have been made 
available .
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
30
Approved , Date: 28 August 2019Pharmacokinetics, Product Metabolism, and Pharmacodynamics
After single -dose administration of JNJ-67953964 in Study  LAFA, PK analy sis revealed rapid 
absorption with peak plasma concentrations typically  occurring at 1.5 to 2 hours postdose, 
followed by a bi-exponential disposition. Overall, dose-proportional incre ases in exposure were 
observed with increasing dose.
After multiple -dose administration of JNJ-67953964 in Study  LAFB, exposure of JNJ-67953964 
increased with increasing multiple doses of JNJ-67953964 and reached stead y-state within 7 to 
8days of once -daily (QD) dosing.
The accumulation ratios for Cmaxand AUC were around 1.5 and 2, respectively , indicating that 
some moderate accumulation would be expected on multiple dosing. The mean Cmax(and 
coefficient of variation percentage [CV%] after 10mg QD (the maximum dose assessed in this 
LAFB -study ) was 34.4 ng/mL (37%). This is well below the maximum desired mean exposure 
(MDE) of 180 ng/mL, which is 30-fold below the NOAEL for convulsive or potentially  
pre-convulsive activity  from the rabbit pilot embryo/fetal (EF) development study .
No appreciable interactions between steady  state JNJ-67953964 plasma levels and single dose 
ethanol were detected.
Using the KOR tracer [11C]-JNJ-67953964 and positron emission tomography  (PET), data from 
Study  LAFC showe d that single oral doses of 0.5 mg up to 25 mg JNJ-67953964 penetrated the 
blood -brain barrier, led to specific target engagement, and blocked, significantly  and in a dose-
related manner, KORs in the brain.
Approximately  2.5 hours postdose (“peak scan”), brain KORs were almost saturated at a single 
dose of 10mg or more. Sustained and substantial target engagement was observed for at least 
22.5 hours.
Safety and Tolerability
JNJ-67953964 was well tolerated after single -dose administration up to 60 mg in Study LAFA, 
multiple -dose administration up to 35 mg in Study  LAFB, and single-dose administration up to 
25mg in Study  LAFC. There were no deaths or serious adverse events (SAEs) reported in any 
study . One subject in Study LAFA was discontinued due to a mild treatment -related adverse 
event (AE) of 5-beat ventricular tachy cardia; no subjects were discontinued due to AEs in Study 
LAFB and Study  LAFC.
In Study  LAFA, 126 AEs were reported by 20 of 32 subjects; 18 AEs were considered by the 
investigator to be related to JNJ-67953964, with the most common (occurring >1 incidence) in 
JNJ-67953964 -treated subjects being headache (5 events), diarrhea (3events), nausea (2events), 
and anxiety  (2 events). 
In Study  LAFB, 52 AEs were reported by 19 of 37 subjects; 22 AEs were considered by the 
investigator to be related to JNJ-67953964, with the most common (occurring >1 incidence) in 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
31
Approved , Date: 28 August 2019JNJ-67953964 -treated subjects being dyspepsia (5events), pruritus generalized (3 events), 
headache (2 events), diarrhea (2 events), and abdominal pain (2 events).
In Study LAFC, 21 AEs were reported by 11 of 13 subjects; none of the AEs wasconsidered by 
the investigator to be related to JNJ -67953964. Most AEs in these 3 Phase 1 studies were of mild 
to moderate severity .
In the 3 Phase 1 studies, there were no overall trends in mean clinical laboratory  data. Six
subjects experienced transient increases in liver function enzy mes: 
Study  LAFA: 1 subject experienced ALT and AST >2 X ULN after a single dose of 4 mg, 
not considered to be relate d to study  drug. Both AST and ALT returned to normal values 
within 4 day s.
Study  LAFB: 5subjects experienced increases in AST and/or ALT: 2 on placebo and 3 on 
10mg JNJ-67953964 . All subjects had normal values at the end of the 14-day treatment 
period with study  drug, which had been administered in combination with alcohol. All
elevations were reported 2 weeks after the last dose of study  drug and returned to normal 
within up to 17days. Most of the elevations of AST and/or ALT remained below 2 x ULN. 
Only one subject treated with JNJ-67953964 experienced ALT 6.8 x ULN and one subject 
treated with placebo experienced AST 3.2 x UL N.
No clinically  significant changes were observed in, prolactin, and luteinizing hormone. There 
were no clinicall y significant c hanges in vital signs and electrocardiograms (ECGs), including no 
evidence of QTc prolongation. In Study  LAFB, cortisol ratios (concentrations normalized to 
predose) declined less on Day 1 in subjects who received 10 mg or 35 mg doses, 2 to 8 hours 
after dose compared to placebo controls (n=2 for 10 mg, n=6 for 35 mg).  This was not seen on 
Day 14.  There was no effect on adrenocorticotropic hormone (ACTH). 
In Study  D, the compound was well tolerated. The most common AEs were transient mild 
pruritus, ‘modestly  positive’ mood changes, somnolence and abdominal discomfort. 
A total of 71 subjects were randomized in study E, of which 62 (87%) received at least one dose 
of 15 mg JNJ-67953964 and 67 (94%) received at least one dose of placebo. JNJ-67953964 was 
generall y well tolerated with AEs that were mostly  considered mild in severity . There were no 
discontinuations due to AEs, and there were no SAEs. Fifteen (21%) subjects discontinued the 
study , 13 subjects (18%) discontinued in Period 1 and 2 subjects (3%) discontinued in Period 2 
of the study . Two subjects on placebo discontinued due to AE.
In study  G,the AE’s that showed an incidence greater than 5% and were at least double that 
observed in the placebo group were prurit us, anxiety , rash, constipation, tinnitus, blurred vision, 
abnormal coordination, disturbance in attention, postural dizziness, non-cardiac chest pain and 
dysuria.
No SAEs have been reported from an y of the clinical s tudies.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
32
Approved , Date: 28 August 2019Based on safet y data from the 3 Phase 1 clinical studies and the studies D to G , no potential risks 
related to JNJ-67953964 administration have been identified. Only  a limited number of AEs 
observed in the single -dose and multi- dose PK studies, Study  LAFA and Study  LAFB, were 
considered by the investigator to be related to JNJ-67953964. Additionally , there were no 
clinically  significant changes in vital signs or ECGs in the studies .
An update of safet y data from ongoing studies will be presented in the IB or addenda to the IB.
2.3. Benefit/Risk Assessmenta
To date, 3Phase 1 clinical studies have been completed and 4efficacy studies have been 
completed or are ongoing (See Section 2.2.2).
In total, 73 health y subjects have been exposed to single or multiple doses of JNJ-67953964 in 
the 3 completed (LAFA, LAFB, and LAFC) clinical pharmacology  studies . No significant safety  
concerns were encountered in Study  LAFA after single -dose administration of JNJ-67953964 up 
to 60 mg, in Study  LAFB after multiple -dose administration of JNJ-67953964 up to 35 mg, and 
in Study  LAFC after single -dose administration of JNJ -67953964 up to 25 m g.
In Study G,recruitment of study  subjects has been completed. In total 45subjects have been 
dosed with 10 mg JNJ-67953964 over 8 weeks. No SAE shave been reported in this study  up to 
now.
The primary  objective of this study  is to investigate the efficacy  of JNJ-67953964 as an 
adjunctive therap y in subjects with MDD. Subjects will receive double -blind treatment for a 
period of 11weeks during which active study medication (JNJ-67953964 ) or placebo will be 
administered for 6 weeks. During the other days during the double -blind treatment period, 
subject will receive placebo. Subject smay not benefit from the study  in terms of long term 
improvement of their symptoms. However , subjects with poor response to their current treatment
may benefit from the e xtensive medical review and disease follow -up during the study . 
Additionally , the safet y and tolerability  data so far accumulated for JNJ-67953964 in both 
healthy  subjects and subjects with MDD were generall y acceptable based on a thorough review 
of the safety information from completed and ongoing clinical studies. No death or SAEs have 
been reported after subjects received JNJ-67953964 . The most commonly  reported treatment -
emergent adverse events (TEAEs )in JNJ-67953964 -treated subjects were dyspepsia, p ruritus 
generalized, headache, diarrhea, and abdominal pain. 
The antidepressant effect of JNJ-67953964 has not been established yet, however in a proof -of-
mechanism study , ALKS 5461 , a combination of buprenorphine, which is a partial -opioid 
receptor agonist and KOR antagonist , and samidorphan, a potent -opioid receptor antagonist , 
showed a signal of efficacy  in MDD subject when given as adjunctive therapy .
                                                
aThis section has been amended by amendment INT -2.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
33
Approved , Date: 28 August 2019To ensure safe use of the study  drug, besides routine safety  monitoring and subject management,
this protocol also includes specific risk mitigation strategies such as paying special attention to 
clinically  significant AEs that are known to have been reported in this drug (e.g., assess ment of
the status of stomach mucosa) ; and reducing suicidality  risk inherent in the underl ying 
depression by excluding high risk subjects (Section 5.3, Exclusion Criteria) and performing the 
Colombia suicide severity  rating scale (C- SSRS )at every  site visit (Section 8.4.5 , Safety 
Evaluations/C- SSRS).
The risk/benefit of JNJ-67953964 is positive and the currentl y available safety  and efficacy  data 
support the proposed clinical trial 67953964 MDD2001 to investigate efficacy  of JNJ-67953964
after 42days of QDdosing in subjects suffering from MDD.
More detailed information about the known and expected benefits and risks ofJNJ-67953964
may be found in the IB for JNJ-67953964 (Janssen R&D 2019).
3. OBJECTIVE S 
OBJECTIVES
Primary Objective
The primary  objective of this study  is to evaluate the efficacy  of JNJ-67953964 compared to 
placebo when administered as adjunctiv e treatment in subjects with MDD partiall y responsive to 
SSRI /SNRI treatment in terms of reduction of symptoms of depression, as assessed by the 
change from baseline on the Montgomery  Asberg Depression Rating Scale (MADRS) in non-
responders during the placebo lead -in period.
Secondary Objectives
The secondary  objectives of this study  are:
To evaluate the efficacy  of JNJ-67953964 compared to placebo when administered as 
adjunctive treatment in subjects with MDD partially  responsive to SSRI /SNRI  treatment in 
terms of reduction of symptoms of depression, as assessed by the change from baseline on 
the Montgomery  Asberg Depression Rating Scale (MADRS) in both responders and non-
responders during the placebo lead -in period.
To investigate the overall safety  and tolerability  of treatment with adjunctive JNJ-67953964
in subjects with MDD when used in combination with a SSRI  or SNRI .
To investigate the effect of JNJ-67953964 versus placebo on depression related anhedonia 
as assessed b y the Snaith -Hamilton Pleasure Scale (SHAPS).
To investigate the effect of JNJ-67953964 on symptoms of depression using the Clinical 
Global Impression- Severity  (CGI-S), the patient reported Symptoms of Major Depressive 
Disorder Scale (SMDDS) and the self -assessment of treatment experience (SATE). 
To investigate the effect of JNJ-67953964 on symptoms of anxiety  using the Hamilton 
Anxiety  Scale ( HAM -A) and on core s ymptoms of anxiety using the HAM -A6subscale .
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
34
Approved , Date: 28 August 2019To assess the plasma PK of JNJ-67953964 in subjects with MDD and explore its 
relationship with efficacy and safet y parameters.
Exploratory Objectives
To explore the effect of JNJ-67953964 on aspects of cognitive and executive function using 
the Cognitive and Ph ysical Functioning Questionnaire (CPFQ ).
To explore mood -related biomarkers (including but not limited to growth factors, 
hypothalamic –pituitary –adrenal [HPA] axis markers, immune system activation, metabolic 
markers) and genetic/epigenetic variation that may be related to clinical response, 
nonresponse, or safety and tolerability parameters of JNJ -67953964.
Hypothesis
The primary  hypothesis is that 6 -weeks of adjunctive treatment with JNJ -67953964 is superior to 
placebo in improving symptoms of depression, as measured by the change from baseli ne in the 
MADRS , in subjects with MDD.
4. STUDY DESIGN
4.1. Over allDesigna
This will be a multi -center, placebo -controlled, randomized, double -blind study  in subjects with 
MDD who have had inadequate response to SSRI/SNRI treatment . Approx imately  142 subjects 
will be included in the study .
For each subject, the study  will consist of twophase s: a screening phase of up to 5weeks and a 
double -blind treatment phase lasting 11 weeks.
Subjects with MDD who have had treatment initiated with an SSRI /SNRI  allowed by the 
protocol and have had an inadequate or only  partial response to this treatment will be screened at 
the investigation alsite. Assessments by qualified site personnel including the Mini International 
Neurops ychiatric Interview (MINI), Antidepressant Treatment History  Questionnaire (ATRQ), 
and MADRS will be audio recorded at screening for review of eligibility  of the subject for 
enrollment into the study  by an independent central reviewer contracted by the sponsor. The 
following key inclusion criteria/asse ssments will be reviewed by a central independent reviewer: 
the clinical history  of MDD, SSRI /SNRI treatment of adequate dose and duration for the current 
episode of depression, and current symptom severity  on the MADRS. In case of discrepancy  of 
central reviewer and local rater, the central reviewer will discuss the discrepancy  with the local 
rater. If the discrepancy  persists, the local rater will overrule central review.
If 2 weeks or more elapse between the MADRS rating at screening and Visit 2, the local rater 
will complete the MADRS again by a telephone interview up to 4 days before Visit 2 to 
determine whether the subject still meets the thresholds for inclusion. 
                                                
aThis section has been amended by amendment INT -1and INT -2
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
35
Approved , Date: 28 August 2019Subjects who meet the inclusion and exclusion criteria and are enrolled will be maintain ed on the 
SSRI /SNRI without change throughout the study  to determine whether adjunctive treatment with 
JNJ-67953964 can reduce symptoms of MDD.
The treatment phase of the trial will consist of 3 periods. Aplacebo lead-in period of concealed 
duration , after which subjects will enter thedouble -blind treatment period when they will be 
randomly  assigned to 10 mg JNJ-67953964 or continue placebo for 6weeks. Subjects who 
complete the treatment period, will then enter the withdrawal period and be treated with placebo 
for the remaining time of the treatment phase of the study . The total study  duration for each 
subject will be approximately  
16 w eeks. There will be 11 scheduled visits to the clinical research 
center including screening during the study . An overall flow diagram of the study  is shown in 
Figure 2:
Figure 2: Flow diagram  of the study
Eligibility  Screening E xamination
After giving written informed consent, subjects will be screened within 35to 2 days prior to 
Day 1 to ascertain their eligibility  for the study  per the inclusion and exclusion criteria. Upon 
completion of allinformed consent form (ICF)procedures, recording of AEs and concomitant 
medication will start.
The symptoms of depression will be assessed using the (structured interview guide for the) 
MADRS .
Double -blind Treatment Phase
The duration of the double -blind treatment phase will be 11weeks divided into 3 periods.
Subjects will visit the study  center for baseline visits on Day 1.The subject will receive study 
medication after completion of the visit on Day  1. The first dose wi ll be taken at home on Day  2.

JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
36
Approved , Date: 28 August 2019Medication will be dispensed at each study  visit during this double -blind period. All study  
medication will be taken in fasting condition. 
During the double -blind study  phase, the subjects will visit the study  center for out-patient visits 
every  1-2 weeks as indicated in the TES.
Lead -in period
Subjects who successfully  complete the baseline examination visit at the clinical site/unit, will b e 
treated with placebo for the entire duration of the lead-in period . Investigators and subjects will 
be blinded to the exact duration of lead -in period for each subject in the study .
Treatment period
At the end of the lead-in period both placebo lead-in responders and placebo lead-in 
non-responders will be randomized to receive either placebo or 10 mg JNJ-67953964 in a 1:1 
ratio for 6 week s.Investigators and subjects will remain blinded to exact timing of the 
randomization, response criterion and stud y drugtreatment assignment for each subject.
Withdrawal period
Subjects who complete the double -blind treatment period prior to the end of Week 11will enter 
the withdrawal period where they will be treated with placebo for the remaining time of the 
treatm ent phase of the study . Investigators and subjects will be blinded to the exact duration of 
withdrawal period for each subject in the study .
Early withdrawal visit
Subject who prematurely withdraw from the study  are encouraged to complete Visit 11. The 
procedures to be completed during thisvisit are listed in the TES.
4.2. Scientific Rationale for Study  Design
Design aspects, blinding and control
Randomization will be used to minimize bias in the assignment of subjects to treatment groups, 
to increase the likelihood that known and unknown subject attributes (e.g., demographic and 
baseline characteristics) are evenly  balanced across treatment groups, and to enhance the validity 
of statistical comparisons across treatment groups. 
A placebo control will be used to establish the frequency  and magnitude of changes in clinical 
endpoints, both efficacy  and AEs, that may occur in the absence of active treatment. A placebo 
lead-in period will be used to enrich the population in the treatment phase and minimize the
impact of the expectation bias on the part of subjects and investigators on treatment effect. For 
the same reason, the investigators and subjects will be blinded for the definition of 
responder/non-responder during the lead- in period. 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
37
Approved , Date: 28 August 2019The primary  analysis includes only those subjects who do not have a significant decline during 
the placebo run-in period (‘non -responders to placebo treatment’) to increase the sensitivity  to a 
signal of efficacy  of JNJ -67953964 .
Placebo lead-in responders will also be rando mized to active or placebo during the treatment 
period to expose more subjects to JNJ-67953964 and to obtain the estimate of its effect and 
safet y in a more general population.
Withdrawal placebo period will be used to aid the blinding of the lead-in perio d duration and 
exact beginning and ending of the treatment period and will allow exploration of duration of 
effect and for indication of symptoms of withdrawal from treatment with JNJ-67953964 
including re -emergence of sy mptoms.
Blinding of the lead-in and withdrawal period duration, exact point of randomization and 
treatment assignment will be used to reduce potential expectation bias from subjects and 
investigators during evaluation of clinical endpoints as well as AEs.
The double -blind treatment duration is 6 weeks. This is considered an acceptable duration of 
treatment in a study  with antidepressant medication and is supporte d by available preclinical data 
(US FDA 1977).
As there will be a placebo withdrawal period after the active treatment period, there will be no 
separate follow -up period in this study .
Study population
The target population for this study  is male or female subjects with MDD who are at least 
18years old but less than 65 y ears old and have an inadequate response to SSRI /SNRI  treatment.
As ascertainment of the degree of symptom improvement will rely on clinical history , failure to 
show an adequate response will be defined as subjects with MDD who have been treated for a 
current episode with an adequate dose of SSRI /SNRI treatment for at least 6 weeks and manifest 
depressive symptom severity  as measured by  thetotal score MADRS ≥25 . Both men and women 
will be recruited to participate in the study . Inclusion of women of childbearing potential 
(WOCBP) is enabled by the Segment II reproductiv e toxicology  studies. WOCBP will use a 
highl y effective birth control method as outlined in the in/exclusion criteria below. 
Placebo as the control
All subjects will receive placebo in the lead-in period and withdrawal period in addition to 
ongoing treatm ent with an SSRI /SNRI. Subjects will be randomly  assigned to receive placebo or 
JNJ-67953964 for 6consecutive weeks during the double -blind treatment phase. Subjects 
randomized to receive placebo will receive no other active medication for 11 weeks during the 
study  apart from the ongoing SSRI /SNRI. The placebo group controls for any further 
improvement on the existing SSRI /SNRI .
In this study , subjects with at least moderate depression (MADRS total score ≥25) will be 
included. Depression is a serious menta l condition with significant morbidity  and mortalit y. 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
38
Approved , Date: 28 August 2019Therefore, withholding other adjunctive active treatment than the study  medication could result 
in increased s ymptoms of depression with the subject. 
For this reason, stopping criteria have been established in this study  (see Section 7.3) which will 
ensure subjects who experience any harmful worsening of their symptoms are withdrawn from
the study  to permit transfer onto alternative active adjunctive treatment and referral to a 
psychiatrist when required (see Section 6.6).Subjects will be seen weekly  or every  2 weeks so 
any deterioration will be detected quickl y. The weekl y self-assessment of treatment experience 
questions will be linked to an alert s ystem in case of deterioration of the depressive s ymptoms.
Biomarkers of d epression
As part of a more extensive investigational project to identify  MDD related biomarkers, different 
biomarkers in blood will be measured in this study  to explore a relation to the seriousness of 
depressive s ymptoms or exposure to JNJ -67953964 . 
Clinical depression has long been associated with abnormalities of the HPA axis and increased 
ACTH and cortisol levels. In Study  LAFB, cortisol ratios (concentrations normalized to predose) 
declined less on Day 1 in subjects who received 10 mg or 35 mg doses, 2 to 8 hours after dose 
compared to placebo controls (n=2 for 10 mg, n=6 for 35 mg).  This was not seen on Day  14, and 
no increase in ACTH was observed on either day.  In a 4-day open-label study  with 
JNJ-67953 964 in cocaine users, (Reed 2018 ), modest increases in plasma ACTH and serum 
cortisol levels have been noticed. The effect on ACTH and cortisol after 6-week treatment with 
JNJ-67953964 will be investigated in this study.
Negative emotions and stress stimulate the release of interleukin (IL)-6, mainly in the morning 
hours. At the same time, IL-6 has significant neuroendocrine effects including being a strong 
activator of the HPA axis (Alesci 2005). Alesci noticed that that the increased morning IL-6 may  
be a more consistent marker of chronic stress than cortisol. For this reason, both morning IL-6 
and cortisol levels will be measured in this study . 
Disruption of the ky nurenine pathway  also is linked to major depression ( DeWitt 2018 , Umehara 
2017, Sorgdrager 2017) and this pathway  is triggered by  the pr esence of inflammatory  cytokines. 
Cytokines stimulate tryptophan to enter the kynurenine pathway  (thus depleting levels of 
monoamines) where kynurenic acid and quinolinic acid are synthesized in astrocy tes and 
microglia respectivel y, leading to the disrupt ion of glutamatergic function. Understanding the 
role of kynurenine pathway  dysregulation by monitoring concentrations of pathway  metabolites 
may provide additional information related to stress and MDD .
Clinical assessments
Depression
Montgomery –Åsberg Depression Rating Scale (MADRS )
The 10-item clinician -administered MADRS was designed tobeused insubjects with MDD
tomeasure theoverall severit yofdepressive symptoms (Montgomery  1979). The MADRS
scale hasbeen selected astheprimary efficacy measure forthisstudy because it is validated,
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
39
Approved , Date: 28 August 2019reliable, andacceptable toregulatory health authorities as a primary scale to determine efficacy
in major depression. The MADRS be administered using the Structured Interview Guide for the 
MADRS (SI GMA) .
Theprimary efficacy endpoint isthechange intheMADRS total score from baseline
(Day 1)to the end of the 6-week double -blind treatment phase.
Clinical Global Impression – Severity (CGI -S)
The CGI-Sisincluded torate theseverity ofthesubject’s illness atthetime ofassessment,
relative totheclinician’s past experience with subjects who have thesame diagnosis and
improvement with treatment (Gu y 1976 ).
Symptoms of Major Depressive Disorder Scale (SMDDS) 
Apart from assessment of the severity  of depression by  the investigator, also the subjective rating 
of the patient self could contribute to the correct interpretation of the clinical efficacy  of 
JNJ-67953964. The SMDDS ( McCarrier 2016) is a 16-item patient reported outcome (PRO)
measure intended for use as an endpoint in MDD clinical trials to support medical product 
labeling. The SMDDS uses a 7 -day recall period and verbal rating scales.
Self-assessment of treatment experience (SATE)
A one or two -question SATE will be administered weekl y when the subject is at home to follow -
up on improvement or deterioration of depressive symptoms of the subjects over a short period 
of time.
Anhedonia
Snaith -Hamilton Pleasure Scale (SHAPS ) 
Anhedonia is one of the core symptoms of depression. At least mild symptoms of anhedonia are 
present in about 90% of patients suffering from MDD (Snaith 1995). Kappa receptor agonists 
produce dysphoria and anhedonia (see Knoll 2010 for overview). Therefore , it may be expected 
that a kappa antagonist may have a positive effect on these key characteristics of depression. To 
assess a potential effect on anhedonia, the SHAPS (Snaith 1995) will be completed by the 
subject at the timepoints specified in the TES. The SHAPS is a validated scale for the 
measurement of anhedonia. The SHAPS is a subject completed scale in which subjects score 
whether or not they  experience pleasure in performing a list of activities or experiences.
Anxiety
Structured Interview Guide fo r the Hamilton Anxiety scale (SIGH -A)
This original HAM -A scale assesses the severity  of different anxiety -related symptoms 
(Hamilton 1959; Hamilton 1969) with a score range of 0 to 52. It is the most widely  used 
symptom severit y measure for anxiety . Each of the 14items is rated by  the clinician on a 5 -point 
scale ranging from 0 (not present) to 4 (maximum degree) . The HAM -A has an inter-rater 
reliability  correlation of r = .74 (Maier 1988) and the internal consistency  of the measure is 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
40
Approved , Date: 28 August 2019reported to be high with a coefficient alpha of .86 (Clark andDonovan ,1994 ). The symptoms 
can be grouped into two clusters: psy chic anxiety  and somatic anxiety .
As the original HAM -A lacks instructions for administration and clear anchor points for the 
assignment of sever ity ratings, the structured interview guide version will be used in the current 
study  (Shear 2001).  The SIGH-A has been shown to have high inter-rater and test-retest 
reliability  and produced similar but consistently  higher (+ 4.2) scores compared to the original 
HAM -A. Correlation with a self-report measure of overall anxiety  has also been shown to be 
high (Shear 2001). Subscales, such as the HAM -A6which focuses on ps ychic anxiety  and may 
be more sensitive to certain treatments, can be derived from the S IGH-A.
HAM -A6
The HAM -A6is a 6-item subscale derived from the original (HAM -Ascale ) (Hamilton 1959; 
Hamilton 1969). Because the HAM -A, is a multi -dimensional scale, Bech derived a 6-item 
subscale, the HAM -A6, compr ising five psychic anxiety  symptoms: anxious mood, psychic 
tension, fears, intellectual disturbances, and anxious behavior observed at the interview, as well 
as one somatic item, muscular tension (Bech 2007), with a score range of 0to 24. In an analy sis 
of four pooled dose-response trials ingeneralized anxiety  disorder (GAD) , a Mokken analy sis of 
the HAM -A6yielded Loevinger coefficients above 0.40 individually  and combined, indicating 
that unlike the full HAM -A, the HAM -A6subscale is uni-dimensional. Given a fundamental 
requirement for a drug to be considered to have an anxioly tic effect is that it has shown efficacy  
in terms of symptom reduction in the core symptoms of anxiety , and as these symptoms are 
captured by HAM-A6(which is more in accordance with the Diagnostic and Statistical Manual 
of Mental Disorders 4th edition (DSM -IV)criteria for GAD than the full HAM -A), the total 
HAM -A6score is considered a sufficient statistic. 
Effects on Cognition
The Cognitive and Physical Functioning Questionnaire (CPFQ)
The CPFQ (Fava 2009) is a brief self-report scale that provides additional information regarding 
the impact of adjunctive treatment on aspects of cognitive and executive function including 
attention, memory  and mental acuity . Subjects with MDD are often reported to have diffic ulties 
with functioning in this area.
DNA Collection
It is recognized that genetic variation can be an important contributory  factor to interindividual
differences in drug distribution and response and can also serve as a marker for disease
susceptibility  and prognosis. Pharmacogenomic research may help to explain interindividual
variability  in clinical outcomes and may help to identify  population subgroups that respond
differentl y to a drug. The goal of the pharmacogenomic component is to collect deox yribo nucleic 
acid (DNA )to allow the identification of genetic and/or epigenetic factors that may influence 
PK,PD, safet y and/or tolerability  of JNJ-67953964 , and to identify  genetic and epigenetic 
factors associated with neuropsy chiatric/neurodegenerative disorders. Genes and epigenetic 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
41
Approved , Date: 28 August 2019changes in genes known to be in pathway s relevant to depression (HPA axis, inflammation, 
growth factors, monoamine transporters, ion channels, circadian rh ythm) also will be evaluated .
DNA samples may be used to help address emerging issues and to enable the development of
safer, more effective and ultimately  individualized therapies in the future. Pharmacogenomic
data obtained from this study  may also be included in an ongoing cross -study  analysis to
investigate the relationshi p between depression severity and phenot ypes and biomarkers.
Safety assessments
Standard safet y assessments including physical and neurological exami nation, vital signs, 
12-lead ECG, clinical chemistry , hematology , and urinal ysis will be performed. Based on 
observations of gastrointestinal (GI) complaints in previous studies, a panel including
pepsinogen I (PGI), pepsinogen II (PGII), gastrin -17 (G17) and helicobacter IgG antibodies (Hp 
IgG) will be added to the clinical laboratory  test panel to test for stomach mucosa status (Agréus 
2012, Sy rjänen 2017).
Additionally , emergence of suicidal ideation will be assessed using the C-SSRS (Posner 2007). 
The C-SSRS has been used frequentl y in clinical studies and is a standard measure for suicidal 
ideation assessment according to FDA guidance (US FDA 2012).  
As JNJ-67953964 is a central acting compound, central sedating effects like sleepiness may be 
present. The Karolinska Sleepiness Scale (KSS, Akerstedt 1990) is a subject -reported assessment 
used to rate sleepiness on a scale of 1 to 9, ranging from ‘extremel y alert’ (1) to ‘very sleepy , 
great effort to keep awake, fighting sleep’ (9) .
Sexual dysfunction is one of the most common side effects during the treatment of MDD with 
SSRI’s/SNRI ’s. To investigate whether JNJ-67953964 has a further positive or negative effect 
on sexual function, the Arizona Sexual experiences scale (ASEX, McGahuey  2000), wi ll be used 
in this study .
4.2.1. Study -Specific Ethical Design Considerations
Potential participants will be fully  informed of the risks and requirements of the study  and, 
during the study , participants will be given any new information that may  affect their deci sion to 
continue participation. They  will be told that their consent to participate in the study  is voluntary  
and may be withdrawn at any time with no reason given and without penalty  or loss of benefits 
to which they  would otherwise be entitled. Only  participants who are fully  able to understand the 
risks, benefits, and potential AEs of the study , and provide their consent voluntarily  will be 
enrolled.
Although some of the MDD subjects in this study may  benefit from the 6 -week treatment period, 
subjects will not beallowed to continue the treatment after completion of the study . This is 
explained by the limited experience with long term treatment with JNJ-67953964. So, no long-
term benefit is to be expected in this study . Subjects might benefit from the clinical evaluations 
and the information collected as part of this study . The results of the investigation of 
JNJ-67953964 may help future patients.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
42
Approved , Date: 28 August 2019The primary  ethical concern is the use of placebo in addition to the ongoing treatment with an 
SSRI /SNRI over the complete double -blind treatment period of 11weeks in some of the subjects
while symptoms of at least moderate depression are present at screening and baseline visit. The 
rationale for this placebo treatment and the impact on the study  population has been described in 
Section 4.2, ‘Placebo as the control’. Although placebo treatment may not harm most of the 
subject, subjects who may deteriorate during the treatment period (See Section 7.3),will be 
withdrawn from the study  and will be referred to treatment according to local standards. The 
status of the depres sion will be assessed and documented weekl y or every 2 weeks . 
Moreover, the Q1.6 -app will alert the investigator when a subject has indicated that the 
depression is ‘much worse’ or very much worse’ when answering the weekly  SATE . The Q1.6 -
app will be installed on the subjects’ smartphone. The Q-1.6 app will ask questions to the 
subjects as programmed for this study .The same Q1.6 -app will ask the subjects for their 
engagement to the study  at the start and end of the study  and up to 3 times during the study . For 
the investigators and sponsor, this may help to gain insight into the relationship between patient 
engagement and patient retention in the study .
The total blood volume to be collected is considered to bean acceptable amount of blood to be 
collected over this time period from the population in this study  based upon the standard of a 
Red Cross blood donation .
4.3. Justification for Dose
Single doses between 2 and 60 mg have been given to health y subjects in a human single 
ascending dose study  (LAFA -study ). Multiple doses of 2and 35 mg once daily over 14 days 
have been investigated in the LAFB-study . Single doses of 0.5 to 25 mg were given in the 
LAFC -PET study .About 44 subjects received 10 mg JNJ-679539 64 ove r 8 weeks (ongoing 
study ), 70 subjects received 10 mg JNJ-67953964 over 4 days (Reed 2018 )and 62 subjects 
received 15 mgJNJ-67953964 over 7 days(Study  C501-201). In all these studies JNJ-67953964 
was well tolerated.
In the LAFC study  it was demonstrated that approximately  2.5 hours post-dose, brain KOR’s 
were almost saturated at doses of 10 mg or more. At 22.5 hours after dosing the mean receptor 
occupancy  was still72%. 
Based on the pupillometry  data from the multiple -dose Study  LAFB and RO data from Study 
LAFC, a 10-mg dose appears to provide KOR selectivity , while at the same time near maximal 
KOR occupancy . For this reason, 10 mg has been selected as a clinical dose in this POC study . 
4.4. End of Study  Definitiona
Study Completion Definition
A participan t will be considered to have completed the study  if he or she has completed the 
11-weeks double blind treatment and the assessments at Visit 11 of the study . 
                                                
aThe Section has been amended by Amendment INT -3.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
43
Approved , Date: 28 August 2019Participants who prematurely  discontinue study  medication for any reason before completion of 
the double -blind phase will not be considered to have completed the study . Any subject who 
withdraws after receiving the study  drug will have a nearly withdrawal evaluation as described in 
Section 8.2.4 .
End of Study Definition
The end of study  is considered as the last visit for the last participant in the study . The final data 
from the study  site will be sent to the sponsor (or designee) after completion of the final 
participant visit at that study  site, in the time frame specified in the Clinical Trial Agreement.
5. STUDY POPULA TION
5.1. General Considerations 
Approximately  142subjects with MDD currently  being treated with one SSRI /SNRI  will be 
enrolled in this study .
The inclusion and exclusion criteria for enrolling subjects in this study  are described in the 
following sections. If there is a question about the inclusion or exclusion criteria below, the 
investigator should consult with the study responsible physician before entering the subject into 
the study .Exceptional and limited retesting of abnormal screening values that would otherwise 
lead to exclusion may be allowed after discussion and approval by the sponsor during the 
screening phase (to reassess eligibility ). This should only be considered if there is no anticipated 
impact on subject safet y.
Subjects will be enrolled after reading the subject information sheet and signing the ICF
indicating that they understand the purpose of and procedures required for the study  and are 
willing to participate in the study  and comply  with the study  procedures.
5.2. Inclusion Criteriaa
Each potential subject must satisfy  all the following criteria to be enrolled in the study . 
1. Subjects must be men or women, 18 to 64 years of age, inclusive. 
Note: Subjects should be at least 18 years of age or older as per the legal age of consent in 
the jurisdiction in which the study  is taking place .
2.Have a Bod y Mass Index (BMI) between 18 and 35 kg/m2inclusive (BMI = weight/height2). 
3. Subjects must be medically stable based on clinical laboratory  tests, medical history , vital 
signs, and 12-lead ECG performed at screening and baseline (Visit 2) For clinical laboratory 
tests only screening results will be considered. If the results of the serum chemistry  panel, 
hematology , or urinal ysis are outside the normal reference ranges, retesting of an abnormal 
lab value(s) that may lead to exclusion will be allowed once during the screening phase. In 
12-lead ECG, QTcF should be ≤ 450 msec for males or ≤470 msec for females and 
                                                
aThis section has been amended by amendment INT -2 and INT -3.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
44
Approved , Date: 28 August 2019PR-interval < 220msec at screening. A retest of an abnormal ECG value will be allowed 
once in the screening phase. Blood pressure will be the average of 2 measurements.
The subject may be included only if the investigator judges the abnormalities or deviations
from normal to be not clinically  significant or to be appropriate and reasonable for the 
population under study . This determination must be recorded in the subject's source 
docum ents and initialed by  the investigator.
4.Criterion modified by  Amendment INT -3.
4.1.Population specific:
Subjects must have a primary Diagnostic and Statistical Manual of Mental Disorders 
5th edition (DSM -5)diagnosis of MDD. Subjects with a diagnosis of comorbid 
Generalized Anxiety  Disorder (GAD), Social Anxiety  Disorder (SAD) , or Panic 
Disorder may be included, if the investigator considers MDD to be the primary  
diagnosis (confirmed by an independent centra l rater through review of the MINI 
interview obtained by the site at screening). The current episode should be less than 
18months.
Subjects must be currently  treated with an SSRI /SNRI  antidepressant approved in this 
protocol (see Section 6.5) at an adequate dose, as defined by the ATRQ, and for at least 
6continuous weeks but not more than 12 months.
Have a MADRS total score of ≥25 at screening.  If 2 weeks or more elapse between the 
MADRS rating at screening and Visit 2, the local rater will complete the MADRS again 
by a  telephone interview up to 4 days before Visit 2. At this telephone interview, 
MADRS total score should again be ≥25 and should not demonstrate a clinically 
significant chang e (i.e., an improvement of >20%) . 
In a common population of subject suffering from MDD, about 90% have a SHAPS total 
score >20 . The SHAPS total score will initially  not be an inclusion criterion. However, 
after 50 subjects have b eenrandomized, the subjects’ properties will be reviewed. If less 
than 50% of non-responding subjects have a SHAPS total score >20, then for the 
remaining subjects the following inclusion criterion will be added:
Have a SHAPS total score >20 at screening and baseline (Visit 2) 
5.Criterion modified by  Amendment INT -3. 
5.1.Men who are sexually  active with a woman of childbearing potential and have not had a
vasectom y must agree to use a barrier method of birth control i.e., a condom with 
spermicidal foam/gel/film/cream/suppository  for the duration of the study  plus 3 months 
after receiving the last dose of study  drug, and all men must not donate sperm during the 
study  and for 3months after receiving the last dose of study  drug. In addition, their 
female partners should also use an additional method of birth control (which may 
include a hormonal method, an intrauterine device [IUD] or an intrauterine system 
[IUS]) for at least the same duration.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
45
Approved , Date: 28 August 20196.Criterion modified by  Amendment INT -2
6.1. Criterion modified by  Amendment INT -3
6.2 Before randomization, a woman must be either:
Not of childbearing potential defined as: 
oPostmenopausal (amenorrhea for at least 12 months without an alternative medical 
cause. A serum follicle stimulating hormone (FSH) level at screening >40 IU/L  in 
women not using hormonal contraception or hormonal replacement therapy  may  be 
used for confirm ation, however in the absence of 12 months of amenorrhea, a single 
FSH measurement is insufficient) or 
oPermanently  sterilized (including hy sterectom y, bilateral salpingectom y and bilateral 
oophorectom y) or
oOtherwise be incapable of pregnancy .
Of childbear ing potential and practicing a highl y effective method of birth control consistent 
with local regulations regarding the use of birth control methods for subjects participating in 
clinical studies (i.e. one that results in a less than 1% per year failure rate when used 
consistently and correctly ). This may  include:
oEstablished and ongoing use of oral hormonal methods of contraception in 
combination with barrier methods.
oEstablished and ongoing use of patch, injected or implanted hormonal methods of 
contraception.
oPlacement of an IUD or IUS. 
Accepted barrier methods as indicated above include:
condom with spermicidal foam/gel/film/cream/suppository
occlusive cap (diaphragm or cervical/vault caps) with spermicidal 
foam/gel/film/cream/suppository .
Note that a barrier method on its own is not sufficient.
oMale partner sterilization (the vasectomized partner should be the sole partner for that 
subject). 
oTrue abstinence from heterosexual intercourse (when this is in line with the preferred 
and usual li festy le of the subject). 
Women must agree to continue using these methods of contraception through out the 
study  and for at least 3 months after receiving the last dose of study  medication.
Note: If a woman of childbearing potential who is not heterosexual ly active becomes 
active after the start of the study , she must begin a highl y effective method of birth 
control, as described above.   
7.A woman of childbearing potential must have a negative serum pregnancy  test at screening 
and a negative urine pregnancy  test before the first dose. 
8.A woman must agree not to donate eggs (ova, oocy tes) for the purposes of assisted 
reproduction during the study  and for at least 3 months after receiving the last dose of study  
drug.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
46
Approved , Date: 28 August 20199. Subject must be willing and able to adhere to the prohibitions and restrictions specified in 
this protocol.
10.Sign an ICF indicating that they understand the purpose of and procedures required for the 
study  including peripheral biomarkers research (ie, blood) and are willing to participate in the 
study.
5.3. Exclusion Criteriaa
Any potential subject who meets any  of the following criteria will be excluded from participating 
in the study . The subject will be excluded if he or she:
1.Has current signs/s ymptoms of, liver or renal insuf ficiency , hypothy roidism or 
hyperthy roidism (a normal thyroid-stimulating function is required at screening; subjects 
who are on stable treatment with thyroid supplementation with normal thyroid-stimulating  
hormone [TSH ]may participate but subjects with thyroid supplementation for antidepressant 
purposes are not allowed in the study *), significant cardiac disease (including current or past 
history  of atrial fibrillation/flutter), vascular , pulmonary , endocrine, neurologic (including 
epilepsy ), hematologic, inflammat ory (e.g., rheumatoid arthritis, inflammatory  bowel 
disease, Crohn’ s disease) ormetabolic disturbances. Diabetes mellitus (DM) may be allowed 
when the subject is stable (HbA1c less than 7.5% or 58 mmol/mol).
*Subjects with known hypothy roidism who have been on stable treatment for at least
3months prior to screening are required to have TSH and free thy roxine (FT4) obtained. Any 
subject with an elevated TSH should also have FT4 measured. In any case where the TSH 
value is out of range, but FT4 is normal, the findings should be discussed directly  with the 
medical monitor before the subject isenrolled. If the FT4 value is out of range, the subject is 
not eligible.
2.History  of documented gastric disease (including documented peptic ulcer disease, gastritis, 
upper GI bleeding, esophagitis, or any GI precancerous condition), current clinically  evident 
GIcomplaints. 
3.Chronic use of a proton pump inhibitors (PPIs). History  of incidental use of PPIs is allowed 
but should have been stopped at least 4 weeks before screening. A history  of chronic 
nonsteroidal anti-inflammatory  drug (NSAID )or aspirin use. (Low dose aspirin e.g. in 
cardiovascular disease prevention is allowed).
4.Has a history  of alcohol use disorder within the past y ear. 
5.Criterion modified by  Amendment INT -1 
5.1. Criterion modified by  Amendment INT -2.
5.2.Has failed (no more than 25% response on ATRQ) three or more antidepressant 
treatments including the current SSRI /SNRI during the current depressive episode 
despite an adequate dose (per ATRQ) and duration (at least 6 weeks).
6. Subject has received an investigational drug (including investigational vaccines) or used an 
invasive investigational medical device within 3months before the planned first dose of 
                                                
aThis section has been amended by amendment INT -1, INT -2 and INT -3
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
47
Approved , Date: 28 August 2019study  drug, orhas participated in any interventional clinical studies on MDD in the previous 
1 year , or is currentl y enrolled in an interventional study.
7.Has signs or symptoms of Cushing’ s Disease, Addison’ s Disease, primary  amenorrhea, or 
other evidence of significant medical disorders of the HP A axis.
8.Is breast feeding.
9. Subject has a history  of malignancy  within 5 years before screening (exceptions are 
squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or 
malignancy  that in the opinion of the investigator , with concurrence with the sponsor's study 
responsible ph ysician, is considered cured with minimal risk of recurrence).
10.Has one or more of the following diagnoses:
Aprimary DSM (5th edition) diagnosis of:
-GAD
-panic disorder
-obses sivecompulsive disorder (OCD)
-posttr aumatic stress disorder (PTSD)
Subjects with comorbid GAD, SAD, or panic disorder for whom MDD is considered the 
primary  diagnosis are not excluded .
A current diagnosis or diagnosis in the past 1 year of:
-psychotic disorder
-MDD with psy chosis
-anorexia nervosa or bulimia nervosa. 
- c hronic fatigue syndrome
-bipolar disorder (BD)
-mental retardation
- a ntisocial or borderline personality  disorder
- a utism spectrum disorder .
11.Has a current or recent history  of clinically  significant suicidal ideation within the past 
6months, corresponding to a score of 4 (active suicidal ideation with some intent to act, 
without specific plan) or 5 (active suicidal ideation with specific plan and intent) for ideation 
on the C-SSRS, or a history  of suicidal behavior within the past 1year, as validated by the 
C-SSRS at screening or Visit 2. Subjects with a prior suicide attempt of any sort, or prior 
serious suicidal ideation/plan > 6 months ago, should be carefull y screened for current 
suicidal ideation and only included at the discretion of the investigator .
12.Ongoing psychological treatments (eg, Cognitive Behavior Therapy , Interpersonal 
Psychotherap y, Psychody namic Psychotherap y etc.), initiated within 1 month prior to the 
screening phase. A subject who has been receiving ongoing psychological treatment for a 
period of greater than 1 month from the screening visit is eligible, if the investigator deems 
the psy chological treatment to be of stable duration and frequency .
13.Criterion modified by  Amendment I NT-3
13.1. Subject has a history  of hepatitis B surface antigen (HBsAg) or hepatitis C 
antibody  (anti-HCV) positive, or other clinically active liver disease, or tests 
positive for HBsAg or anti-HCV  at Screening. If subjects have been successfully 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
48
Approved , Date: 28 August 2019treated for or have been spontaneousl y recovered from HCV  and are RNA  
negative, they  will be allowed in the study .
14. Subject has a history  of human immunodeficiency  virus (HIV) antibody positive, or tests 
positive for HIV at Screening. If subjects have been successfully  treated for HIV and are 
ribonucleic acid ( RNA )negative, they  will be allowed in the study .
15. Subject ha s a history  of substance use disorder according to DSM -5criteria, except nicotine 
or caffeine, within 6 months before screening. Mild cases can be reviewed by investigator 
and study  responsible physician on a case by case basis. Subjects who have complete d a 
treatment for (alcohol) addiction more than 1 year prior to first dose administration, may be 
included if the risk of relapse is considered minimal , total duration of alcohol use disorder 
was less than a year,and no significant abnormalities are shown in clinical laboratory  or 
other predose safet y assessments.
16.Criterion modified by  Amendment INT -3.
16.1. Subject has positive test result(s) for alcohol or drugs of abuse (including 
barbiturates, methadone, opiates, cocaine, cannabinoids, 
amphetamine/meth amphetamine, and ecstas y) at Screening or at baseline (Visit 
2).
A positive test result for benzo diazepines is not exclusionary  if the subject is 
taking such drugs per protocol .
Subjects with a positive alcohol or drug screen may have the test repeated once, 
based on the investigator's discretion. This determination, and the reason for 
permitting a repeat test, must be recorded in the subject's source documents and 
initialed by the investigator . A positive, repeat alcohol or drug screen is 
exclusionary .
17.Criterion modified by  Amendment INT -1
17.1. Criterion modified by  Amendment INT -2
17.2. Subject has used :
Monoamine oxidase inhibitors (MAOIs) within 12 weeks before screening
A known inhibitor or inducer of cytochrome P450 (CYP )3A4 activity  (e.g., systemic 
administration of erythromy cin, clarithromy cin, ketoconazole, itraconazole, rifampicin) 
within 14days or a period less than 5-times the drug’ s half-life, whichever is longer , 
before the first stud y drug administration on Day  1. Use of moderate an d strong inhibitors 
and inducers of CYP3A4 are prohibited during the study  (See Appendix 5 ).
St. John’ s wort, ephedra, ginkgo, ginseng, or kava within 2 weeks before screening. 
Antipsy chotic drugs (D2-antagonists) within 2 weeks before screening. However ,
Seroquel (quetiapine) in a do se ≤100 mg is allowed when used in a stable dose for at least 
8weeks prior to screening. Quetiapine treatment should be continued unchanged during 
the study .
Lithium or other mood stabilizers within 2 weeks before screening.
Opioids within 2 weeks before screening.
Psychostimulants such as methy lphenidate or dextroamphetamine within 2 weeks before 
screening.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
49
Approved , Date: 28 August 2019Psychotropics with antidepressant effects such as atomoxetine or thyroid 
supplementation, in addition to their SSRI  or SNRI treatment within 2 weeks before 
screening.
Proton pump inhibitors within 4 weeks before screening.
18.Criterion modified by  Amendment INT -2
18.1. Subject is unable to stop the following medication from the baseline visit (V isit 2) 
and throughout the study  (tapering during screening period allowed): 
Any hypnotics including but not limited to:
• Benzodiazepines when used only as needed (PRN) are not allowed. A  subject 
may continue to take a benzodiazepine treatment only  if:
The subject has been taking a stable dail y dose for at least 6 weeks prior to 
screening .
The dose does not exceed an equivalent of 2 mg of lorazepam per day .
Allowed benzodiazepines are lorazepa m (≤2 mg/day ), clonazepam 
(≤0.5 mg/day ) and alprazolam (≤1 mg/day )being taken daily . Other 
benzodiazepines should be discussed before subject enrollment with the 
study  responsible ph ysician.
Treatment will be continued unchanged during the study .
• Sedating antihistamines, including chronic use of diphenhy dramine. 
• Continuous use of zolpidem, zoplicon, eszopiclone and ramelteon. Note: 
Nonbenzodiazepines sleep aids (including: zolpidem, zaleplon, and
eszopliclone) are allowed on an as needed (PRN ) basis during the study but 
NOT within 24 hours before being in the clinic and not mo re than 2 nig hts in a 
row. 
• S- adenos yl methionine (SAMe) 
• Melatonin, agomelatine
NSAID sand aspirin .
19.Is unwilling or unable to undergo multiple venipunctures because of poor tolerability  or lack 
of eas y access.
20.Is unable to read and understand the ICFand PRO , complete stud y-related procedures, and/or 
communicate with the study  staff.
21. Subject has any condition for which, in the opinion of the investigator , participation would 
not be in the best interest of the subject (e.g., compromise the well- being) or that could 
prevent, limit, or confound the protocol -specified assessments.
22. Subject has had major surger y, (e.g., requiring local or general anesthesia) within 12weeks 
before screening, or will not have fully recovered from surgery, or has surgery planned 
during the time the subject is expected to participate in the study .
23.Is a vulnerable subject (e.g., a person kept in detention).
24.Has received any prior treatment with electroconvulsive therap y, vagal nerve stimulation, or 
a deep brain stimulation device or treatment with ketamine or esketamine for MDD .
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
50
Approved , Date: 28 August 201925.Criterion modified by  Amendment INT -3. 
25.1. Has known allergies, hypersensitivity , or intolerance or any contraindication to 
any of the excipients of JNJ -67953964 or placebo (refer to IB for JNJ-67953964 ).
26.Has either donated 1 or more units (approximately  450 mL) of blood or acutel y lost an 
equivalent amount of blood within 60 day s before the first dose of study  drug. 
27.Has cognitive impairment that would render the informed consent invalid or limit the ability 
of the subject to compl y with the study  requirements. 
28. Subject is an employ ee of the investigator or study  site, with direct involvement in the 
proposed study  or other studies under the direction of that investigator or study  site, as well 
as family  mem bers of the employ ees or the investigator .
NOTE: Investigators should ensure that all study  enrollment criteria have been met at screening. 
If a subject's status changes (including laboratory results) after screening but before first dose of 
study  drug is given such that they  now meet an exclusion criterion, they  should be excluded from 
participation in the study .
5.4. Lifestyle Considerationsa
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the stud y to be eligible for participation . 
1.May not consume food or beverages containing, grapefruit juice, Seville oranges (including 
any orange marmalade), or quinine (e.g., tonic water) from 24 hours (72 hours in the case of 
grapefruit juice and Seville oranges) before the first dose of study medication and 
throughout the duration of the study  until the final study  visit. 
2.Should not take any prohibited medication or food supplements as indicated in the section 
‘concomitant therap y’.For a list of prohibited medications, please see Section 6.5
(Concomitant Therap y).
3.The use of limited amounts of alcohol (up to 2 standard drinks consumptions daily )will be 
allow ed but not within 24hours before any study  visit.  A standa rd drink is defined as: a 
350-mLglass of 5% alcohol-by-volume (ABV) beer (1.7 units) , a 150-mL glass of 12% 
ABV wine (2 units) , or a 45 -mLglass of a 40% ABV  (80proof) spirit (1.7units) .
4.Sleepiness and sedation may be induced by any central action compound .If these adverse 
effects are noticed b y the subject, he/she should not drive a car or operate a machine.
5. Strenuous exercise may affect study  specified assessments and laboratory  safety results; for 
this reason, strenuous exercise should be avoided within 24 hours before all planned study 
visits.
6.May not consume food containing poppy  seeds from 72 hours before the screening visit.
                                                
a aThis section has been amended by amendment INT -2
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
51
Approved , Date: 28 August 20195.5. Screen Failures
The investigator agrees to complete a part icipant identification and enrollment log to permit easy  
identification of each participant during and after the study . This document will be reviewed by 
the sponsor study -site contact for completeness.
The participant identification and enrollment log will be treated as confidential and will be filed 
by the investigator in the study  file. To ensure participant confidentiality , no copy will be made. 
All reports and communications relating to the study  will identify  participants by participant 
identification number and date of birth.
Rescreening will be permitted when the time between the first screening visit and the baseline 
visit exceeds 35days. Individuals who do not meet the criteria for participation in this study  
(screen failure) may be rescreened once . Rescreened participants should be assigned a different
participant number as for the initial screening.
6. STUDY TREATMENTS
6.1. Study Treatments Administereda
JNJ-67953964 will be supplied for this study  as 5-mg capsules. Placebo will be supplied as 
matching capsules. 
All subjects will take 2 capsules QD. The capsules will be taken daily  from Day 2 to Day 78 (at 
home and when being in the clinic) in fasting condition with some water (fasting for at least 
4 hours before dosing; water intake is permitted during that period). Study  medication will be 
taken before breakfast. If the subject has forgotten to take the study  medication before breakfast, 
this should be done before the next following meal, at the latest at dinner of the same day. If the 
subject remembers later than dinner, the dose of that day should be omitted, and the subject 
should take his dose before breakfast on the next day .
When Visit 11 is planned up to 3 days later, continue medication until study Visit11. Spare 
medication is available in each blister.
The capsules must be swallowed whole and not chewed, divided, dissolved or crushed. After 
having taken the study  medication, subjects should try not to eat or drink for at least 30 minutes. 
This period should be controlled when the subject is in the clinic. When outside the clinic, 
violation of this effort (including drug intake in fasting condition) will not be considered a 
protocol violation.
The first dose will be taken in fasting condition on Day 2of the double -blind phase when the 
subject is at home. 
The subjects will take the study  medication with them at each study  visit and will take study  
medication -from the blisters dispensed at the previous study  visit -at the site in fasting 
                                                
aThis section has been amended by amendment INT -1
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
52
Approved , Date: 28 August 2019condit ion after completion of predose study  assessments and blood collections. Dosing will be 
witnessed by  the study  staff .
The dose of the stud y medication is:
10 mg JNJ -67953964: 2 capsules of 5 mg JNJ -67953964 
Placebo: 2 placebo capsules.
Study  medication dose may be adjusted to 5 mg QDbased on the results of a blinded review of 
the safet y data by the study  responsible physician (SRP) or by an unblinded review by the Data 
Review Committee (DRC ) or a physician who is not a member of the study  team (See 
Section 7.1). When a dose reduction has been decided on, this will only apply to new subjects in 
study  and the dose of study  medication will be:
5 mg JNJ -67953964: 1 capsule of 5 mg JNJ -67953964 
Placebo: 1 placebo capsule.
6.2. Preparation, Handling, and Storage 
All study  medication will be stored in a secure area with restricted access. Capsules must be 
stored at controlled room temperatures as indicated on the product specific labeling.
The investigator is responsible for ensuring that all study  medication received at the site is 
inventoried and accounted for throughout the study . The dispensing of study  medication to the 
participant, and the return of study  medication from the participant, must be documented on the 
medication accountability  form. Participants must be instructed to return all original blister 
strips, whether empt y or containing stud y medication .
Study  medication must be handled in strict accordance with the protocol and the blister label . 
Unused stud y medication , and stud y medication returned b y the participant, must be available for 
verification by  the sponsor's study  site monitor during on -site monitoring visits. The return to the 
sponsor of unused study medication , or used returned study  medication for destruction, will be 
documented on the medication return form. When the study  site is an authorized destruction unit 
and study  medication supplies are destro yed on-site, this must also be documented on the 
medication return form.
Study  medication should be dispensed under the supervision of the investigator or a qualified 
member of the study -site personnel, or by a hospital/clinic pharmacis t. Study  medication will be 
supplied only to participants participating in the study . Returned study  medication must not be 
dispensed again, even to the same participant. Study  medication may not be relabeled or 
reassigned for use by other participants. The investigator agrees neither to dispense the study  
medication from, nor store it at, an y site other than the study sites agreed upon with the sponsor.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
53
Approved , Date: 28 August 20196.3. Measures to Minimize Bias: Randomization and Blinding
Procedures for Randomization
Central randomization will be implemented in this study . Subjects will be randomly  assigned to 
one of two treatment groups based on the first of two computer -generated randomization 
schedules prepared before the study  by, or under the supervision of the sponsor. 
The randomization will be balanced by using randomly  permuted blocks stratified by lead-in 
response status and anhedonia (SHAPS total score <20 vs ≥20).
Exact timing of randomization for each subject will be blinded. The interactive web response 
system (IWRS) will assign a unique treatment code, which will dictate the treatment assignment 
and matching study  drug kits for the subject. The requestor must use his or her own user 
identification and personal identification number each time when contacti ng the IWRS, and will 
then give the relevant subject details to uniquely  identify  the subject.
Blinding
Blinded treatment will be used to reduce potential bias during data collection and evaluation of 
clinical endpoints.
The investigator will not be provided with randomization codes. The codes will be maintained 
within the IWRS, which has the functionality  to allow the investigator to break the blind for an 
individual subject.
Data that may potentially  unblind the treatment assignment (e.g., study  medicatio n plasma 
concentrations, plasma biomarkers) will be handled with special care to ensure that the integrit y 
of the blind is maintained and the potential for bias is minimized. This can include making 
special provisions, such as segregating the data in quest ion from view by the investigators, 
clinical team, or others as appropriate until the time of database lock and unblinding. Also, the 
site staff should not discuss insights on unblinding of randomization with the subjects.
Under normal circumstances, the blind should not be broken until all subjects have completed 
the study  and the database is finalized. The investigator may in an emergency  determine the 
identity  of the treatment by contacting the IWRS. While the responsibility  to break the treatment
code in emergency  situations resides solel y with the investigator, it is recommended that the 
investigator contact the sponsor or its designee if possible to discuss the particular situation, 
before breaking the blind. Telephone contact with the sponsor or its designee will be available 
24hours per day , 7days per week. In the event the blind is broken, the sponsor must be informed 
as soon as possible. The date, time, and reason for the unblinding must be documented in the 
appropriate section of theelectronic case report form (eCRF ), and in the source document. The 
documentation received from the IWRSindicating the code break must be retained with the 
subject's source documents in a secure manner. Subjects who have had their treatment 
assignment unblinded should continue to return for required follow -up evaluations.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
54
Approved , Date: 28 August 2019In general, randomization codes will be disclosed fully  only if the study is completed and the 
clinical database is closed. However, if an interim data review by an unblinded reviewer is 
specified (see Section 7.1), the randomization codes and, if required, the translation of
randomization codes into treatment and control groups will be disclosed to those authorized and 
only for those subjects included in the interim review .
6.4. Study Medi cation Compliancea
Study  medication will be taken at home by  the subject. The first dose will be taken by the subject 
on Day  2of the stud y at home .
Dosing will be documented by app’s using the subjects’ smartphone, or on a smartphone 
provided to the subject if they are unable to use their own. The Q1.6 -app will present an 
electronic diary  asking subjects to confirm dosing of study  medication. When available, also a 
medication adherence monitoring platform (AiCure®-app) will be used. The Platform uses 
artificial intelligence on smartphones to visually  confirm proper medication administration and 
ingestion of the study  drug in real time without human intervention.  Video recordings of the 
drug intake are also recorded and stored to AiCure’s secure server forfurther analysis to 
reconfirm proper medication administration, to identify any usability  issues or intentional non-
adherence, and to check for duplicate enrollment. In addition, built-in reminders and a 
communication system allow real-time intervention by study  personnel in case of improper drug 
administration or interruptions by  the subject .
When in the clinic , study medication will be self-administered on site as outlined in Section 6.1.
The administration of study  medication will be witnessed by the investigator or a properl y 
trained designee. The exact date and time of drug administration will be recorded in the eCRF.
The investigator or designated study  personnel will maintain a log of all study  drug dispensed 
and returned. Drug supplies will be inventoried and accounted for throughout the study . 
If appropriate, additional details may be provided in a pharmacy manual/stud y site 
investigational product manual that is provided separatel y and noted in Section 8.1, Study -
Specific Materials.
6.5. Concomitant Therapyb
All p restudy therapies administered up to 30 days before screening must be recorded at screening
(and confirmed b y treating ph ysician) . 
JNJ-67953964 isprimarily  metabolized by  CYP3A . Subjects should not use medic ations that are 
moderate or strong CYP3A inhibitors or inducers from 14 days or at least 5-times the drug’s 
half-life(whichever is longer) prior to study  drug administration until the last study  visit. The 
prohibited medications include but are not limited to: CYP3A inhibitors such as systemically  
                                                
aThis section has been amended by amendment INT -1
bThis section has been amended by amendment INT -2
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
55
Approved , Date: 28 August 2019administered erythromy cin, clarithrom ycin, ketoconazole or itraconazole, and CYP3A inducers 
such as rifampin. Similarly , subjects should avoid consumption of grapefruit, grapefruit juice and 
Seville oranges (including orange marmalade) and herbal products contain ing St. John’s wort, 
ephedra, ginkgo, ginseng, or kava. Appendix 5includes examples of concomitant drugs to be 
avoided (moderate or strong inhibitor/inducer of CYP3A4).
Subjects will be enrolled contingent on having initiated SSRI /SNRI antidepressant treatment for 
their current episode of MDD.  The following antidepressants are permitted: citalopram, 
escitalopram, sertraline, paroxetine, venlafaxine (XR), desvenlafaxine, fluoxetine ,duloxetine, 
milnacipram, vilazodone, levomilnacipran and vortioxetine . Fluvoxamine is a CYP3A4 inhibitor 
and will not be allowed in this study . Subjects will only continue one of these allowed 
antidepressants at an adequate and tolerated dose (i.e. monotherapy ) during the study . No 
changes in the antidepressant or dose are permi tted from s creening until the end of the stud y. 
For safet y reasons, the use of hypnotic drugsor food supplement s should be limited from the 
baseline visit (Visit 2) until the last study  visit (may  be tapered during screening period). 
However: Nonbenzodiazepines sleep aids (including: zolpidem, zaleplon, and eszopliclone) are 
allowed on a PRN basis during the study but NOT  within 24 h ours before being in the clinic and
not more than 2 nights in a row .
Prohibited (from baseline and throu ghout the study )hypnotic drugs or food supplement s include 
but are not limited to:
Benzodiazepines when used only as needed (PRN) are not allowed. A subject may 
continue to take a benzodiazepine treatment onl y if:
•The subject has been taking a stable daily dose for at least 6 weeks prior to screening .
•The dose does not exceed an equivalent of 2 mg of lorazepam per day .
•Allowed benzodiazepines are lorazepam (≤2mg/day ), clonazepam (≤0.5 mg/day ) 
and alprazolam (≤1 mg/day)being taken daily . Other benzodi azepines should be 
discussed before subject enrollment with the study responsible ph ysician.
•Treatment will be continued unchanged during the study .
Sedating antihistamines 
Continuous use of zolpidem, zop iclon, eszopiclone and ramelteon 
SAMe 
Melatonin, agomelatine.
Subject should also not use the following medication from screening and throughout the study :
MAOIs from 12 weeks before screening .
Opioids from 2 weeks before screening .
Psychostimulants such as methy lphenidate or dextroamphetamine within 2weeks 
before screening.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
56
Approved , Date: 28 August 2019Psychotropics with antidepressant effects such as atomoxetine or thyroid 
supplementation, in addition to their SSRI  or SNRI  treatment within 2 weeks before 
screening.
Antipsy chotic drugs(D2-antagonists), lithium and other mood stabilizers from 2 weeks 
before screening .However, Seroquel (quetiapine) ina dose ≤100 mg isallowed when 
used in a stable dose for at least 8weeks prior to screening. Quetiapine treatment should
be continued unchanged during the stud y.
Trazodone for treatment of insomnia in a dose ≤100 mg when used for at least 8 weeks 
at a stable dose will be allowed.
If the administration of any concomitant therap y becomes necessary , it must be reported in the 
appropriate section of the CRF.
The sponsor must be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapies are administered.
6.6. Intervention After the End of the Study
Investigators may re-contact the subject to obtain follow -up information regarding the subjects’
safet yif there are an y safety  concerns at the last study  visit visit.
Participants will be instructed that JNJ-67953964 will not be made available to them after they 
have completed/discontinued the study . Subjects should continue taking the SSRI /SNRI they 
were using during the study until such time as changes in their treatment are recommended by 
their treating phy sician. If the subject has persistent sy mptoms of depression at the completion of 
the study  andhas no access to a primary  physician or psychiatrist ,the investigator should ensure
appropriate medical care for the subject after completion of the study .
7. DISCONTINUA TION OF STUDY TREATMENT AND PA RTICIP ANT 
DISCONTINUA TION/ WITHDRA WAL
If a participant discontinues study  medication or withdraws from the study before the end of the
double -blind phase , the early  withdrawal assessments should be obtained.
7.1. Unblinded Data Review
Continuous or periodic blinded safet y reviews will be done by the SRP. An unblinded review of 
the data will be conducted ifthere are safet y concerns from this blinded review as a result of 
severe, serious or unexpected AEs that are at least possibly  related to the study  drug . This review 
will be done by a DRC . A DRC will consist of at least one medical expert in the relevant 
therapeutic area and at least one statistician; committee membership responsibilities, authorities, 
and procedures will be documented in its charter.
7.2. Completion
A subject will be considered to have completed the study  if he or she has completed the 
11-week s of treatment and the assessments at Week 11 (Visit 11) of the study . Subjects who 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
57
Approved , Date: 28 August 2019prematurel y discontinue study  treatment for any reason before completion of the study will not 
be considered to have completed the study .
7.3. Participant Discontinuation/ Withdrawal from the Studya
A participant will be withdrawn from the study  for any  of the following reasons:
The investigator or sponsor believes (e.g. that for safet y or tolerability  reasons such as a 
SAE at least possibly  related to the study  drug) it is in the best interest of the subject to 
discontinue the study . 
Increased or intolerable sy mptoms of depression
At the discretion of the investigator after the subject reported a “much worse” or “very 
much worse” condition using the self -assessment of treatment experience or
≥30% increase of MADRS score (compared to Visit2) during the double -blind 
treatment period.
The subject becomes pregnant.
A subject will be discontinued from the study  if the QTcF interval is higher than 500 msec 
or is prolonged >60 msec from the baseline value. QTc interval prolongation should be 
confirmed by collecting 2additional ECGs as soon as possible after the initial ECG. The 
average value of the QTcF interval of the three ECG’s will be used to determine whether a 
subject should be discontinued. If the QTcF is not readily  available, the QTcB may be used 
instead. The subject will continue to be monitored (maximum 12 hours) by repeated 12 lead 
ECGs (at least every  60 minutes) until the ECG normalizes .
A subject who shows signals ofclinicall y meaningful acute suicidal ideation at any time 
during the study should be withdrawn from the study  and referred forappropriate 
medical /psychiatric care.
A subject will be discontinued from the study  ifthe liver function tests exceed the values as 
presented in Section 10.7.
Also, aparticipant will be automaticall y withdrawn from the study  for any of the following 
reasons:
Lost to follow -up
Withdrawal of consent . When a subject withdrawals consent, effort should be made to 
determine if the cause of withdrawal was due to tolerability  or lack of efficacy .
Noncompliance to take the study  medication. Noncompliance will be decided on a case-by-
case basis depending on the number of missed capsules and the interval between missed 
doses. 
Subjects who drop out, other than for safety  reasons related to the study  drug or study  
procedures, will be replaced if the number of subjects completing the study  will be below 96.A 
maximum of 32 subjects (1/3 of targeted subjects) will be allowed to be replaced. Replacement 
                                                
aThis section has been amended by amendment INT -3
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
58
Approved , Date: 28 August 2019subjects will receive a new subject ID-number and will be assigned to a new randomization code 
in the I WRS.
When a subject withdraws before completing the study , the reason for withdrawal is to be 
documented in the eCRF and in the source document. Study  drug assigned to the withdrawn 
subject may  not be assigned to another subject.
Any subject who withdraws after receiving the study  drug will have an early  withdrawal
evaluation as described in Section 8.2.4 .
7.4. Protocol Stopping Criteria
Blinded m edical monitoring by  the s ponsor will occur on a continuous basis including laboratory 
and ECG data . When there is any  concern about the safety  of the participants as a result of severe 
or serious AEs that are at least possibly  related to JNJ-67953964 orif the frequency  of 
discontinuations due to TEAEs exceeds 10% of subjects ,an unblinded review of the safet y data 
will take place drug (see Section 7.1). The study  will be stopped at any timeifsafety concerns 
are related to JNJ-67953964 as per the reviewers’ decision. The principal investigator may 
decide to stop study participation at an y time when he/she estimates there is an acute risk for 
his/her subjects in study .
7.5. Withdrawal f rom the Use of Research Samples
The participant may withdraw consent for use of samples for research (refer to Long-Term 
Retention of Samples for Additional Future Research inSection 10.3). In such a case, samples 
will be destro yed after they are no longer needed for the clinical study . Details of the sample 
retention for research are presented in the ICF. 
7.6. Lost to Follow -up
If a participant is lost to follow -up, every  reasonable effort must be made by the study  site 
personnel to contact the participant and determine the reason for discontinuation/withdrawa l. The 
measures taken to follow -up must be documented . Refer to Section 7.3, Particip ant 
Discontinuation/Withdrawal f rom the Study .
8. STUDY ASSESSMENTS A ND PROC EDURES
8.1. Overviewa
The TES summarizes the frequency  and timing ofefficacy ,PK,PD,biomarker, and safety
measurements applicable to this study .
When possible, all PRO assessments should be conducted /completed before any tests, 
procedures, or other consultations to prevent influencing participant perceptions.
                                                
aThis section has been amended by amendment INT -1.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
59
Approved , Date: 28 August 2019However, during the site visits, it should be considered that the study  medication has tobe taken 
in fasted condition and it is preferred to have the PRO’s and other assessments done in fed 
condition. So, during the site visits it is recommended that procedures should be performed in the 
following sequence: Blood and urine collection (when in fasted condition), dosing, breakfast, 
PRO, interview with investigator (SIGMA, SIGH-A and C-SSRS) , safety  assessments. B lood 
collections for PK and PD assessments should be kept as close to the specified time as possible. 
When a subject is expected to be impacted by  blood draw, the sequence may  be: PRO , blood and 
urine collection (when in fasted condition), dosing, breakfast, interview with investigator 
(SIGMA, SIGH -A and C -SSRS) , safety  assessments.
Additional serum (by central laboratory ) or urine pregnancy  tests may be performed, as 
determined necessary  by the investigator or required by local regulation, to establish the absence 
of pregnancy  at an y time during the participation in the study.
The total blood volume to be collected from each participant will be approximately  217mL.
Repeat or unscheduled samples may be taken for safet y reasons or for technical issues with the 
samples.
For each participant, the maximum amount of blood drawn from each participant in this study 
will not exceed 300 mL.
Volume of Blood to be Collected f rom Each Participant
Type of SampleVolume per 
Sample (mL)No. of Samples 
per ParticipantApprox imate
Total Volume 
of Blood (mL)[a]
Safety (including screening and post -treatment assessments )
-Hem atology 2 5 10
-Serum chemistry ,HbA1c and gastric mucosa panel 6.5 5 32.5
Serology (HIV, hepatitis) 5 1 5
TSH /FT4 2.5 1 2.5
Serum -hCG pregnancy tests , FSH 5 1 5
Pharm acokinetic samples 6 9 54
Biomarkers serum[b]20 3 60
Biomarker plasma 10 3 30
Genotyping /(epi)genetics 6 3 18
Approximate Total[c]217
a.Calculated as number of samples multiplied by amount of blood per sample.
b.Biomarker serum sample represents combined volume of more than one tube
c.   Repeat or unscheduled samples may be taken for safety reasons or technical issues with the samples
Note: An indw elling intravenous cannula may be used for blood sample collection.
Sample Collection and Handling
The actual dates and times of sample collection must be recorded onthe laboratory  requisition 
form. If blood samples are collected via an indwelling cannula, an appropriate amount 
(depending of the length of the line during daytime or at night ) of serosanguineous fluid slightly  
greater than the dead space volume of the lock will be removed from the cannula and discarded 
before each blood sample is taken. After blood sample collection, the cannula will be flushed and 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
60
Approved , Date: 28 August 2019charged with a volume equal to the dead space volume of the lock. If a mandarin (obturator) is 
used, blood loss due to discard is not expected.
Refer to the TES for the timing and frequency  of all sample collections.
Instructions for the collection, handling, storage, and shipment of samples are found in [the 
laboratory  manual] that will be provided. Collectio n, handling, storage, and shipment of samples 
must be under the specified, and where applicable, controlled temperature conditions as indicated 
in the laboratory  manual.
Study -Specific Materials
The investigator will be provided with the following supplies :
IB for JNJ -67953964
Pharmacy  manual/study site investigational product manual or equivalent document e.g., 
Investigational Product Preparation Instructions
Laboratory  manual , tubes and labels
Electronic systems or paper documents for the completion of C- SSRS, ASEX, KSS, 
SMDDS, CPFQ , SHAPS , CGI-S, SI GH-Aand SIGMA .
Manual sfor investigator and subject for the Q1.6 -app to complete the follow -up on 
treatment compliance, saliva collection, follow -up on subject retention and self-assessment 
of treatment experience . The Q1.6 -app will be downloaded on the subjects’ own 
smartphone. The Q1.6 -app will ask the pre-programmed study  related questions after 
opening/unlocking the smartphone by the subject. Aprivacy  statement will be provided by 
the Q1.6 provider. The Q1.6 -app will report non-compliance of the subject to the 
investigator.
Manual sfor investigator and subject for the AiCure -app to assess treatment compliance by 
video recording the drug intake. The AiCure- app will be downloaded on the subjects’ own 
smartphone , or a smartphone with the app included will be provided to the subject .
Paper forms for MINI 7.0
Sample I CF
IWRS Manual
Electronic data capture ( eDC)Manual .
8.2. Study procedures
8.2.1. Screening
Subjects will report to the clinical unitfor the first eligibility  screening assessment within 35to 
2days prior to Day 1. Before any study  specific procedures are conducted andfollowing an 
explanation of the purpose and risks of the study , subjects will sign an ICF. Recording of 
AEs/concomitant medication will start following consent and will continue until end of 
Week 11/earl y withdrawal examination.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
61
Approved , Date: 28 August 2019As duplicate enrollment and protocol violations are risk factors for poor quality  data and safet y 
concerns, each subject in this study  will have their current study  status checked by a clinical 
trials verification system when available . After having the ICF signed, each subject will be 
checked in the vendors’ database. Partial identifiers will be utilized. This will include checking a 
valid form of picture ID such as a driver’s license, national ID card, passport, or government 
issued picture ID when possible. The first 3 initials of the first and last name will be entered 
along with the middle initial, date of birth, sex, and last 5 digits of that ID. If the re search subject 
is a verification success they  may  proceed in the study . Verification failures will not be permitted 
to screen.
The Structured I nterview for MADRS will be completed during the screening visit. If 2week sor 
more transpires between the MADRS rating at screening and Visit 2, the local rater will 
complete the MADRS by  a telephone interview up to 4 day s before Visit 2 to determine whether 
the subject still meets the threshold for inclusion.
After all inclusion and exclusion criteria have been met and confirmed, and disallowed 
medication stopped, the subject will be invited to return to the study  center for Day 1  of the 
double -blind study  period. The subject should be supplied with tubes and instructions for the 
collection of saliva at home. The su bject should also be instructed to come to the study  center on 
Day 1 in fasted condition when possible.
During the screening visit, the Q1.6 -appwill be downloaded and the date of Visit2 should be 
entered in the dashboard when the subject is eligible and the date available .
8.2.2. Baseline V isit(Visit 2) 
The study  subject will be asked to come to the study  center in fasted condition. Baseline blood 
collections should be completed first. Thereafter the subject will have a meal. followed by 
completion of all other study  assessments planned for Day  1 (see TES).
If the subject still complies with the in-and exclusion criteria, the subject will be randomized 
and supplied with study  medication. The subject will start taking the study  medication from Day 
2 onward s.
8.2.3. Double -blind T reatment Perioda
The double -blind treatment period will start on the day of first dosing. From Day 2 onwards, the 
subject will take the study  medication at home in fasting condition at least 30 minutes before 
breakfast. The subject will visit the study  center weekl y or every  2  w eeks (between visit 6 
and7). At each study  visit, the subject should come to the study  center in fasted condition and 
will be dosed at the study  center after predose blood collections. Dosing should be witnessed by 
the study  staff. At each study  visit, subjects should take their study  medication with them and 
return used and partl y used blisters. 
                                                
aThis section has been amended by amendment INT -2
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
62
Approved , Date: 28 August 2019AtVisits 3, 4 and 5, the subjects will be re-randomized to blind subjects and investigators for the 
duration of the placebo lead-in period. At each visit new blisters with study  medication will be 
supplied to the subject.
During the study  visits,all assessments will be completed per the TES. For the sequence of 
assessments see Section 8.1.
Between visits the Q1.6 -app will ask the subject about the self-assessment of treatment 
experience , compliance to intake of study  medication and interest in the study .The Q1.6 -app 
will ask the subjects also about their engagement to the study . This will be done at the start and 
the end of the stud y and up to 3 times during the study.
At their last study  visit, each study  participant will be invited to complete an IEC/IRB approved 
Experience Survey , to share to his/her experience as a volunteer in this study . The responses will 
be collected b y an external part y and anon ymously  provided to the sponsor.
8.2.4. Early  Withdrawal Visit
All subject will have to complete Visit 11(final visit and early  withdrawal visit). Subject who 
prematurel y withdrawal from the study  are encouraged to complete Visit 11. During Visit 11,all 
assessments will be completed per the TES. 
For the sequence of assessments, see Section 8.1.
8.3. Efficacy  Assessments 
8.3.1. Rater Qualification
Only  qualified raters will be allowed to perform rating scales and questionnaires during the 
study . This applies to the MADRS, ATRQ, MINI, C -SSRS and CGI -S. Each rater should compl y 
with rater qualification criteria in terms of educational background and experience with MDD 
and the applicable scales. Also, each rater not having received the status of qualified rater in the 
past 2years, should pass a training and certification process. The process of rater qualification , 
the rater qualification criteria and exceptions to it, aredescribed in aseparate qualification 
methodology  document. 
8.3.2. Primary
MADRS
The primary  efficacy  evaluation will be th e MADRS total score. The MADRS will be performed 
by qualified raters during the study , using the SIGMA (Williams 1988 ) and will be completed at 
screening and during the visits indicated in the TES.
The MADRS is a clinician -rated scale designed to measure depression severit y and detects 
changes due to antidepressant treatment. (Montgomery  1979). The scale consists of 10 items, 
each of which is scored from 0 (item not present or normal) to 6 (severe or continuous presence 
of the symptoms), for a total possib le score of 60. Higher scores represent a more severe 
condition. The MADRS evaluates apparent sadness, reported sadness, inner tension, sleep, 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
63
Approved , Date: 28 August 2019appetite, concentration , lassitude, inability to feel (interest level), pessimistic thoughts, and
suicidal thoughts. The testexhibits high inter -rater reliability .
The typical recall period fortheMADRS is7daysandwill beused fortheprimary efficacy
evaluation.
8.3.3. Secondary
Evaluation of depression
CGI -S
The CGI-Sprovides anoverall clinician -determined summary measure oftheseverity of
thesubject’s illness that takes into account allavailable information, including knowledge
ofthesubject’s history ,psychosocial circumstances, symptoms, behavior, andtheimpact of
thesymptoms onthesubject’s ability tofunction (Guy 1976). The CGI-Sevaluates the
severit y of psychopathology on a scale of 0 to7.Considering total clinical experience, a
subject isassessed onseverit y of mental illness atthetime ofrating according to:0=not
assessed; 1=normal (not atallill);2=borderline mentally ill; 3=mildly ill;4=moderately ill;
5=markedl yill;6=severely ill;7=among themost extremely illpatients. TheCGI-S permits a
global evaluation ofthesubject’s condition atagiven time.
SMDDS 
The SMDDS (McCarrier 2016) is a 16-item PRO measure intended for use as an endpoint in 
MDD clinical trials. Each item will be rated by the subject according to a 5-point Likert scale. 
The SMDDS uses a 7-day recall period and verbal rating scales. It was developed in 
accordance with the US Food and Drug Administration (FDA)'s PRO Guidance and best 
practices.
SATE .
The Self-Assessment of Treatment Experience questionnaire is a 1-or 2-item self-report scale 
designed to provide additional information regarding the subjec t’s subjective experience while 
taking the treatment. This is an internal Janssen questionnai re and the questions will be asked to 
the subject weekl y by the Q1.6 -app. The Q1.6 -app will send an alert to the investigator when the 
subject replies that her/his depression is much worse or very much worse . For details see 
Section 10.9.
Evaluation of Anhedonia
SHA PS
The SHAPS (Nakonezny 2010, Snaith 1995) is a self-report 14 -item, instrument, developed for 
the assessment of hedonic capacit y. It has excellent internal consistency , with construct validity , 
and is unidimensional in assessing hedonic capacity  among adult patients with MDD . The 
SHAPS possesses excellent psychometric properties, is not influenced by participant 
demographic and clinical characteristics, and is appropriate for use in both clinical and research 
settings.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
64
Approved , Date: 28 August 2019Subjects score whether they experience pleasure in performing a list of activities or experiences. 
Subjects can rate the answers a “definitel y/strongl y agree”, “agree”, “disagree” or “strongly  
disagree”. Answers will be rated according to Franken (2007): “Definitely  agree” will be rated 1, 
“Agree” will be rated 2, “Disagree” will be rated 3, a nd “Definitel y disagree” will be rated 4. So, 
the score of the scale will range from 14 to 56.The mean score in a population of patients 
hospitalized for treatment of depression was 34.4 (Franken, 2007).
For more details see Section 10.8
Evaluation of anxiety
SIGH -A
The SIGH-A is included to determine the frequency  and severity  of signs and symptoms of 
anxiety  and determine both their influence on treatment and their responsi veness to treatment.  
This original HAM -A scale assesses the severity  of different anxiety -related symptoms 
(Hamilton 1959; Hamilton 1969) with a score range of 0 to 52. It is the most widely  used 
symptom severit y measure for anxiety . Each of the 14 items is rated by  the clinician on a 5 -point 
scale ranging from 0 (not present) to 4 (maximum degree) . The HAM -A has an inter-rater 
reliability  correlation of r = .74 (Maier 1988) and the internal consistency  of the measure is 
reported to be high with a coeffic ient alpha of .86 (Clark andDonovan ,1994 ). The symptoms 
can be grouped into two clusters: psy chic anxiety  and somatic anxiety .
As the original HAM -A lacks instructions for administration and clear anchor points for the 
assignment of severit y ratings, the structured interview guide version will be used in the current 
study  (Shear 2001). The SIGH-A has been shown to have high inter-rater and test-retest 
reliability  and produced similar but consistently  higher (+ 4.2) scores compared to the original 
HAM -A. Correlation with a self-report measure of overall anxiety  has also been shown to be 
high (Shear 2001). 
HAM- A6
The HAM -A6is a 6-item subscale derived from the original HAM -A (Hamilton 1959; Hamilton 
1969). Because the HAM -A, like the Hamilton rating scale for depression -17 ( HDRS 17), is a 
multi- dimensional scale, Bech derived a 6-item subscale, the HAM -A6, comprising five psychic 
anxiety  symptoms: anxious mood, psychic tension, fears, intellectual disturbances, and anxious 
behaviour observed at the interview, as well as one somatic item, muscular tension (Bech 2007), 
with a score range of 0 to 24. In an analysis of four pooled dose-response trials in GAD, a 
Mokken analysis of the HAM -A6yielded Loevinger coefficients above 0.40 individua lly and
combined, indicating that unlike the full HAM -A, the HAM -A6subscale is uni-dimensional. 
Given a fundamental requirement for a drug to be considered to have an anxioly tic effect is that 
it has shown efficacy  in terms of symptom reduction in the core symptoms of anxiety , and as 
these symptoms are captured by HAM-A6(which is more in accordance with the DSM -IV 
criteria for GAD than the full HAM -A), the total HAM -A6score is considered a sufficient 
statistic.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
65
Approved , Date: 28 August 20198.3.4. Exploratory
CPFQ 
The CPFQ is a brief self-report scale that provides additional information regarding the impact of 
adjunctive treatment on aspects of cognitive and executive function including attention, memory 
and mental acuity . Subjects with MDD are often reported to have difficulties with functioning in 
this area. For details see Section 10.10 .
8.4. Safety  Assessments 
The collection of AEs and concomitant medications will start after the ICFhas been signed and 
will continue until the final study visit. All safet y assessments listed below will be performed as 
specified in the TES.
Any clinically  relevant changes occurring during the study  must be recorded on the Adverse 
Event section of the CRF.
Any clinically  significant abnormalities persisting at the end of the study/earl y withdrawal will 
be followed b y the investigator until resolution or until a clinically stable endpoint is reached. 
The study  will include the following evaluations of safet y and tolerability  according to the time 
points provi ded in the TES :
8.4.1. Physical and Neurological Examination
The study  investigator, or other authorized and appropriatel y qualified designee, will perform the 
physical examinations.
Body weight will be measured as per the TES. Body  weight will be measured using a calibrated 
scale. Subjects will be weighed at approximately  the same time of day on the same scale, 
wearing underwear and a gown and without shoes; they  will be instructed to empty  their bladders 
before being weighed. (Note: if disrobing for weighing islogisticall y impossible, the subject 
should be dressed as lightly  as possible, with c onsistency  from visit to visit) . 
The neurological examination at minimum will include a mental status exam, an assessment of 
cranial nerves (III to VII: oculomotor, pupils, and facial muscles) , the motor system (basic 
strength) , and coordination (gait) .Sensory  testing if guided b y history of change in sensation .
8.4.2. Vital Signs
Blood pressure and pulse/heart rate measurements will be assessed in supine positions with a 
completely  automated device. Manual techniques will be used only  if an automated device is not 
available.
Supine blood pressure and pulse/heart rate measurements should be preceded by at least 
5 minutes of rest in a quiet setting without distractio ns (e .g., television, cell phones). 
In addition, oral or t ympanic temperature will be measured.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
66
Approved , Date: 28 August 2019Vital signs should be measured in non fasting conditions whenever possible.
8.4.3. Electrocardiogram (ECG)
Twelve -lead ECGs, intended for safety  monitoring, will be re corded supine (following 5 minutes 
rest) so that the different ECG intervals (RR, PR, QRS, QT) can be measured at multiple time 
points at screening and during the study  (see TES). The ECG will be recorded until 4 regular 
consecutive complexes are available in good readable quality . 
During the collection of ECGs, subjects should be in a quiet setting without distractions (e.g., 
television, cell phones). Subjects should rest in a supine position for at least 5minutes before 
ECG collection and should refrain from talking or moving arms or legs. If blood sampling or 
vital sign measurement is scheduled for the same time point as ECG recording, the procedures 
should be performed in the following order: ECG, vital signs, blood draw. Please note that 
fasting blood draw may  precede the ECG and vital signs in this study .
Hot and cold drinks and food should be avoided 30 minutes before an ECG measurement 
whenever possible.
8.4.4. Clinical Safety  Laboratory  Assessments
Blood samples for serum chemistry  and hematology  [and a random urine sample for urinal ysis] 
will be collected as noted in Section 10.2, Clinical Laboratory Tests. A central laboratory  willbe 
used for testing. The investigator must review the laboratory  results, document this review, and 
record an y clinicall y relevant changes occurring during the stud y in the AEsection of the eCRF. 
8.4.5. Suicidal Risk Monitoring
JNJ-67953964 is considered to be a central nervous system (CNS )-active compound . The 
sponsor considers it important to monitor for such events before and during this clinical stud y.
Columbia Suicide Severity Rating Scale ( C-SSRS)
An interview to assess the risk of suicidal ideation and behavior will be cond ucted at screening ,
through the double -blind treatment phase and at Week 11 / early  withdrawa l. The C-SSRS is a 
low-burden measure of the spectrum of suicidal ideation and behavior that was developed in the 
National Institute of Mental Health Treatment of Adolescent Suicide Attempters Study  to assess 
severit y and track suicidal events through any  treatment (Posner 2007) . The C -SSRS is a clinical 
interview providing a summary  of both ideation and behavior that can be administered during 
any evaluation or risk assessment to identify  the occurrence and intensity  of suicidal thoughts 
and suicidal behaviors. It can also be used during treatment to monitor for clinical worsening. 
See Section 10.11 for details.
8.4.6. Other Safety  Evaluations
ASEX
ASEX (McGahuey 2000) will be used to assess sexual dysfunction .The ASEX is a 5-item, self-
administered rating scale based on a 6 -point Likert scale.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
67
Approved , Date: 28 August 2019The scale quantifies sex drive, arousal, vaginal lubrication/penile erection, ability  to reach 
orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30, with the higher 
scores indicating more sexual dy sfunction. See Section 10.12 for details.
KSS
The KSS is a subject -reported assessment used to rate sleepiness on a scale of 1 to 9, ranging 
from ‘extremely  alert’ (1) to ‘very  sleepy , great effort to keep awake, fight ing sleep’ (9).See 
Section 10.13 for details.
8.5. Adverse Events and Serious A dverse Events
Timely, accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of participants, investigators, and the sponsor, and are mandated by 
regulatory  agencies worldwide. The sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by the sponsor or its affiliates will be conducted in 
accordance with those procedures.
AEs will be reported by the participant (or, when appropriate, by a caregiver, surrogate, or the 
participant's legall y acceptable representative) for the duration of the stud y.
As with any CNS -active medication, investigators should monitor carefully  and document any 
CNS -related AE including tremor, ataxia, abnormal sensation, confusion, or possibility  of 
seizure .
For further details on AEs and SAEs (Definitions and Classifications; Attribution Definitions; 
Severity  Criteria; Special Reporting Situations; Procedures) as well as product qualit y 
complaints (PQCs) , refer to Section 10.4,Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow- Up, and Reporting.
Adverse Events of Special Interest
The following AEs are considered to be of special interest in this study :
Pruritus
GI complaints such as d yspepsia, abdominal pain, constipation, or diarrhea.
Investigators are instructed to inquire about the occurrence of such events during the collecti on 
of AEs at each visit. When reported and ifthese are of moderate or severe intensity  (sufficient 
discomfort to cause interference with normal activity  and/or warrant treatment), investigators 
should provide a narrative to describe the event. At a minimum, a description of the event 
(including any known precipitating circumstances), the time relative to dose administration, the 
duration, concomitant treatment, and outcome of the event will be reported. 
Note: If the event meets the seriousness criteria (see Section 10.4), the Serious Adverse Event
Form must also be completed according to the SAEs reporting timeline described in 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
68
Approved , Date: 28 August 2019Section 10.4,ie, within 24 hours of having become aware of the event, even if all details are not 
available.
8.5.1. Time Period and Frequency  for Collecting A dverse E ventand S erious 
Adverse E vent Informationa
All Adverse Events
All AEs and special reporting situations, whether serious or non-serious, will be reported from 
the time a signed and dated I CF is obtained until completion of the participant's last study -relate d 
procedure, which may include contact for follow -up of safet y. Serious AEs, including those 
spontaneously  reported to the investigator within 30days after the last dose of study  medication , 
must be reported using the Serious AEForm. The sponsor will evaluate any safety information 
that is spontaneously  reported by  an investigator bey ond the time frame specified in the protocol.
Serious Adverse Events
All SAEs occurring during the study  must be reported to the appropriate sponsor contact person 
by study-site personnel immediately , without undue delay , under no circumstances later than 24 
hours after their knowledge of the event.
Information regarding SAEs will be transmitted to the sponsor using the Serious Adverse Event
Form and the CRF, which must be completed and reviewed by aphysician from the study  site, 
and transmitted to the sponsor within 24 hours. The initial and follow -up reports of a SAE should 
be transmitted electronically  or by facsimile (fax).
8.5.2. Follow -up of A dverse E vents and S erious Adverse E vents
AEs, including pregnancy , will be followed by the investigator as specified in Section 10.4,
Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow -up, and 
Reporting.
8.5.3. Regulatory  Reporting Requirements for S erious Adverse E vents
The sponsor assumes responsibilit y for appropriate reporting of AEs to the regulatory  authorities. 
The sponsor will also report to the investigator (and the head of the investigational institute 
where required) all suspected unexpected serious adverse reactions (SUSARs). The investigator 
(or sponsor where required) must report SUSARs to the appropriate Independent Ethics 
Committee/I nstitutional Review Board (IEC/I RB) that approved the protocol unless otherwise 
required and documented by the IEC/I RB. A SUSAR will be reported to regulatory  authorities 
unblinded. Participating investigators and IEC/IRB will receive a blinded SUSAR summary, 
unless otherwise specified. 
8.5.4. Pregnancy
All initial reports of pregnancy  in female participants or partners of male participants must be 
reported to the sponsor by the study -site personnel within 24 hours of their knowledge of the 
                                                
aThis section has been amended by amendment INT -3.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
69
Approved , Date: 28 August 2019event using the appropriate pregnancy  notification form. Abnormal pregnancy  outcomes (eg, 
spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy ) are 
considered serious AEs and must be reported using the Serious Adverse Event Form. Any 
participant who becomes pregnant during the study  must be promptly  withdrawn from the study  
and discontinue further study  medication .
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required.
8.6. Treatment of Overdose
For this study , any dose of JNJ-67953964 greater than 4 capsules within a 24-hour time period
will be considered an overdose. The sponsor does not recommend specific intervention for an 
overdose. 
In the event of an overdose, the investigator or treating ph ysician should:
Contact the Medical Monitor immediately .
Closely  monitor the participant for AE/SAE and laboratory  abnormalities until 
JNJ-67953964 can no longer be d etected s ystemically  (at least 2days).
Obtain a plasma sample for PK anal ysis within 2days from the date of the last dose of study  
medication if requested by  the Medical Monitor (determined on a case -by-case basis).
Document the quantit y of the excess dose as well as the duration of the overdosing in the 
CRF.
Decisions regarding dose interruptions or modifications will be made by the investigator in 
consultation with the Medical Monitor based on the clinical evaluation of the participant.
8.7. Pharmacokinetics
Plasma samples will be analy zed to determine concentrations of JNJ -67953964 using a validated, 
specific and sensitive liquid chromatography -mass spectrometry / mass spectrometry 
(LC-MS/MS) method. If required, some plasma samples may be analy zed to document the 
presence of circulating metabolites or to determine protein binding using a qualified research 
method . In addition, some samples may be used to measure plasma concentrations of the 
SSRI /SNRI used by  the subject.
Venous blood samples of 6 mL will be collected for determination of JNJ-67953964 plasma 
concentrations when required specified in the TES. A PK blood sample will be collected at the 
same time as the blood samples for b iomarkers when indicated in the TES.
The exact dates and times of blood sampling must be recorded in the laboratory  requisition form.
Data will be listed for all subject swith available plasma concentrations per treatment and study 
day. All concentrations below the limit of quantification (LOQ) or missing data will be labeled 
as such in the concentration data listings. Concentrations below the LOQ will be treated as zero 
in the summary  statistics. 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
70
Approved , Date: 28 August 20198.8. Genetics
Blood sample s(6 mL) will be collected to allow forthe identification of pharmacogenomic
factors that may influence the PK,PD, safety and/or tolerability  of JNJ-67953964 , and to 
identify  genetic and epigenetic factors associated with neuropsy chiatric/neurodegenerative 
disorders. They  may also be used to develop tests/assay s related to JNJ-67953964 or 
neurops ychiatric/neurodegenerative disorders. 
Pharmacogenomic research may consist of the analy sis of one or more candi date genes or of the 
analysis of (epi)genetic markers throughout the genome or analy sis of the entire genome (as 
appropriate) in relation to JNJ-67953964 or neuropsy chiatric/neurodegenerative disorders. All 
pharmacogenomic data obtained during this study  may be included in ongoing cross- study 
analyses to investigate the relationship between depression severit y and phenoty pes and 
biomarkers .Participation in the genetic/pharmacogenomic part of this study  is mandatory .
8.9. Biomarkers
During the study , blood and saliva will be collected for the assessment of biomarkers at the time 
points indicated in the TES. Additional instructions for collection of biomarker samples: 
Blood biomarkers will be collected under fasting conditions –at least 4 hours, water 
permitted.
Subjects should be informed not to do strenuous sports or exercises within 24 hours before 
blood sample collection.
Food, drinks (except water) and oral care (brushing, flossing, mouthwash) are not permitted 
for 1 hour prior to saliva collectio n. 
Subjects should refrain from alcohol consumption for 12 hours prior to saliva sampling.
Subjects may  receive a reminder via the smartphone to collect the saliva samples on time.
In blood and/or saliva , biomarkers related to the HPA axis activation incl uding but not limited to
ACTH and cortisol, neurotropic factors , inflammation and metabolic factors may be investigated.
Biomarkers may be added or deleted based on scientific information or technical innovations 
under the condition that the total volume o f blood collected will not be increased. The biomarker 
data obtained from this study  may also be included in an ongoing cross -study  analysis to 
investigate the relationship between depression severity and phenot ypes and biomarkers.
Subject data
To evaluate thebiomarker results, the following information needs to be documented on each 
day of collection of blood samples for biomarker anal ysis.
Diet (extremes during the previous week)
In WOCBP: Follicular phase b y documenting first day of last menses.
Any sickness or allergy  in the previous 2 weeks
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
71
Approved , Date: 28 August 20199. STATISTICA L CONSIDERA TIONS
9.1. Sample Size Determination
The sample size for the study  is determined based on the assumption of a treatment effect size of 
0.45in the mean change from baseline in MADRS total score betw een JNJ-67953964 treatment 
group and placebo. The assumed effect size is based on review of the literature looking at the 
adjunctive treatment with ALKS 5461 , a combination of buprenorphine (partial m-opioid 
receptor agonist and KOR antagonist) and samidorphan (a potent m-opioid receptor antagonist )
inMDD patients with an inadequate response to one or two courses of an antidepressant 
(Fava 2016 and Enrich 2015).
Using the data from the same studies, an estimate of 11for standard deviation in the change in 
MADRS total score from baseline was made. Detection of 0.45 effect size with a power of 90% 
at an overall 1-sided significance level of 0.20, requires 45 subje cts in each treatment group 
(90subjects i n total).
The choice of alpha and beta (1-power) for this Phase study  was made in order to increase 
sensitivity  for detecting a therapeutic signal while also maintaining a modest sample size. Thus, 
power was set to a high value (power=90%; beta= 0.10) but the type 1 error rate was specified at 
1-sided alpha=0.20. This choice is supported by  a publication by  Lindborg et al (Lindborg 2014) 
in which authors note that type 1 and 2 error levels commonly  employ ed in Phase 3 study  
designs (simple hypothesis tests with 2-sided alpha=0.05 and beta=0.2) are suboptimal for early 
phase studies and that switching these values (increasing alpha while decreasing beta) can 
increase Phase 2 productivity  and reduce the risk of rejecting a compound with significant 
therapeutic potential. 
When adjusted for a drop-out rate of approximately  5% of subjects during the treatment period, 
the required number of subjects to be randomized is 96. To achieve this, the estimated number of 
subjects to enter the lead inperiod is 142, after adjusting for an estimated placebo response rate 
of 25% and drop -out rate of 10% during the lead -in period. 
A blinded sample size re -estimation is anticipated with 180 as the maximal number of subje cts to 
be enrolled in the trial.
9.2. Efficacy  Analyses 
9.2.1. Primary
Primary  efficacy  analyses will be based on the intention -to-treat analysis set from enriched
population (eITT) which consists of randomized lead-in placebo non -responders receiving at
least one dose of study medication and having at least one post-treatment baseline efficacy  
measurement.
The JNJ-67953964 treatment group will be compared with placebo using the primary  efficacy
endpoint: change from treatment baseline in MADRS score during the treatment period. The 
comparison will be performed by means of a mixed- effects model forrepeated measures 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
72
Approved , Date: 28 August 2019(MMRM), with time, treatment (placebo, JNJ-67953964 ) and time-by-treatment interaction as 
factors andbaseline total MADRS score as a continuous covariate. Other covariates of interest 
may be included in the MMRM model. The treatment -placebo differences will be obtained using 
the appropriate contrast in the MMRM models at the 6 -week endpoint.
Sensitivity  analyses of the primary  endpoint will be performed using an analysis of covariance 
(ANCOVA )model; these will be detailed further in the Statistical Analy sisPlan.
In addition, same MMRM model will be fitted on full intention -to-treat analysis (fITT) set
consisting of all the randomized subjects receiving at least one dose of study  medication and
having at least one post- treatment baseline efficacy  measurement . 
Missing data mechanisms exploration and possible imputation methods for primary  efficacy  
variable will be described in detail in Statistical Analy sis Plan.
Descriptive statistics for actual values and changes from baseline for MADRS Score at each time 
point of the double -blind treatment phase will beprovided by treatment group using both: eITT 
and fITT analysis sets. Mean differences between the treatments with corresponding confidence 
intervals (CIs) will be reported.
Frequency  tables for response and remission of depressive symptoms (derived from the 
MADRS ) will be provided by treatment group at each time point of the double -blind treatment 
phase using both: eITT and fITT analysis sets. Chi square test to test the overall differences 
between the tr eatment groups will be performed .
9.2.2. Secondary
Evaluation of Anhedonia
Change from treatment baseline in SHAPS score during the treatment period will be analyzed 
with the same MMRM model as primary  efficacy  variable (MADRS) using both: eITT and fITT 
analysis sets. The JNJ-67953964 treatment group will be compared with placebo using the 
appropriate cont rast in the MMRM model at the 6-week endpoint.
Descriptive statistics for actual values and changes from baseline for SHAPS total score at each 
time point of the double -blind treatment phase will be provided by treatment group using both: 
eITT and fITT analysis sets. Mean differences between the treatments with corresponding CIs 
will be reported.
The effect of JNJ-67953964 on depression symptoms across different baseline levels of 
anhedonia will be explored. Descriptive statistics for actual values and changes from baseline in 
MADRS Score within different anhedonia levels (no anhedonia, low level of anhedonia and high 
level of anhedonia; cutoff values will be provided in Statistical Analy sis Plan) will be presented 
by treatment group using both: eI TT and fITT analy sis set.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
73
Approved , Date: 28 August 2019Evaluation of Depression
Descriptive statistics for actual values and changes from baseline for CGI-S, SATE and SMDDS 
(total) scores at each time point of the double -blind treatment phase will be provided by 
treatment group using both: eI TT and fITT analy sis sets. In addition , for CGI -S, frequency  tables 
will be provided by  treatment and time -point.
Evaluation of Anxiety
Descriptive statistics for actual values and changes from baseline for SIGH-A total score as well 
as HAM -A6score at each time point of the double -blind treatment phase will be provided by 
treatment group using both: eITT and fITT analy sis sets. Mean diffe rences between the 
treatments with corresponding CIs will be reported.
9.2.3. Exploratory
Cognitive Functioning Analysis
The actual values of CPFQ and changes from baseline will be summarized at each scheduled 
time p oint by  treatment. These analy ses will be performed on both: eITT and fITT analy sis sets .
9.3. Biomarker A nalyses
Biomarker levels will be tabulated for each time point and summary  statistics will be calculated. 
Post-treatment changes in biomarker levels will be assessed by treatment group. Analy sis of 
variance (ANOVA) and t-test will be used to assess differences across groups and time points. 
Correlations between biomarker levels and clinical endpoints will be evaluated.
The additional exploratory  biomarkers will be tabulated by  treatment and summary  statistics will 
be calculated. Post-treatment changes in exploratory  biomarkers will be summarized by 
treatment group. Associations between baseline biomarker levels and clinical endpoints may be 
explored. Additional exploratory  analyses may also be perform ed. Results of all exploratory  
analysis (including the genetic/epigenetic results) will be presented in a separate report. 
All biomarker data obtained from this study  may also be included in an ongoing cross- study 
analysis to investigate the relationship between depression severit y, phenotypes, and biomarkers.
9.4. PK analy sis
Plasma concentrations for JNJ-67953964 will be analyzed. Based on the individual plasma 
concentration -time data from all subjects, exposure parameters of JNJ-67953964 will be derived 
using population PK (popPK) modeling. Potential baseline covariates (eg, demographics such as 
age, sex and race, body  weight, laboratory  variables such as creatinine clearance, etc.) may be 
included in the models, if relevant. The following exposure parameters will be derived using 
Bayesian feedback analysis: AUC 24hand C0h.Results will be tabulated and summary  statistics 
will be generated. Individual plasma concentrations per study  visit will be listed. PKand PD
relationship will be explored, if feasible. Details of population PK analy sis and PK/PD analy sis 
will be given in a nanalysis plan and the results will be presented in a separate report.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
74
Approved , Date: 28 August 20199.5. Safety  Analyses
Statistical analy sis of the safet y data will be done by the sponsor or under the authorit y of the 
sponsor. Specific details will be provided in the Statistical Analy sis Plan .
All safet y analy ses will be performed based on the safety  analysis set, which will include all 
randomized subjects who receive at least 1 dose of study  drug. Safety  summaries will be 
provided b y treatment, unless specified otherwise.
AEs will be coded using the current version of Medical Dictionary  for Regulatory  Activities 
(MedDRA )and tabulated by system organ class, by severit y and relationship to study  drug and 
will be presen ted b y treatment. SAEs will be summarized separately .
The safet y analysis will include the incidence of AEs,actual data and changes in blood pressure, 
pulse rate, laboratory  safety  data, 12-lead ECG and physical and neurological examination data 
from pred ose to all post dose assessments .
The suicidal ideation and suicidal behavior data collected from the C-SSRS will be summarized 
descriptivel y at each scheduled timepoint by treatment group. Sexual dysfunction (ASEX) and 
KSS data collected will be summarized descriptively  at each scheduled timepoint by treatment 
group.
Adverse Events
The verbatim terms used in the CRF by investigators to identify  AEs will be coded using the 
MedDRA. All reported AEs with onset during the double -blind treatment phase (i.e., TEAE s, 
and AEs that have worsened since baseline) will be included in the analy sis. For each AE, the 
percentage of subjects who experience at least oneoccurrence of the given event will be 
summarized by treatment group. Summaries will be provided for all subjects receiving at least 
one dose of stud y drug in this study, and will include AE s from this study . 
Summaries, listings, datasets, or subject narratives may be provided, as appropriate, for those 
subjects who die, who withdraw due to an AE, or who experience a severe AE or a SAE .
Clinical Laboratory Tests
Laboratory  data will be summarized by type of laboratory  test. Descriptive statistics will be 
calculated for each laboratory  analyte at baseline and at each scheduled time point, and for 
changes from baseline.  
The number and percentage of subjects experiencing a laboratory  result below or above normal 
reference ranges will be provided for each laboratory  analyte by treatment group. Summaries 
will be provided for all subjects receiving at least one dose of study  drug in this study . 
A listing of subjects with any  laboratory  result outside the reference ranges will be provided.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
75
Approved , Date: 28 August 2019ECG
Heart rate and ECG intervals (RR, PR, QRS and QT) as well as corrected QT intervals according 
to Bazett’s formu la (QTcB) and Fridericia’s formula (QTcF) (Bazett 1920, Sagie 1992, Hodges 
1983, International Conference on Harmonization [ICH] 2005 ) from the 12-lead ECG will be 
summarized at baseline and at each scheduled time point and for changes from baseline using 
descriptive statistics. 
The number and percentage of subjects with at least one occurrence of a treatment -emergent 
potentially  clinically  important QTc measurement (QTc value >450, >480, or >500 msec ) or 
with a change from baseline in QTc>30 msec or 60 msec,will be summarized by treatment 
group. 
Data listings of subjects with any potentiall y clinically  important values or with a change from 
baseline in QTc will be provided.
Vital Signs
Descriptive statistics of temperature, pulse, and blood pressure (sy stolic and diastolic ) values and 
changes from baseline will be summarized at each scheduled time point. The percentage of 
subjects with values beyond clinically  important limits will be summarized. 
Physical and Neurological Examination s
Subjects with abnor mal findings will be presented in a data listing .
Other Safety Measures
C-SSRS
The suicidal ideation and behavior data collected from the C-SSRS will be summarized 
descriptivel y at each scheduled timepoint by treatment group. Data from the subjects with 
suicidal ideation and behavior will be presented in data listing.
ASEX and KSS
Sexual dysfunction and KSS data collected will be summarized descriptively  at each scheduled 
timepoint by  treatment group.
9.6. Interim A nalysis
An interim analy sis may be executed. The procedures for the interim analy sis will be described 
in a separate charter.
A blinded data review for purpose of sample size re-estimation may be performed during the 
study after minimally  50% of the subjects are randomized and have complete d Week 6 of the 
double -blind treatment period. Sample size may be re-adjusted if the observed SD substantiall y
deviates from the hypothesized SDor if the lead-in response and dropout rate substantially 
deviate from the assumed values. The maximal number o f subjects to be enrolled in the trial will 
not surpass 180.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
76
Approved , Date: 28 August 201910. SUPPORTING DOCUMENTA TION A ND OPERA TIONA LCONSIDERA TIONS
10.1. Appendix 1: Abbrev iations
ABV Alcohol -by-volume
ACTH Adrenocorticotropic hormone
AE Adverse Event
ALKS Alkermes
ALT alanine aminotransferase 
AMA Anti-mitochondrial antibody
ANA Antinuclear antibody
ANCOVA Analysis of covariance
ANOVA Analysis of variation
Anti-HAV (IgM) Anti-hepatitis A virus (Immunoglobulin M)
Anti-HEV (IgM) Anti-hepatitis E virus (Immunoglobulin M)
AP Alkaline phosphatase
ASEX Arizona sexual experiences scale
ASMA Anti-smooth muscle antibody
AST Aspartate transaminase 
ATRQ Antidepressant Treatment History Questionnaire
AUC Area under the plasma concentration -time curve (time period specified by 
subscript).
BBB bundle branch block
BD Bipolar disorder
BDNF Brain -derived neurotropic factor
BMI Body  mass index 
BUN Blood urea nitrogen
CBC Com plete blood count
CERC Cerecor
CGI-S Clinical Global Impression –  Severity
CHF Congestive heart failure
CI Confidence interval
Cmax maximum drug concentration 
CMV Cytomegalovirus
CNS Central nervous system
CPFQ Cognitive and Physical Functioning Questionnaire
CPK Creatine phosphokinase 
CRP C-reactive -protein
C-SSRS Columbia Suicide Severity Rating Scale
CV coefficient of variation
CYP cytochrome P450
DILI Drug induced liver injury
DM Diabetes mellitus
DNA desoxyribonucleic acid
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
77
Approved , Date: 28 August 2019DRC Data Review Committee
DSM -IV/5 Diagnostic and Statistical Manual of Mental Disorders fourth/fifth edition
EBV Epstein -Barr virus
ECG Electrocardiogram
(e)CRF (electronic) case report form
eDC Electronic data capture
EF embryo/fetal 
eITT Enriched intent -to-treat (population)
EOT End-of-treatment
ERCP endoscopic retrograde cholangiopancreatography
ESR Erythrocyte sedimentation rate
FDA Food and Drug Administration
fITT Full intent -to-treat (population)
FSH follicle stimulating hormone
FT4 Free thyroxine
G17 gastrin -17
GAD General anxiety disorder
GCP Good Clinical Practice
GGT Gamma -glutamyltransferase 
HAM -A Ham ilton Anxiety Scale
HAM -A6 6 item subscale from HAM -A
HBsAg Hepatitis B surface antigen
HCV Hepatitis C antibodies 
HDRS17 Ham ilton rating scale for Depression -17
HIV Human immunodeficiency virus
HPA Hypothalamus pituitary adrenal
Hp IgG helicobacter IgG antibodies 
hs-CRP High -sensitivity C -reactive protein
IB Investigator’s Brochure
ICD International Classification of Diseases
ICF Informed consent form  
ICH International Conference on Harm onization
IEC Independent Ethics Committee
IRB Institutional Review Board
IGF1 Insulin -like grow th factor 1
IL-X Interleukin -X (1β, 2, 6, 10…)
INR International normalized ratio
IUD Intrauterine device
IUS Intrauterine system
IWRS Interactive web response system
KOR kappa opioid receptor
KSS Karolinska Sleepiness Scale
LC-MS/MS Liquid chromatography/mass spectrometry/mass spectrometry
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
78
Approved , Date: 28 August 2019LDH Lactic acid dehydrogenase 
LFT liver function test
LKM Liver kidney microsomal antibody
LKM1 Liver kidney microsomal antibody type 1
LOQ Limit of quantification
LT Liver test
MADRS Montgomery Asberg Depression Rating Scale
MAOI Monoamine oxidase inhibitor
MDD Major Depressive Disorder 
MDE Maximum desired mean exposure
MedDRA Medical Dictionary for Regulatory Activities
MINI Mini International Neuropsychiatric Interview
MMRM Mixed -effects model for repeated measures
MOS Margin of Safety
MRCP magnetic resonance cholangiopancreatography
MRI Magnetic resonance imaging
MTD Maximum tolerated Dose
NOAEL no-observed -adverse -effect -level  
NSAID Nonsteroidal anti -inflammatory drug
OCD Obsessive compulsive disorder
OTC Over the counter
pANCA Anti-neutrophil cytoplasmic antibody
PD pharmacodynamics(s)
PET Positron emission tomography
PGI/II pepsinogen I / II 
PK Pharm acokinetic(s)
popPK Population Pharmacokinetics
PPI Proton pump inhibitor
PQC Product Quality Complaint
PRN As needed
PRO Patient reported outcome
PT Prothrombin time
PTSD Post-traumatic stress disorder
PTT Partial thromboplastin time
QD Once daily
RBC Red blood cell 
RNA ribonucleic acid
SAD Social anxiety disorder
SAE Serious adverse event
SAMe S-adenosyl methionine
SATE Self-Assessment of Treatment Experience
SD Standard deviation 
SHAPS Snaith -Hamilton Pleasure Scale
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
79
Approved , Date: 28 August 2019SIGH-A Structured Interview Guide for the Hamilton Anxiety scale
SIGMA The Structured Interview Guide for the MADRS 
SMDDS Symptoms of Major Depressive Disorder Scale
SNRI serotonin -norepinephrine reuptake inhibitor 
SRP Study responsible physician
SSRI Selective serotonin reuptake inhibitor
SUSAR suspected unexpected serious adverse reaction
Tbili Total bilirubin
TEAE Treatment- emergent adverse event
TES Time and Events schedule
TIBC Total iron binding capacity
TNFα Tumor necrosis factor alpha
TSH thyroid -stimulating hormone
ULN Upper Limit of Normal
US United States
VAS Visual Analogue Scale
WBC White blood cell 
WOCBP women of childbearing potential 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
81
Approved , Date: 28 August 2019 For postmenopausal women only: Follicle stimulating hormone (FSH)
 Serology (HIV antibody, HBsAg , and HCV antibody)
 Thyroid function (TSH, FT4) at screening
 HbA1c at screening in diabetic subjects only
 Urine drug screen [opiates (including methadone), ecstasy, cocaine, 
(meth)amphetamines, cannabinoids , barbiturates].
 Alcohol breath test.
The following biomarkers will be tested in this study . Biomarkers may  be added or deleted based 
on the latest scientific insights without amending the protocol if the total volume of blood to be 
collected will not increase as a result of adding biomarkers.
analytes
saliva cortisol
serumHigh -sensitive C -reactive protein 
(hs-CRP)
serum cortisol
serum IL-6
serum Tumo rnecrosis factor alpha (TNFα)
serum IL-1b
serum grow th horm one
serum adiponectin
serum leptin
serumBrain -derived neurotropic factor 
(BDNF)
serum Insulin -like grow th factor 1 (IGF1)
plasma ACTH
plasma Kynurenine metabolites
whole blood genotyping/epigenetics
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
82
Approved , Date: 28 August 201910.3. Appendix 3 : Regulatory , Ethical, and Study Oversight Considerations
Regulatory  Ethics Compliance
Investigator Responsibilities
The investigator is responsible for ensuring that the clinical study  is performed in accordance 
with the protocol, current ICH guidelines on Good Clinical Practice (GCP ), and applicable 
regulatory  and country -specific requirements.
GCP is an international ethical and scientific quality  standard for designing, conducting, 
recording, and reporting studies that involve the participation of human subjects. Compliance 
with this standard provides public assurance that the rights, safety , and well-being of study  
subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki, and that the clinical study  data are credible.
Independent Ethics Committee /Institutional Review Board
Before the start of the study ,the investigator (or sponsor where required) will provide the 
IEC/IRBwith current and complete copies of the following documents:
Final protocol and, if applicable, amendments
Sponsor -approved ICF(and any  other written materials to be provided to the su bjects) .
IB(or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator's curricul um vitae or equivalent information (unless not required, as 
documented b y the IEC /IRB )
Information regarding funding, name of the sponsor, institutional affiliations, other potential 
conflicts of interest, and incentives for subjects
Any other documents th at the IEC/IRBrequests to fulfill its obligation
This study  will be undertaken only after the IEC/I RBhas given full approval of the final 
protocol, amendments (if any), the ICF, applicable recruiting materials, and subject 
compensation programs, and the sponsor has received a copy of this approval. This approval 
letter must be dated and must clearl y identify the IEC/IRB and the documents being approved.
During the study ,the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
Protocol amendments
Revision(s) to ICFand any  other written materials to be provided to subjects
If applicable, new or revised subject recruiting materials approved b y the sponsor
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
83
Approved , Date: 28 August 2019Revi sions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the IBand amendments/addenda
Summaries of the status of the study  at intervals stipulated in guidelines of the IEC/I RB
(atleast annually )
Reports of adverse events that are serious, unlisted/unexpected, and associated with the 
investigational drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Annual Safet y Report and L ine Listings, where applicable
Any other requirements of the IEC/I RB
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or trial conduct), the amendment and applicable ICFrevisions 
must be submitted promptly  to the IEC/I RBfor review and approval before implementation of 
the change(s). 
At least once a year, the IEC/IRB will be asked to review and reapprove this clinical study . The 
re-approval should be documented in writing (excluding the ones that are purely  administrat ive, 
with no consequences for subjects, data, or stud y conduct).
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/IRB
about the study  completion.
Informed Consent
Each subject must give written consent according to local requirements after the nature of the 
study  has been fully explained. The ICFmust be signed before performance of any study-related 
activity . The ICFthat is used must be approved by both the sponso r and by the reviewing 
IEC/IRB and be in a language that the subject can read and understand. The informed consent 
should be in accordance with principles that originated in the Declaration of Helsinki, current 
ICH and GCP guidelines, applicable regulatory requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the investigational 
staff must explain to potential subjects the aims, methods, reasonabl y anticipated benefits, and 
potential hazards of the study, and any discomfort that participation in the study  may entail. 
Subjects will be informed that their participation is voluntary  and that they may withdraw 
consent to participate at any time. They  will be informed that choosing not to participate will no t 
affect the care that they will receive. Finall y, they will be told that the investigator will maintain 
a subject identification register for the purposes of long-term follow -up if needed and that their 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
84
Approved , Date: 28 August 2019records may be accessed by health authorities and authorized sponsor staff without violating the 
confidentiality  of the subject, to the extent permitted by the applicable law(s) or regulations. 
Bysigning the ICF,form the subject is authorizing such access, and agrees to allow his or her 
study  physician to recontact the subject for the purpose of obtaining consent for additional safety 
evaluations, if needed.
Where local regulations require, a separate ICF may  be used for the required DNA component of 
the study .
The subject will be given sufficient time to read the ICFand the opportunity  to ask questions. 
After this explanation and before entry  into the study , consent should be appropriatel y recorded 
by means of the subject's personally  dated signature. After having obtained the consent, a copy 
of the ICFmust be given to the subject.
Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study  will be 
limited to those data that are necessary  to fulfill the objectives of the stud y.
These data must be collecte d and processed with adequate precautions to ensure confidentialit y 
and compliance with applicable data privacy  protection laws and regulations. Appropriate 
technical and organizational measures to protect the personal data against unauthorized 
disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be 
put in place. Sponsor personnel whose responsibilities require access to personal data agree to 
keep the identit y of stud y subjects confidential.
The informed consent obtained from the subject includes explicit consent for the processing of 
personal data and for the investigator to allow direct access to his or her original medical records 
for stud y-related monitoring, audit, IEC/I RBreview, and regulatory  inspection. T his consent also 
addresses the transfer of the data to other entities and to other countries.
The subject has the right to request ,through the investigator ,access to his or her personal data 
and the right to request rectification of any data that are notcorrect or complete. Reasonable 
steps will be taken to respond to such a request, taking into consideration the nature of the 
request, the conditions of the study, and the applicable laws and regulations.
Exploratory  PK and DNA research is not conducted u nder standards appropriate for the return of 
data to subjects. In addition, the sponsor cannot make decisions as to the significance of any 
findings resulting from exploratory  research. Therefore, exploratory  research data will not be 
returned to subjects or investigators, unless required by law. Privacy  and confidentiality  of data 
generated in the future on stored samples will be protected by the same standards applicable to 
all other clinical data.
Long -Term Retention of Samples for Additional Future Rese arch
Samples collected in this study  may be stored for up to 15 years (or less, according to local 
regulations) for additional research. Samples will be used to understand JNJ-67953964 , 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
85
Approved , Date: 28 August 2019neurops ychiatric/neurodegenerative disorders ,differential drug respon ders, and to develop 
tests/assays related toJNJ-67953964 .  The research may begin at any time during the study  or 
the post study  storage period. 
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research (refer to Section 7.5, Withdrawal from the Use of Research Samp les.
Country Selection
This study  will only be conducted in those countries where the intent is to launch or otherwise 
help ensure access to the developed product, unless explicitly  addressed as a specific ethical 
consideration in Section 4.2.1 ,Study -Specific Ethical Design Considerations.
Administrative requirements
Protocol Amendments
Neither the investigator nor the sponsor will modify  this protocol without a formal amendment 
by the sponsor. All protocol amendments must be issued by  the sponsor, and signed and dated by 
the investigator. Protocol amendments must not be implemented witho ut prior IEC/IRB
approval, or when the relevant competent authority has raised any grounds for nonacceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly  submitted to the IEC/I RBand relevant competent authority . 
Documentation of amendment approval by  the investigator and IEC/IRB must be provided to the 
sponsor or its designee. When the change(s) involves only logistic or administrative aspects of 
the study , the IEC/IRB only needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact the appropriate sponsor 
representative (see Contact Information page(s) provided separately). Except in emergency 
situations, this contact should be made before implementing any departure from the protocol. In 
all cases, contact with the sponsor must be made as soon as possible to discuss the situation and 
agree on an appropriate course ofaction. The data recorded in the eCRF and source documents 
will reflect any departure from the protocol, and the source documents will describe this 
departure and the circumstances requiring it.
Regulatory  Documentation
Regulatory Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory 
requirements are met.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
86
Approved , Date: 28 August 2019Required Prestudy Documentation
The follow ing documents must be provided to the sponsor before shipment of study  drug to the 
investigational site:
Protocol and amendment(s), if an y, signed and dated by the principal investigator
A copy  of the dated and signed, written IEC/IRB approval of the protocol, amendments, 
ICF, any recruiting materials, and if applicable, subject compensation programs. This 
approval must clearly  identify  the specific protocol by title and number and must be signed 
by the chairman or authorized designee.
Name and address of the IEC/IRB , including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a  letter of explanation, orequivalent, 
from the IEC/I RB, a general statement may be substituted for this list. I f an investigator or a 
member of the investigational staff is a member of the IEC/IRB , documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opinion of the study.
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator (e .g.,Form FDA 1572), if applicable
Documentation of investigator qualifications (e .g.,curriculum vitae)
Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and dated clinical trial agreement, which includes the financial agreement
Any other documentation required by  local regulations
The following documents must be provided to the sponsor before enrollment of the first subject:
Completed investigator financial disclosure forms from all clinical subinvestigators
Documentation of subinvestigator qualifications (e .g., curriculum vitae)
Name and address of any local or central laboratory  conducting tests for the study , and a 
dated cop y of current laboratory  normal ranges for these tests, if applicable
Local or central laboratory  documentation demonstrating competence and test reliability  
(e.g.,accreditat ion/license), if applicable
Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by the 
sponsor site contact for completeness.
The subject identification and enrollment log will be treated as confidential and will be filed by 
the investigator in the study  file. To ensure subject confidentiality , no copy  will be made. 
Allreports and communications relating to the study  will identify  subjects by  assigned number.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
87
Approved , Date: 28 August 2019The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility  for inclusion in the study .
Source D ocumentation
At a minimum, source documentation must be available for the following to confirm data 
collected in the eCRF: subject identification, eligibility , and study identification; study  
discussion and date of signed informed consent; dates of visits; results of safety  and efficacy  
parameters as required by the protocol; record of all AEs and follow -up of AEs; concomitant 
medication; drug receipt/dispensing/return records; study  drugadministration information ; and 
date of study  completion and reason for early discontinuation of study  drug or withdrawal from 
the study , if applicable. 
In addition, the author of an entry  in the source documents should be identifiable.
At a minimum, the type and level of detail of source data available for a subject should be 
consistent with that commonly  recorded at the study  site as a basis for standard medical care. 
Specific details required as source data for the study  will be reviewed with the investigator 
before the study  and will be described in the monitoring guidelines (or other equivalent 
document) .
Following the ICH/GCP guidelines, direct access to source documentation (medical records) 
must be allowed for the purpose of verify ing that the data recorded in the eCRF are consistent 
with the original source data.
Case Report Form Completion
eDC will be used for this study . The study  data will be transcribed by study-site personnel from 
the source documents onto an electronic CRF, and transmitted in a secure manner to the sponsor 
within the timeframe agreed upon between the sponsor and the study  site. The electronic file will 
be considered to be the CRF .
Worksheets may be used for the capture of some data to facilitate completion of the CRF. Any 
such worksheets will become part of the subject's source documentation. All data relating to the 
study  must be recorded in CRFs prepared by the sponsor. Data must be entered into CRFs in 
English. Study  site personnel must complete the CRF as soon as possible after a subject visit, and 
the forms should be available for review at the next scheduled monitoring visit.
The responsible study  monitor will check data at the monitoring visits to the clinical study  site. 
The Investigator will ensure that the data collected are accurate, complete and legible.
All clinical work conducted under this protocol is subject to GCP regulations. This includes an 
inspection by  the Sponsor and Competent Authority  representatives at any  time. The Investigator 
will agree to the inspection of study -related recor ds by Competent Authority  representatives and 
the audits of the S ponsor or third parties, named by the Sponsor.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
88
Approved , Date: 28 August 2019Every  effort should be made to ensure that all subjective measurements (e.g., pain scale 
information or other questionnaires) to be recorded in the CRF are completed by the same 
individual who made the initial baseline determinations. The investigator must verify  that all data 
entries in the eDC s ystem are accurate and correct.
All eCRF entries, corrections, and alterations must be made by the investigator or other 
authorized study -site personnel. If necessary , queries will be generated in the eDC tool. The 
investigator or an authorized member of the investigational staff must adjust the eCRF 
(ifapplicable) and complete the query . 
If corrections to a eCRF are needed after the initial entry  into the eCRF, this can be done in 
3different way s:
Site personnel can make corrections in the eDC tool at their own initiative or as a response 
to an auto query  (generated by  the eDC tool)
Site manager can gen erate a query  for resolution by  the investigational staff
Clinical data manager can generate a query  for resolution by  the investigational staff 
Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
associated personnel before the study , and periodic monitoring visits by the sponsor .Written 
instructions will be provided for collection, preparation, and shipment of samples. 
Guidelines for eCRF completion will be provided and reviewed with study  personnel before the 
start of the study . 
The sponsor will review eCRFs for accuracy  and completeness during on-site monitoring visits 
and after transmission to the sponsor; any discrepancies will be resolved with the investigator or 
designee, as appropriate. After upload of the data into the clinical study  database ,they will be 
verified for accuracy  and consistency  with the data sour ces. 
Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all CRFs 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by the applicable regulatory  requirement(s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents .
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
89
Approved , Date: 28 August 2019retained for a longer period if required by the applicable regulatory  requirements or by an 
agreement with the sponsor. It is the responsibilit y of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keeping the study  records, custo dy must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name and address of the 
new custodian. Under no circumstance shall the investigator relocate or dispose of any study  
documents before havi ng obtained written approval from the sponsor.
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator must permit access to such reports.
Monitoring
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study  site visit log that will be kept at the site. The first post-
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compare the data entered into the eCRFs with the hospital or clinic records (source 
documents) ; a sample may be reviewed . The nature and location of all source documents will be 
identified to ensure that all sources of original data required to complete the eCRF are known to 
the sponsor and investigational staff and are accessible for verification by the sponsor site 
contact. If electronic records are maintained at the investigational site, the method of verification 
must be discussed with the investigational staff. 
Direct access to source documentation (medical records) must be allowed for the purpose of 
verify ing that the data recorded in the e CRF are consistent with the original source data. Findings 
from this review of eCRFs and source documents will be discussed with the investigational staff. 
The sponsor expects that, during monitoring visits, the relevant investigational staff will be 
available, the source documentation will be accessible, and a suitable environment will be 
provided for review of study -related documents. The monitor will meet with the investigator on a 
regular basis during the study  to provide feedback on the study  conduct.
In addition to on-site monitoring visits, remote contacts can occu r. It is expected that during 
these remote contacts, study -site personnel will be available to provide an update on the progress 
of the study  at the site .
Study Completion/Termination
Study Completion
The study  is considered completed with the last visit (Visit 11/Early  withdrawal visit )for the last 
subject participating in the study . The final data from the investigational site will be sent to the 
sponsor (or designee) after completion of the final subject visit at that site, in the time frame 
specified i n the Clinical Trial Agreement.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
90
Approved , Date: 28 August 2019Study Termination
The sponsor reserves the right to close the investigational site or terminate the study  at any time 
for any reason at the sole discretion of the sponsor. Investigational sites will be closed upon 
study  completion. An investigational site is considered closed when all required documents and 
study  supplies have been collected and a site closure visit has been performed.
The investigator may initiate site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of an investigational site by  the sponsor or investigator may  include 
but are not limited to:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RBor 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  the investigator
Discontinuation of further drug development
On-Site A udits
Representatives of the sponsor's clinical quality  assurance department may visit the site at any 
time during or after completion of the study  to conduct an audit of the study  in compliance with 
regulatory  guidelines and compan y policy . These audits will require access to all study  records, 
including source documents, for inspection and comparison with the CRFs. Subject privacy 
must, however, be respected. The investigator and staff are responsible for being present and 
available for consultation during routinel y scheduled site audit visits conducted by the sponsor or 
its designees. 
Similar auditing procedures may also be conducted by agents of any regulatory  body, either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify  the sponsor if they have been 
contacted b y a regulatory agency  concerning an upcoming inspection.
Use of Information and Publication
All information, including but not limited to information regarding JNJ-67953964 or the 
sponsor's operations (e.g.,patent application, formulas, manufacturing processes, basic scientific 
data, prior clinical data, formulation information) supplied by the sponsor to the investigator and 
not previously  published, and any data,includin g pharmacogenomic or exploratory  biomarker 
research data, generated as a result of this study , are considered confidential and remain the sole 
propert y of the sponsor. The investigator agrees to maintain this information in confidence and 
use this informat ion only to accomplish this study, and will not use it for other purposes without 
the sponsor's prior written consent.
The investigator understands that the information developed in the clinical study  will be used by 
the sponsor in connection with the continued development of JNJ-67953964 ,and thus may be 
disclosed as required to other clinical investigators or regulatory  agencies. To permit the 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
91
Approved , Date: 28 August 2019information derived from the clinical studies to be used, the investigator is obligated to provide 
the sponsor wi th all data obtained in the study .
The results of the study  will be reported in a Clinical Study  Report generated by the sponsor and 
will contain eCRF data from all investigational sites that participated in the study . Recruitment 
performance or specific e xpertise related to the nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator. Results of pharmacogenomic or 
exploratory  biomarker analy ses performed after the Clinical Study  Report has been issued will
be reported in a separate report and will not require a revision of the Clinical Study  Report. 
Study  subject identifiers will not be used in publication of results. Any work created in 
connection with performance of the study  and contained in the data that can benefit from 
copy right protection (except any publication by the investigator as provided for below) shall be 
the propert y of the sponsor as author and owner of cop yright in such work.
The sponsor shall have the right to publish such data and informa tion without approval from the 
investigator. If an investigator wishes to publish information from the study , a copy of the 
manuscript must be provided to the sponsor for review at least 60days before submission for 
publication or presentation. Expedited reviews will be arranged for abstracts, poster 
presentations, or other materials. If requested by the sponsor in writing, the investigator will 
withhold such publication for up to an additional 60days to allow for filing of a patent 
application. In the event that issues arise regarding scientific integrit y or regulatory  compliance, 
the sponsor will review these issues with the investigator. The sponsor will not mandate 
modifications to scientific content and does not have the right to suppress information. For 
multicenter study  designs and substudy  approaches, secondary  results generall y should not be 
published before the primary  endpoints of a study  have been published. Similarly , investigators 
will recognize the integrity  of a multicenter study  by not submitting for publication data derived 
from the individual site until the combined results from the completed study  have been submitted 
for publication, within 12months of the availability  of the final data (tables, listings, graphs), or 
the sponsor confirm s there will be no multicenter study  publication. Authorship of publications 
resulting from this study will be based on the guidelines on authorship, such as those described 
in the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, whic h state that 
the named authors must have made a significant contribution to the design of the study  or 
analysis and interpretation of the data, provided critical review of the paper, and given final 
approval of the final version.
Registration of Clinical S tudies and Disclosure of Results
The sponsor will register and/or disclose the existence of,and the results of,clinical studies as 
required b y law.
Other Ethical Considerations
For stud y-specific ethical design considerations, refer to Section 4.2.1 .
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
92
Approved , Date: 28 August 2019Financial disclosure
Investigators and subinvestigators will provide the sponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the sponsor to submit complete and 
accurate financial certification or disclosure statements to the appropriate regulatory  authorities. 
Investigators are responsible for providi ng information on financial interests during the course of 
the study  and for 1 y ear after completion of the study .
Refer to Required Prestudy  Documentation (above) and contracts for details on financial 
disclosure.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
93
Approved , Date: 28 August 201910.4. Appendix 4 : Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
ADVERSE EVENT DEFINITIONS A ND CL ASSIFICA TIONS
Adverse Event
An AEis any untoward medical occurrence in a clinical study  participant administered a 
medicinal (investigational or non-invest igational) product. An AEdoes not necessarily  have a 
causal relationship with the medication . An AEcan therefore be any  unfavorable and unintended 
sign (including an abnormal finding), symptom, or disease temporall y associated with the use of 
a medicinal (investigational or non-investigational) product, whether or not related to that 
medicinal (investi gational or non- investigational) product. (Definition per ICH)
This includes any  occurrence that is new in onset or aggravated in severit y or frequency  from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects AEs starting with the signing of the ICF(refer to All AEsunder 
Section 8.5.1 , Time Period and Frequency  for Collecting Adverse Events and Serious Adverse 
Events Information, for time of last adverse event recording).
Serious Adverse Event
A SAE based on ICH and EU Guidelines on Pharmacovigilance for Medicinal Products for 
Human Use is an y untoward medical occu rrence that at any  dose:
Results in death
Is life -threatening
(The subject was at risk of death at the time of the event. It does not refer to an event that 
hypothetically  might have caused death if it were more severe)
Requires inpatient hospitalization or prolongation of existing hospitalization
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defe ct
Is a suspected transmission of an y infectious agent via a medicinal product
Is Medicall y Important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be 
immediately  life-threatening or result in death or hospitalization but may jeopardize the subject 
or may require intervention to prevent one of the other outcomes listed in the definition above. 
These should usually  be considered serious.
If a serious and unexpected AE occurs for which there is evidence suggesting a causal 
relationship betw een the study  drug and the event (eg, death from anaph ylaxis), the event must 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
94
Approved , Date: 28 August 2019be reported as aSUSAR even if it is a component of the study  endpoint (e.g., all-cause 
mortality ).
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An AEis considered unlisted if the nature or severit y is not consistent with the applicable 
product reference safety information. ForJNJ-67953964 , the expectedness of an AEwill be 
determined b y whether or not it is listed in the IB.
Adverse Event Associated with the Use of the Medication
An AEis considered associated with the use of the medication if the attribution ispossible, 
probable, or very  likel yby the definitions listed below (see Attribution Definitions).
ATTRIBUTION DEFINITIONS
Not Related
An AE that is not related to the use of the drug .
Doubtful
An AE for which an alternative explanation is more likely , eg,concomitant drug(s), concomitant 
disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An AE that might be due to the use of the drug. An alternative explanation, eg,concomitant 
drug(s), concomitant disease(s), is inconclusive. The relationship in time is reasonable; therefore, 
the causal relationship cannot be excluded.
Probable
An AE that might be due to the use of the drug. The relationship in time is suggestive 
(e.g., confirmed by dechallenge). An alternative explanation is less likely , e.g. ,concomitant 
drug(s), concomitant disease(s).
Very Likely
An AE that is listed as a possible adverse reaction and cannot be reasonably  explained by an 
alternative explanation, e.g.,concomitant drug(s), concomitant disease(s). The relationship in 
time is very  suggestive (e .g.,it is confirmed b y dechallenge and rechallenge).
SEVERITY CRITERIA
An assessment of sever ity grade will be made using the following general categorical 
descriptors :
Mild : Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with every day activities.
Moderate : Sufficient discomfort is present to cause interference with normal activity .
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
95
Approved , Date: 28 August 2019Severe : Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal every day activities.
The investigator should use clinical judgment in assessing the severit y of events not directl y 
experienced b y the subject ( e.g., laboratory  abnormalities).
SPECIA L REPORTING SITUA TIONS
Safety  events of interest on a sponsor study  drug that may require expedited reporting or safet y 
evaluation include, but are not limited to:
Overdose of a sponsor study  drug
Suspected abuse/misuse of a sponsor stud y drug
Accidental or occupational exposure to a sponsor study  drug
Medication error involving a sponsor product (with or without subject exposure to the 
sponsor study  drug, e.g., name confusion)
Exposure t o a sponsor study  drug from breastfeeding
Special reporting situations should be recorded in the CRF. Any special reporting situation that 
meets the criteria of a SAE should be recorded on the S erious A dverse Event page of the CRF .
PROCEDURES
All Adverse E vents
All AEs, regardless of seriousness, severit y, or presumed relationship to study  medication , must 
be recorded using medical terminology  in the source document and the CRF. Whenever possible, 
diagnoses should be given when signs and sy mptoms are due to a common etiology  (e.g., cough, 
runny  nose, sneezing, sore throat, and head congestion should be reported as "upper respiratory  
infection"). Investigators must record in the CRF their opinion concerning the relationship of the 
AEto study  therap y. All measures required for AEmanagement must be recorded in the source 
document and reported according to sponsor instructions.
For all studies with an outpatient phase, including open -label studies, the participant must be 
provided with a "wallet (study ) card" and instructed to carry  this card with them for the duration 
of the study  indicating the following: 
Study  number
Statement, in the local language(s), that the participant is participating in a clinical study
Investigator's name and 24- hour contact telephon e number
Local sponsor's name and 24 -hour contact telephone number (for medical staff only )
Site number
Participant number
Any other information that is required to do an emergency  breaking of the blind
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
96
Approved , Date: 28 August 2019Serious Adverse Events
All SAEs that have not resolve d by the end of the study , or that have not resolved upon 
discontinuation of the participant's participation in the study , must be followed until any of the 
following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a basel ine value/status is available
The event can be attributed to agents other than the study  medication or to factors unrelated 
to study  conduct
It becomes unlikel y that any additional information can be obtained (participant or health 
care practitioner refusal to provide additional information, lost to follow -up after 
demonstration of due diligence with follow -up efforts)
Suspected transmission of an infectious agent by a medicinal product will be reported as a SAE . 
Any event requiring hospitalization (or prolongation of hospitalization) that occurs during the 
course of a participant's participation in a study  must be reported as a SAE , except 
hospitalizations for the following:
Hospitalizations not intended to treat an acute illness or AE(e.g., social reasons such as 
pending placement in long -term care facility )
Surgery  or procedure planned before entry  into the study  (must be documented in the CRF). 
[Note: Hospitalizations that were planned before the signing of the ICF, and where the 
underly ing condition for which the hospitalization was planned has not worsened, will not 
be considered SAEs . Any AEthat results in a prolongation of the originall y planned 
hospitalization is to be reported as a new SAE .]
The cause of death of a participant in a study  with in30 day sof the last dose of study  medication , 
whether or not the event is expected or associated with the study  medication , is considered a 
SAE .
CONTA CTING SPONSOR REGA RDING SAFETY
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding safet y issues or questions regarding the study  are listed in the Contact Information 
page(s), which will be provided as a separate document.
PRODUCT QUA LITY COMPLA INT HA NDLING
A PQC is defined as any suspicion of a product defect related to manufacturing, labeling, or 
packaging, ie, any dissatisfaction relative to the identity , quality , durability , or reliability  of a 
product, including its labeling or package integrity . A PQC may  have an impact on the safet y and 
efficacy  of theproduct. Timely , accurate, and complete reporting and analysis of PQC 
information from studies are crucial for the protection of participants, investigators, and the 
sponsor, and are mandated by regulatory  agencies worldwide. The sponsor has established 
procedures in conformity  with regulatory  requirements worldwide to ensure appropriate 
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
97
Approved , Date: 28 August 2019reporting of PQC information; all studies conducted by the sponsor or its affiliates will be 
conducted in accordance with those procedures.
Procedures
All initial PQCs must be reported to the sponsor by  the study -site personnel within 24 hours after 
being made aware of the event .
If the defect is combined with a SAE , the study -site personnel must report the PQC to the 
sponsor according to the SAE reporting timelines (refer to Section 8.5.1 , Time Period and 
Frequency  for Collecting Adverse Event and serious Adverse Event Information ). A sampl e of 
the suspected product should be maintained for further investigation if requested by the sponsor.
Contacting Sponsor Regarding Product Quality
The names (and corresponding telephone numbers) of the individuals who should be contacted 
regarding product quality  issues are listed in the Contact Information page(s), which will be 
provided as a separate document.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
98
Approved , Date: 28 August 201910.5. Appendix 5: Drugs to be avoided
Examples ofConcomitant Drugs tobeAvoided (Moderate orStrong Inhibitor/Inducer of
CYP3A 4)
Enzyme Inhibitors Inducers
Strong Moderate Strong Moderate
CYP3A4 Boceprevir, Amprenavir, Avasimibe, Bosentan,
clarithromycin, aprepitant, carbamazepine, efavirenz,
conivaptan, atazanavir, phenytoin, etravirine,
grapefruit juice, ciprofloxacin, rifampin, St. modafinil,
indinavir, crizotinib, John’s wort nafcillin.
itraconazole, darunavir/ritonavir,
ketoconazole, diltiazem,
lopinavir/ritonavir, erythromycin,
mibefradil, fluconazole,
nefazodone, fosamprenavir,
nelfinavir, imatinib, verapamil
posaconazole, fluvoxamine
ritonavir,
saquinavir,
telaprevir,
telithromycin,
voriconazole
Notes:
This isnotanexhaustive list.
Source: USFDA -Drug Development andDrug Interactions: TableofSubstrates, Inhibitors andInducers.
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm09
3664 htm. Accessed 04November 2015
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
99
Approved , Date: 28 August 201910.6. Appendix 6 : Contraceptive Guidance and Collecti on of Pregnancy  
Information
Participants must follow contraceptive measures as outlined in Section 5.2, Inclusion Criteria. In 
addition to the procedures described in Section 5.2, male subjects must also use a condom if their 
female partner becomes pregnant to avoid exposure to the unb orn child .
Pregnancy  information will be collected and reported as noted in Section 8.5.4, Pregnancy and 
Section 10.4, Adverse Events: Definitions and Procedures for Recording, Evaluating, Follow -up, 
and Reporting .
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
102
Approved , Date: 28 August 2019should be followed until normal, along with documentation of whether parenteral vitamin K was 
given along with the effect of such treatment on INR.
If initial liver function tests (LFTs)and ultrasound do not suggest Gilbert’s syndrome, biliary
tract disease or obstruction, viral hepatitis serology should be obtained including anti-hepatitis A 
virus immunoglobin M (anti- HAV IgM), anti-HAV total,  HBsAg, anti -HBs,  anti -HB core total,  
anti-HB core IgM, anti-HCV,  anti-hepatitis E virus IgM (anti-HEV IgM) (even if has not 
traveled to an endemic area for hepatitis E), Epstein -Barr virus (EBV) and Cytomegalovirus 
(CMV) screen.
If subject is immunosuppressed, test for HCV RNA and HEV RNA.
If HBsAg or anti-HB core IgM or anti-HB core IgG positive , also get HBV DNA to 
detect active HepB, especially  in subject s who are immunosuppressed.
If all other hepatitis B serologic tests are negative and anti -HBc total is the only  positive 
test, HBV DNA should be obtained to detect reactivation of hepatitis B.
Assuming that the history , phy sical, and initial imaging and laboratory  has not revealed a cause 
of elevated LTs, screen for other causes of liver disease including: Total protein and albumin 
(estimate globulin fraction and obtain quantitative immunoglobu lins if elevated), antinuclear 
antibody  (ANA), anti-liver kidney  microsomal antibody  type 1 (anti-LKM1), anti-liver-kidney  
microsomal antibodies (anti-LKM antibodies), anti-smooth muscle antibodies (ASMA), 
erythrocy te sedimentation rate (ESR), and CRP. If the pattern of laboratory  abnormalities is not 
hepatocellular, but cholestatic or a mixed pattern (see definitions in table above), then GGT, anti -
mitochondrial antibody  (AMA) and anti-neutrophil cytoplasmic antibody  (pANCA) should also 
be tested.  If there is an indication by history  or elevated baseline LTs that there may be an 
underly ing chronic liver disease possibly  exacerbated by exposure to the study  medication in the 
clinical trial or making the participant more susceptible to DILI, test iron/Total iron binding  
capacity  (TIBC) and ferritin (hemochromatosis), and alpha -1-antitry psin level.  If subject is <50 
years of age, ceruloplasmin should also be tested to screen for Wilson’s disease.  If subject is 
sick enough to be hospitalized and is under age 50, a slit lamp examination to detect Kayser-
Fleischer rings and a 24-hour urine collection for copper should be measured. Consider serum 
ethanol and/or acetaminophen level and urine drug screen as clinicall y appropriate.
A liver biopsy  should be considere d if autoimmune hepatitis remains a competing etiology  and if 
immunosuppressive therapy  is contemplated.
A liver biopsy  may  be considered:
if there is unrelenting rise in liver biochemistries or signs of worsening liver function 
despite stopping the suspec ted offending agent.
if peak ALT level has not fallen by >50% at 30-60 days after onset in cases of 
hepatocellular DILI, or if peak Alk P hosphatase has not fallen by >50% at 180 days in 
cases of cholestatic DILI despite stopping the suspected offending age nt.
in cases of DILI where continued use or re -exposure to the implicated agent is expected.
if liver biochemistry  abnormalities persist beyond 180 days to evaluate for the presence 
of chronic liver diseases and chronic DILI.
If pertinent, copies of hospital discharge summary , radiology , pathology  and autops y reports 
should be obtained.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
103
Approved , Date: 28 August 201910.8. Appendix 8: The SHAPS
This questionnaire is designed to measure your ability to experience 
pleasure in the last few days.  It is important to read each statement 
verycarefully .
Tick one of the boxes to indicate how much you agree or disagree 
with each statement.
1. I would enjoy my favourite television or radio programme
Strongly disagree ..............................................   
Disagree ...........................................................   
Agree ...............................................................   
Strongly agree ..................................................   
2. I would enjoy being with my family or close friends
Definitely agree .................................................   
Agree ...............................................................   
Disagree ...........................................................   
Strongly disagree ..............................................   
3. I would find pleasure in my hobbies and pastimes
Strongly disagree ..............................................   
Disagree ...........................................................   
Agree ...............................................................   
Strongly agree ..................................................   
4. I would be able to enjoy my favourite meal
Definitely agree .................................................   
Agree ...............................................................   
Disagree ...........................................................   
Strongly disagree ..............................................   
5. I would enjoy a warm bath or refreshing shower
Definitely agree .................................................   
Agree ...............................................................   
Disagree ...........................................................   
Strongly disagree ..............................................   
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
104
Approved , Date: 28 August 20196. I would find pleasure in the scent of flowers or the smell of a 
fresh sea breeze or freshly baked bread
Strongly disagree ..............................................   
Disagree. ..........................................................   
Agree ...............................................................   
Strongly agree ..................................................   
7. I would enjoy seeing other people's smiling faces
Definitely agree .................................................   
Agree ...............................................................   
Disagree ...........................................................   
Strongly disagree ..............................................   
8. I would enjoy looking smart when I have made an effort with 
my appearance
Strongly disagree ..............................................   
Disagree ...........................................................   
Agree ...............................................................   
Strongly agree ..................................................   
9. I would enjoy reading a book, magazine or newspaper
Definitely agree .................................................   
Agree ...............................................................   
Disagree ...........................................................   
Strongly disagree ..............................................   
10. I would enjoy a cup of tea or coffee or my  favourite drink
Strongly disagree ..............................................   
Disagree ...........................................................   
Agree ...............................................................   
Strongly agree ..................................................   
11. I would find pleasure in small things e.g. a bright sunny day, a 
telephone call from a friend
Strongly disagree ..............................................   
Disagree ...........................................................   
Agree ...............................................................   
Strongly agree ..................................................   
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
105
Approved , Date: 28 August 201912. I would be able to enjoy a beautiful landscape or view
Definitely agree .................................................   
Agree ...............................................................   
Disagree ...........................................................   
Strongly disagree ..............................................   
13. I would get pleasure from helping others
Strongly disagree ..............................................   
Disagree ...........................................................   
Agree ...............................................................   
Strongly agree ..................................................   
14. I would feel pleasure when I receive praise from other people
Definitely agree .................................................   
Agree ...............................................................   
Disagree ...........................................................   
Strongly disagree ..............................................   
Reproduced from: Snaith et al. (1995) A scale for the assessment of 
hedonic tone. The Snaith -Hamilton Pleasure Scale. British Journal of 
Psychiatry , 167, 99-103.
© 1995 The Royal College of Psychiatrists.  Written permiss ion must be obtained 
from the Royal College of Psychiatrists for copying and distribution to others or for 
republication (in print, online or by any other medium).
This version may  be different from the final version in study .
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
106
Approved , Date: 28 August 201910.9. Appendix 9: Self-Assessment of Treatment Experience
Questions are asked once weekl y from Day 1 of dosing until Visit11.
Question 1:
Since starting this study  medication, overall would y ou say  your depression is: 
oImproved
oNot changed
oGot worse
If the subject selects answer 1 (I mproved), following question is asked:
Question 2:
How much did y our depression improve?
oSlightly  improved
oMuch improved
oVery  much improved
If the subject selects answer 3 (Got worse), following question is asked:
Question 3:
How much did y our depression worsen?
oSlightly  worse
oMuch worse
oVery  much worse
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
107
Approved , Date: 28 August 201910.10. Appendix 10: Cognitive and Physical Functioning Questionnaire (CPFQ)
This version may  be different from the final version in study .

JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
110
Approved , Date: 28 August 2019Appendix 11b: Columbia Suicide Severity Rating Scale (Since Last Visit)

JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
111
Approved , Date: 28 August 2019

JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
112
Approved , Date: 28 August 201910.12. Appendix 12 : Arizona sexual experiences scale ( ASEX)©
Male: 

JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
113
Approved , Date: 28 August 2019Female:
This version may be different from the final version in study

JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
114
Approved , Date: 28 August 201910.13. Appendix 13 : The Karolinska Sleepiness Scale .
Please, indicate your sleepiness during the 5minutes before this rating through circling the 
appropriate description:
1=extremely  alert
2=very  alert
3=alert
4=rather alert
5=neither alert nor sleepy
6=some signs of sleepiness
7=sleep y, but no effort to keep awake
8=sleep y, some effort to keep awake
9=very  sleepy, great effort to keep awake, fighting sleep
(This version may  be different from the final version in study )
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
115
Approved , Date: 28 August 201910.14. Appendix 14 : Protocol A mendment History
DOCUMENT HISTORY
Document Date
Amendment INT -3 28August 2019
Amendment INT2, GER -1 04 July 2019
Amendment INT2, GBR -1 21 May 2019
Amendment INT -2 26February 2019
Amendment INT -1 18-June-2018
Original Protocol 14-March -2018
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
116
Approved , Date: 28 August 201911. REFERENCES
1.Agréus L, Kuipers EJ, Kupcinskas L, et al. Rationale in diagnosis and screening of atrophic gastritis with 
stomach -specific plasma biomarkers. Scand J Gastroenterol. 2012;47(2):136 -147.
2.Akerstedt T, Gillberg M Subjective and objective sleepiness in the active individuals. J Neurosci. 
1990;52(1 -2):29 -37.
3.Alesci S, Martinez PE, Kelkar S, et al. Major depression is associated with significant diurnal elevations in 
plasma interleukin -6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its 
secretion: clinical implications. J Clin Endocrinol Metab. 2005;90(5):2522 -2530.
4.Bazett HC. An analysis of the time -relationship of electrocardiograms. Heart. 1920;7:353 -380.
5.Bech P. Dose- response relationship of pregabalin in patients w ith generalized anxiety disorder. A pooled 
analysis of four placebo -controlled trials. Pharmacopsychiatry 2007; 40(4): 163 -168.
6.Chandler G, Iosifecu D, Pollack M, Targum S, Fava M. Validation of the Massach usetts General Hospital 
Antidepressant Treatment History Questionnaire (ATRQ). CNS Neuroscience & Therapeutics 2010, 16(5): 
322-325.
7.Clark DB, Donovan JE. Reliability and validity of the Hamilton Anxiety Rating Scale in an adolescent 
sample. J Am Acad Chil d Adolesc Psychiatry. 1994;33(3):354 -360.
8.DeWitt SJ, Bradley KA, Lin N, Yu C, Gabbay V. A pilot resting -state functional connectivity study of the 
kynurenine pathway in adolescents with depression and healthy controls. J Affect Disord. 2018 ;227:752 -
758. 
9.Ehrich E, Turncliff R, Du Y, et al. Evaluation of opioid modulation in major depressive disorder. 
Neuropsychopharmacology. 2015;40(6):1448 -1455.
10.Fava M, Iosifescu DV, Pedrelli P, Baer L. Reliability and validity of the Massachusetts general hospital 
cogniti ve and physical functioning questionnaire. Psychother Psychosom. 2009;78(2):91 -97
11.Fava M, Memisoglu A, Thase ME ,et al. Opioid Modulation with Buprenorphine/Samidorphan as 
Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double -Blind Placebo -
Controll ed Trial. Am J Psychiatry. 2016 ;173(5):499 -508.
12.Franken IH, Rassin E, Muris P. The assessment of anhedonia in clinical and non -clinical populatio ns: 
further validation of the Snaith -Hamilton Pleasure Scale (SHAPS). J Affect Disord. 2007;99(1 -3):83 -89.
13.Guy W.ECDEU Assessment Manual forPsychopharmacology. Rockville, MD: U.S. Departm entof
Health, Education, andWelfare; 1976.
14.Ham ilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32(1): 50 -55.
15.Ham ilton M. The diagno sis and rating of anxiety, In Studies of Anxiety , MM Lader, Ed., Meedley Bros., 
Kent, 1969.
16.Hodges M, Salerno D, Erlien D. Bazett’s QT correction review ed: evidence that a linear QT correction for 
heart rate is better. J Am Coll Cardiol. 1983;1:694.
17.International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals 
for Human Use. ICH Harmonized Tripartite Gu ideline E14: Clinical evaluation of QT/QTc interval 
prolongation and proarrhythmic potential for non -antiarrhythmic drugs. ICH 12 May 2005.
18.Janssen Research & Development, L.L.C. Investigators Brochure JNJ -67953964, Edition 3 , January 2019 .
19.Knoll AT, Carlezon WA Jr. Dynorphin, stress, and depression. Brain Res. 2010;1314:56 -73.
20.Lindborg SR, Persinger CC, Sashegyi A, Mallinckrod C, Ruberg SJ. Statistical refocusing in the design of 
Phase II trials offers promise of increased R&D productivit y. Nat. Rev. Drug Discov. 2014; 13 (8), 638 –
640.
21.Maier W, Buller R, Philipp M, Heuser I. The Hamilton Anxiety Scale: reliability, validity and sensitivity to 
change in anxiety and depressive disorders. J Affect Disord. 1988;14(1):61 -68.
JNJ-67953964
Clinical Protocol 67953964MDD2001, Amendment INT -3
117
Approved , Date: 28 August 201922.McCarrier KP, Deal LS, Abraham L, et al. Patient -Centered Research to Support the Development of the 
Symptoms of Major Depressive Disorder Scale (SMDDS): Initial Qualitative Research. Patient. 
2016;9(2):117 -134
23.McGahuey CA, Gelenberg AJ, Laukes CA, et al. The Arizona Sexual Experience Scale (A SEX): 
Reliability and Validity. J Sex Marital Ther . 2000; 26(1):25-40.
24.McIntyre A. Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or 
venlafaxine in patients with major depression, comorbid anxiety, and residual depressi ve symptoms: A 
randomized, placebo -controlled pilot study. Depress Anxiety.2007;24(7):487 -494
25.Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 
1979 Apr;134:382 -9.
26.Nakonezny PA, Carmody TJ, Morris DW, Kuri an BT, Trivedi MH. Psychometric evaluation of the Snaith –
Ham ilton Pleasure Scale (SHAPS) in adult outpatients with major depressive disorder. Int Clin 
Psychopharmacol 2010;25(6):328 -333.
27.Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classifi cation Algorithm of Suicide 
Assessment (C -CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analysis of 
antidepressants. Am J Psychiatry. 2007;164(7):1035 -1043.
28.Reed B, Butelman ER, Fry RS, Kimani R, Kreek MJ. Repeated Administr ation of Opra Kappa 
(LY2456302), a Novel, Short -Acting, Selective KOP -r Antagonist, in Persons with and without Cocaine 
Dependence. Neuropsychopharmacology. 2017, preview  online Aug 31.
29.Sagie A, Larson MG, Goldberg RJ, Bengston JR, Levy D. An improved method for adjusting the QT 
interval for heart rate (the Framingham Heart Study). Am J Cardiol. 1992;70 (7):797-801.
30.Shear MK, Vander Bilt J, Rucci P, et al. Reliability and validity of a structured interview guide for the 
Ham ilton Anxiety Rating Scale (SIGH- A). Depress Anxiety. 2001; 13(4): 166– 178.
31.Sorgdrager FJH, Doornbos B, Penninx BWJH, de Jonge P, Kema IP. The association between the 
hypothalamic pituitary adrenal axis and tryptophan metabolism in persons with recurrent major d epressive 
disorder and healthy controls. J Affect Disord. 2017;222:32 -39
32.Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigw ell P. A scale for the assessment of 
hedonic tone the Snaith -Hamilton Pleasure Scale. Br J Psychiatry. 1995;167(1):99 -103.
33.Syrjänen K. Role of Serological Biomarker Testing (GastroPanel®) in Diagnosis of Symptomatic 
Dyspepsia and in Screening of the Risks of Stomach Cancer . EC Gastroenter ology and Digestive System. 
2017 ;1.6: 209 -222.
34.Umehara H, Numata S, Watanabe SY, et al. Altered KYN/TRP, Gln/Glu, and Met/methionine sulfoxide 
ratios in the blood plasma of medication -free patients with major depressive disorder. Sci Rep. 
2017;7(1):4855. 
35.U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Researc h (CDER): 
Guidance for Industry: Guidelines for the clinical evaluation of antidepressant drugs , February 1977.
36.U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research (CDER): 
Guidance for Industry: Suicidal Ideation and Be havior: Prospective Assessment of Occurrence in Clinical 
Trials, August 2012, Revision 1.
37.Williams JBW. A structured intervie w guide for the Hamilton Depression Rating Scale. Archives of Gen . 
Psych. 1988;45 (8):742-747.